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 CHAPTER 1 
 
General introduction and outline of the thesis 
Review: Immune suppressor cells and checkpoints in    
liver cancer 
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7 Aims and outline of this thesis 
In the current thesis we investigate some of the abovementioned immune suppressive 
mechanisms in the tumor microenvironment of liver cancers with the goal to identify new and 
potentially promising immunotherapeutic targets to overcome the intra-tumoral immune 
inhibition and enhance anti-tumor reactivity of tumor-infiltrating T cells in patients with liver 
cancer. We study how to reduce the immunosuppressive capacity of pro-tumor regulatory T 
cells, and how to activate anti-tumor functions of effector T cells in hepatocellular carcinoma, 
cholangiocarcinoma and liver metastasis of colorectal cancer by manipulating co-inhibitory 
and co-stimulatory pathways. For this purpose, we use leukocytes isolated from resected 
liver tumors, tumor-free liver tissues and peripheral blood collected from patients that 
undergo liver tumor resection, and perform flow cytometry analyses and in vitro immune cell 
culture assays. The ultimate aim of these studies is to provide new immunotherapeutic 
approaches to treat patients with primary liver cancer or CRC liver metastasis. 
Part I focuses on two types of pro-tumor T cells, immunosuppressive conventional regulatory 
T cells and type 1 regulatory T cells. We study how to abrogate the immune suppression 
exerted by these cells in the tumor microenvironment (Figure 4). In Chapter 2, we study the 
phenotype and suppressive capacity of conventional regulatory T cells in hepatocellular 
carcinoma and liver metastasis of colorectal cancer, and demonstrate that stimulation of 
these cells via the co-stimulatory molecule GITR in combination with blockade of the co-
inhibitory molecule CTLA4 can completely alleviate ex vivo inhibition of effector T cell 
functions by human liver tumor-derived regulatory T cells. In Chapter 3, we identify an intra-
tumoral population of IL-10-producing Type 1 regulatory T cells in hepatocellular carcinoma 
and liver metastasis of colorectal cancer, and show in co-cultures that plasmacytoid dendritic 
cells enhance IL-10 production by these cells through engagement of their co-stimulatory 
molecule inducible T cell costimulator (ICOS). In Chapter 4, we challenge the use of anti-
CD25 antibodies to deplete regulatory T cells from human tumors and propose the risk of 
depleting CD25-expressing non-Treg cells that may be important for anti-tumor immunity.    
Part II focuses on two types of anti-tumor T cells, CD4+ T helper cells and CD8+ cytotoxic T 
cells. We study how to invigorate effector functions of tumor-infiltrating T cells by targeting 
co-inhibitory and co-stimulatory immune checkpoint pathways (Figure 4). In Chapter 5, we 
investigate which co-inhibitory pathways suppress intra-tumoral helper and cytotoxic T cells 
in hepatocellular carcinoma, and demonstrate that blocking PD-L1, TIM3, or LAG3 increases 
anti-tumor antigen responses of tumor-infiltrating CD4+ and CD8+ T cells in ex vivo assays. 
Importantly, combining antibody against PD-L1 with antibodies against TIM3, LAG3, or 
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CTLA4 further increases ex vivo functions of tumor-infiltrating T cells. In Chapter 6, we 
examine co-inhibitory molecules in liver metastasis of colorectal cancer with mismatch repair-
proficient type, and compare the immune cell infiltration and expression of co-inhibitory 
molecules in LM-CRC with those in primary CRC and peritoneal metastasis of colorectal 
cancer. We show that antibody blockade of LAG3 or PD-L1 enhances ex vivo functions of 
tumor-infiltrating CD4+ and CD8+ T cells from LM-CRC. In Chapter 7, we analyze the 
composition and characteristics of immune infiltrates in cholangiocarcinoma, and test the 
effect of blocking co-inhibitory and activating co-stimulatory pathways on ex vivo effector 
functions of tumor-infiltrating T cells from cholangiocarcinoma. In Chapter 8, we demonstrate 
that agonistic targeting of the co-stimulatory molecule GITR by GITR ligand or anti-GITR 
antibody promotes ex vivo functions of T cells isolated from hepatocellular carcinoma.  
A summary of the work presented in this thesis, as well as the importance and implications of 
these studies as a whole are discussed in Chapter 9. 
 
 
 
Figure 4. Outline of the thesis 
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ABSTRACT 
In liver cancer tumor-infiltrating regulatory T cells (Ti-Treg) are potent suppressors of tumor-
specific T-cell responses and express high levels of the Treg-associated molecules cytotoxic 
T lymphocyte-associated antigen 4 (CTLA-4) and glucocorticoid-induced tumor necrosis 
factor receptor (GITR). In this study, we have evaluated the capacity of GITR-ligation, CTLA-
4-blockade and a combination of both treatments to alleviate immunosuppression mediated 
by Ti-Treg. Using ex vivo isolated cells from individuals with hepatocellular carcinoma (HCC) 
or liver metastases from colorectal cancer (LM-CRC) we show that treatment with a soluble 
form of the natural ligand of GITR (GITRL), or with blocking antibodies to CTLA-4, reduces 
the suppression mediated by human liver tumor-infiltrating CD4+Foxp3+ Treg, thereby 
restoring proliferation and cytokine production by effector T cells. Importantly, combined 
treatment with low doses of both molecules exhibited stronger recovery of T cell function 
compared with either treatment alone. Our data suggest that in patients with primary and 
secondary liver cancer both GITR-ligation and anti-CTLA-4 mAb can improve the anti-tumor 
immunity by abrogating tumor-infiltrating Treg mediated suppression. 
Keywords: Hepatocellular carcinoma (HCC), liver metastases from colorectal cancer (LM-
CRC), regulatory T cells (Treg), cytotoxic T lymphocyte-associated antigen 4 (CTLA-4) and 
glucocorticoid-induced tumor necrosis factor receptor (GITR). 
 
 
 
 
 
 
 
 
 
This work was supported by grants to D.S. (Erasmus MC Fellowship) and A.P.-G. (Erasmus 
MC Grant 2011) from Erasmus MC. 
Chapter 2 
- 23 - 
 
Introduction 
Hepatocellular carcinoma, the sixth most frequent tumor in the world 1 and the third most 
common cause of cancer-related death, 2 is an aggressive tumor with poor prognosis. HCC 
accounts for most of primary liver malignancies. However colorectal cancer (CRC), the third 
most common cancer worldwide, commonly metastasizes to the liver, which is the leading 
cause of CRC mortality. 3, 4 The current therapeutic options for HCC and liver metastasis 
from CRC (LM-CRC) include surgery (resection and liver transplantation) and local (ablative) 
therapy. Unfortunately, less than 20% of HCC patients are eligible for curative procedures 5 
because most of them have advanced disease at the time of diagnosis. Furthermore, over 
50% of LM-CRC patients that undergo surgery develop recurrence within 2 years. 6, 7 
Chemotherapy has showed limited efficacy and provides a survival advantage of only 2.3-2.8 
months in advanced HCC. 8, 9 An attractive alternative to these current therapeutic options is 
immunotherapy, which is based on the sensitivity, specificity and memory of the immune 
system. However, immune regulation in the liver and tumor environment may contribute to 
tumor outgrowth and limit the efficacy of immunotherapeutic strategies. 10, 11 In support of this 
we and others have described the presence of regulatory CD4+Foxp3+ T cells in liver 
tumors, that suppress local anti-tumor immunity and that are associated with poor patient 
prognosis. 12-16 Liver Ti-Treg are characterized by high expression of glucocorticoid-induced 
tumor necrosis factor receptor related gene (GITR), cytotoxic T lymphocyte-associated 
antigen 4 (CTLA-4) and inducible T cell co-stimulator (ICOS). 12 These molecules are 
important for the immunosuppressive function of Treg and can be targets for 
immunotherapeutic interventions. Abrogation of Ti-Treg function may allow the induction of 
anti-tumor immunity at the tumor site and improve the outcome of immunotherapy aimed to 
activate anti-tumor responses. In advanced melanoma, CTLA-4-blocking has demonstrated a 
survival advantage 17, 18 and CTLA-4-blockade was shown to induce antiviral immunity in 
HCC-patients infected with hepatitis C virus (HCV). 19 However, only limited tumor-responses 
were reported, emphasizing the need to improve this strategy. Combining several candidate-
immunomodulators may achieve synergistic immunoregulatory activity.  
In this study we have evaluated ex vivo the capacity of GITR-ligation, CTLA-4-blockade and 
a combination of both to alleviate immunosuppression mediated by Ti-Treg isolated from 
patients with primary and secondary liver cancer. 
Results 
GITR+CTLA-4+ Treg accumulate in liver tumors and have an increased suppressive 
capacity  
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In order to confirm our previous finding showing that activated CD4+Foxp3+Treg are 
sequestered at the liver tumor site, we analyzed Treg in lymphocytes isolated from fresh liver 
tumors, tumor-free liver (TFL) tissues, and peripheral blood (PB) in a new cohort of HCC and 
LM-CRC patients by flow cytometry. Treg were present in all the three compartments 
analyzed, but were significantly more concentrated in the tumor areas compared with TFL (p 
= 0.0004) and blood (p < 0.0001) (Fig. 1A). We also corroborate in this new cohort that Ti-
Treg are more suppressive than circulating Treg by analyzing their impact on T cell 
proliferation of autologous CD4+CD25- T cells stimulated with CMV-activated dendritic cells 
(DC). Ti-Treg showed a stronger suppression of T cell proliferation compared with blood Treg 
(p = 0.0005) (Fig. 1B). In addition, we analyzed the surface expression level of GITR and 
intracellular expression of CTLA-4 (Figure 1C). GITR expression was significantly higher on 
tumor Treg than on Treg isolated from TFL (p = 0.0005) and blood (p = 0.0002). Tumor Treg 
were also distinguishable from blood and TFL Treg by their elevated intracellular expression 
of CTLA-4, which is a key negative regulator of T-cell activation (p = 0.0004 and 0.0018 
respectively). Moreover, we found that a big proportion of Ti-Treg expressed both molecules, 
in contrast with blood or TFL derived Tregs that have a very low proportion of double positive 
cells (Figure 1D). Thus, Ti-Treg derived from liver tumors express high levels of GITR and 
CTLA-4 and have an enhanced suppressive capacity. 
GITR engagement reduces suppressive capacity of Ti-Treg  
Soluble GITRL (sGITRL) was able to lower T cell suppression by Ti-Treg derived from liver 
tumors of patients with HCC or LM-CRC (Figure 2). CD4+CD25- effector T cells proliferated 
robustly in response to autologous DC activated with CMV. This proliferative response, as 
well as the production of TNFα was not affected by the addition of 10 or 20 µg/ml of sGITRL. 
However, GITRL induced an increased amount of IFNγ suggesting a limited direct effect on 
CD4+CD25- T cells. CMV-specific T cell proliferation and cytokine production were inhibited 
by Ti-Treg derived from both groups of patients (Figure 2A). Importantly, the addition of 10 
µg/ml of sGITRL significantly reduced the suppression mediated by Ti-Treg on CMV-specific 
T cells, recovering both T-cell proliferation (57 ± 17 % vs 69 ± 20 % proliferating CD4+ T 
cells, p = 0.0005) and cytokine production by proliferating cells (TNFα: 42 ± 25 % vs 63 ± 28 
%, p < 0.0001; IFNγ: 44 ± 24 % vs 80 ± 37 %, p = 0.0001) (Figure 2A-B). However, 10 µg/ml 
of sGITRL did not abrogate suppression of T cell proliferation completely, and a higher dose 
of sGITRL (20 µg/ml) could not further restore antigen-specific T cell proliferation nor 
cytokine production (Figure 2 A-B), and induced T cell death instead in most patients 
investigated (data not shown). Thus, sGITRL is able to partially decrease T cell suppression 
mediated by Ti-Treg isolated from liver cancer patients. 
Chapter 2 
- 25 - 
 
CTLA-4 blockade prevents T cell suppression mediated by Ti-Treg in a dose-
dependent manner  
To address the impact of CTLA-4 in the suppression mediated by Ti-Treg we used a 
neutralizing antibody for CTLA-4 in our in vitro model of T cell proliferation. The anti-CTLA-4 
antibody at a concentration of 10 µg/ml did not affect T cell proliferation or TNFα and IFN 
production in the absence of Treg, however treatment with 20 µg/ml of anti-CTLA-4 antibody 
induced an increase in the production of IFNγ (Figure 3B), suggesting a direct effect of this 
antibody on CD4+CD25- effector T cells at this concentration. Anti-CTLA-4 treatment 
reduced the suppression mediated by Ti-Treg in a dose-dependent manner (Figure 3A). 
Recovery of T cell function was observed in both T-cell proliferation (52.8 ± 22.5 % when Ti-
Treg were present vs 69.3 ± 23 % in the presence of Ti-Treg and 10 µg/ml of anti-CTLA-4, p 
= 0.008, vs 78.6 ± 19.9 % with 20 µg/ml of anti-CTLA-4 antibody, p = 0.008) and cytokine 
production by proliferating cells (TNFα: 43 ± 23 % in the presence of Ti-Treg vs 67 ± 18 % 
with Ti-Treg and 10 µg/ml of anti-CTLA-4 antibody, p = 0.025, and 83 ± 42 % with Ti-Treg 
and 20 µg/ml of anti-CTLA-4 antibody, p = 0.008; IFNγ: 44 ± 26 % vs 59 ± 33 %, p = 0.48, vs 
101 ± 69 %, p = 0.014, respectively) (Figure 3 A-B). Because T cell proliferation was not 
recovered completely with 20 µg/ml of anti-CTLA-4 antibody, as opposed to (near) full 
recovery of cytokine production, we were interested in investigating the effect of increasing 
the concentration of anti-CTLA-4 antibody further. Therefore, another set of antibody 
blocking experiments was performed with 40 and 80 µg/ml of anti-CTLA-4 antibody, which 
showed that higher concentrations of the neutralizing antibody for CTLA-4 resulted in 
complete recovery of T cell proliferation (Figure 4). 
GITRL and anti-CTLA-4 antibody combination additively abolish T cell suppression 
mediated by Ti-Treg  
We next asked whether a low dose of GITRL combined with a low dose of neutralizing anti-
CTLA-4 antibody could fully recover T cell function in the presence of Ti-Treg. Blood derived 
CFSE-labeled CD4+CD25- stimulated with autologous DC activated with CMV were cultured 
in the presence of Ti-Treg and treated with 10 µg/ml of GITRL and anti-CTLA-4 antibody, 
either as monotherapy or in combination. Monotherapy with GITRL or anti CTLA-4 antibody 
induced partial recovery of T cell proliferation and cytokine production as observed in the 
experiments mentioned above (Figure 5, 2 and 3). In comparison with the effect of each 
treatment alone, the combination of low doses of anti-CTLA-4 and GITRL resulted in marked 
enhancement of T cell proliferation and cytokine production (Figure 5 A-B). Importantly, the 
combination of low doses of both molecules provided similar effects as those observed with a 
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high dose of anti-CTLA-4 antibody, restoring T cell proliferation and TNFα production 
completely.  
Combination of GITRL and anti-CTLA-4 antibody restored tumor-specific T cell 
response.  
To investigate whether the combination of GITRL and anti-CTLA-4 antibody is able to 
reestablish tumor-specific T cell responses, we used blood derived CFSE-labeled 
CD4+CD25- T cells stimulated with DC cultured with Tumor Lysates (TL-DC). Cells were co-
cultured in the presence of Ti-Treg and treated with 10 µg/ml of GITRL and 10 µg/ml of anti-
CTLA-4 antibody. All cell types and the TL were autologous. After one week of culture we 
observed that Ti-Treg suppressed efficiently cell proliferation and cytokine production of T 
cells against TL (Figure 6). However when the cells were treated with both GITRL and anti-
CTLA-4 antibodies the tumor specific response can be completely restored. 
Discussion 
New treatment modalities are required to prolong survival in patients with liver cancer. 
Immunotherapy is an attractive option for HCC patients and patients with liver metastasis of 
CRC because increasing evidence suggests that immune responses play an important role 
in the control of these types of cancer. It has been reported that the composition of the tumor 
infiltrating lymphocytes (TILs) is associated with the prognosis of both diseases, for example 
increased numbers of Treg are correlated with disease progression 20-24 and recurrence. 25 
Furthermore Treg frequencies have been associated with increased numbers of intra-tumoral 
macrophages, 13, 26 circulating myeloid-derived suppressor cells (MDSC), 27 and with a 
compromised CD8 T cell response. 14, 15 Altogether these observations suggest that 
depletion or inhibition of Treg and concomitant stimulation of effector cells may be effective 
to reduce recurrence and prolong survival in patients with liver cancer. Indeed, depletion of 
CD25+ T cells in patients or animals models can result in induction of tumor-specific 
responses. 28, 29 Moreover, in a small clinical trial in advanced HCC patients, treatment with 
low doses of cyclophosphamide resulted in reduced numbers of Treg and unmasking of 
circulating tumor-specific CD4+ T cell responses. 30  
We previously reported the presence of highly activated CD4+Foxp3+ Treg in liver tumors of 
individuals with HCC or LM-CRC. 12 These tumor-infiltrating Treg are characterized by the 
expression of high levels of GITR and CTLA-4, which are important molecules for their 
regulatory function and which can be targets for immunotherapy. 12, 16 GITR activation by its 
ligand acts as a co-stimulatory molecule for effector T cells that confers them less 
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susceptible to Treg mediated suppression, whereas engagement of GITR expressed by Treg 
transiently inhibits their suppressive capacity (reviewed in 31). The GITR agonist antibody 
DTA-1 represents a very effective antitumor therapy in murine tumor models by increasing 
antitumor CD4+ and CD8+ T-cell effector functions as well as destabilizing and causing 
apoptosis of Tregs in the tumor microenvironment. 32, 33 Importantly, our findings support a 
role for GITR engagement as (part of) an immunotherapy for liver cancer patients, since 
treatment with sGITRL reduced Treg mediated inhibition of T cell functions. However, the 
observed effect was only partial and could not be enhanced by dose escalation. Indeed, a 
high dose of sGITRL had a cytotoxic effect on effector T cells in our in vitro system. In 
preclinical animal models, treatment with agonistic antibodies for GITR has been shown to 
cause anaphylaxis upon repeated doses. 34 These observations warrant careful design and 
dosing strategies of drugs engaging GITR to prevent serious side effects during 
immunotherapy for patients with liver tumors.  
On the other hand, CTLA-4 is constitutively expressed at high levels in CD4+Foxp3+ Treg 
and is a negative regulator of T-cell activation. By binding the B7 molecules CD80 and CD86, 
CLTA-4 reduces the T-cell stimulatory capacity of antigen-presenting cells such as dendritic 
cells (DC). 35 Therefore, by using monoclonal antibodies (mAb) which block CTLA-4, it is 
possible to alleviate inhibition of DC function by Treg and thereby restore conventional T-cell 
proliferation after activation. 36 Recent studies have demonstrated that anti-CTLA-4 mAb 
administration augments clinical anti-tumor responses and improves survival in patients with 
metastatic melanoma 18, 37 resulting in FDA approval of Ipilimumab, an anti-CTLA-4 antibody, 
for the treatment of unresectable or metastatic melanoma. The promising clinical activity of 
anti-CTLA-4 mAb in melanoma encourages to explore its therapeutic applicability in other 
malignancies, especially because it does not require specific targets expressed on tumor 
cells. However, there is scarce evidence for efficacy in liver cancer. Only one clinical trial 
using the anti-CTLA-4 mAb tremelimumab in HCC patients infected with HCV has been 
conducted, but it showed a partial tumor response in merely 17% of patients. 19 Even though 
the clinical response was limited, the results point to a potential use for anti-CTLA-4 mAb in 
immunotherapeutic regimens for these patients. In our study 20 µg/ml of anti-CTLA-4 
antibody (BNI3) showed a 60% recovery of T cell proliferation, whereas a concentration of 10 
µg/ml only provided a recovery of 35% of T cell proliferation. Higher doses were able to 
recover T cell functions completely. However, therapy with anti-CTLA-4 mAb ipilimumab has 
induced life-threatening adverse events, 17, 38, 39 which is a major limitation in exploring higher 
doses for the treatment. The current clinically approved dosing for anti-CTLA-4 antibody 
(Ipilimumab) is 3 mg/kg which results in a steady state serum concentration (Cmin) of about 
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10 µg/ml, 18, 40 and an overall response rate of 4% in patients with advanced melanoma with 
3% of patients experiencing severe immune-related adverse events. A higher dose of 
Ipilimumab of 10 mg/kg (Cmin 32 µg/ml) showed a better response rate of 11% but also 
higher frequency (15%) of severe adverse events. 18  
Based upon results from murine models, it has previously been suggested that GITR 
stimulation and CTLA-4 inhibition can be combined to enhance the induction of immune 
responses and might even work synergistically. 41 Importantly, combination of low doses of 
anti-CTLA-4 antibody and GITRL resulted in a complete recovery of in vitro T cell 
proliferation and TNFα production. Even though the mechanisms by which these molecules 
exert their immunomodulatory effects is still elusive, it has been suggested that they can act 
either by abrogating the immunosuppressive function of Treg or by rendering effector T cells 
resistant to Treg mediated suppression. In our experiments we observed that both molecules 
had limited direct effects on effector T cells, only inducing an increase in the production of 
IFN, but this effect was not evident for TNFα and T cell proliferation, suggesting that both 
mechanisms can play a role in abrogation of the suppression mediated by Ti-Treg. It remains 
to be seen whether combination therapy of anti-CTLA-4 mAb and GITRL has a more 
beneficial safety profile compared to treatment with a high dose of either compound alone, 
but our data show that the combination of both treatments at low doses exhibited stronger 
inhibition of ex vivo Treg-mediated suppression compared with either treatment alone, 
suggesting that this combination may be more effective to induce anti-tumor immunity in 
patients with liver cancer.  
In conclusion our data suggest that in patients with primary and secondary liver cancer both 
GITR-ligation and anti-CTLA-4 mAb can improve antigen-specific T cell responses in the 
tumors by protecting against tumor-infiltrating Treg mediated suppression of their function. 
However, as part of an immunotherapeutic strategy, combining low doses of both drugs may 
be at least as effective as monotherapy with higher doses of either of the drugs.  
Materials and Methods 
Patients 
Between June 2011 and November 2013 a total of 28 individuals who were eligible for 
surgical resection of HCC (n=10) or LM-CRC (n=18) were enrolled. Paired samples of fresh 
liver tumor tissue and tumor-free liver tissue (TFL) obtained at the maximum distance from 
the tumor (>1cm), were used for isolating tumor-infiltrating lymphocytes (TILs) and intra-
hepatic lymphocytes. In addition, peripheral blood was collected. None of the patients was 
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treated with chemotherapy or radiation prior to resection. The clinical characteristics of the 
patients are summarized in table 1. The study was approved by the local ethics committee 
and all patients in the study gave informed consent before tissue donation. 
Cell preparation 
Peripheral blood mononuclear cells (PBMC) were isolated by Ficoll density gradient 
centrifugation. Single cell suspensions from TFL and tumor tissue were obtained by tissue 
digestion. Fresh tissue was cut into small pieces and digested with 0.5 mg/ml of collagenase 
(Cat. C5138, Sigma-Aldrich) and 0.2 mg/ml of DNase I (Cat. 10104159001, Roche), for 30 
minutes at 37 ºC. Cell suspensions were filtered through 100 and 70 µm pore cell-strainers 
(BD, biosciences) and mononuclear cells (MNC) were obtained by Ficoll density gradient 
centrifugation. Viability was determined by trypan blue exclusion. 
Flow cytometry analysis 
PBMC and MNC isolated from TFL or tumor tissue were analyzed for expression of surface 
and intracellular markers using the following anti-human antibodies: PE-labeled anti-IFN 
(B27, BD Biosciences) and anti-CD25 (BC96) from ebiosciences; APC-labeled anti-FoxP3 
(236A/E7) and anti-TNFa (Mab11) from e-biosciences; APC-H7-labeled anti-CD4 (SK3, BD 
Biosciences); PeCy7-labeled anti-CD3 (UCTH1); eFluor®450-labeled anti-CD127 
(eBioRDR5) from e-biosciences. Cells were incubated with the antibodies 10 min at room 
temperature in the dark, then washed and fixed with 1% paraformaldehyde. For intracellular 
cytokine staining, cells were permeabilized using the BD Cytofix/cytoperm 
fixation/permeabilization kit, and for FoxP3, cells were treated with the FoxP3 staining buffer 
set from e-biosciences. Dead cells were excluded by using the LIVE/DEAD fixable dead cell 
stain kit with aqua fluorescent reactive dye (Invitrogen). Cells were analyzed using a 
FACSCanto II system (BD Biosciences).  
Suppression assay 
Myeloid dendritic cells (mDC) were isolated from PBMC by positive selection (BDCA-1 DC 
isolation kit, Cat. 130-090-506, Miltenyi Biotec). mDC were cultured overnight with 10 µg/ml 
of Cytomegalovirus antigens (CMV, Cat. EL-01-02, Microbix biosystems, Canada). 
Autologous CD4+CD25- cells were isolated from PBMCs that were kept overnight at 4 ºC in 
medium supplemented with 10% of bovine fetal serum, by magnetic sorting (Cat. 130-091-
301, Miltenyi Biotec). CD4+CD25- T cells were labeled with 0.1 µM of carboxyfluorescein 
diacetate succinimidyl ester (CFSE, C34554, Invitrogen) and co-cultured with the autologous 
mDC activated with CMV, at a ratio of 1 to 10 for 5 days in round-bottom 96-well plates with 
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at least 5 x 104 CD4+CD25- T cells. Proliferation was measured by dilution of CFSE. 
CD4+CD25+ Treg were isolated by magnetic sorting as previously described. 12 Treg were 
added at 1:5 ratio versus CD4+CD25- T cells, and co-cultured for 5 days. Treg were labeled 
with CellTrace Violet (Invitrogen) in order to be excluded from proliferating T cells. 12 
Furthermore, after co-culture T cells were re-stimulated overnight with autologous monocyte-
derived DC activated with CMV, in the presence of brefeldin A and monensin (BD 
Biosciences). Proliferation and cytokine production were analyzed by flow cytometry and 
reported as relative proliferation or relative cytokine production where the numbers of 
proliferating and cytokine-producing cells induced by CMV-DCs were considered 100%. In 
some experiments azide-free and low endotoxin soluble GITRL (R and D systems, Cat. 
6987-GL/CF), anti-CTLA-4 neutralizing (BNI3, Beckman Coulter, Cat. IM2070) or isotype 
control (IgG2a, Biolegend) antibodies were added to the co-cultures. Monocyte-derived DC 
were obtained by culturing monocytes with 10 ng/ml IL-4 and 50 ng/ml GM-CSF for 5 days, 
then immature DC were activated with CMV as described previously for mDC. 
Tumor-specific T cell proliferation and suppression assay 
Tumor lysates (TL) were generated from freshly dissected tumors by five cycles of freezing 
and thawing in phosphate buffered saline, followed by filtration (0.2 μm). mDC isolated from 
PBMC were cultured overnight with media or 20 μg/mL of autologous TL in the presence of 
10 ng/mL of granulocyte-macrophage colony-stimulating factor (GM-CSF) (Miltenyi Biotec) 
and 0.5 μg/mL of polyinosinic:polycytidylic acid (InvivoGen, San Diego, CA). CD4+CD25- 
cells were isolated from PBMC that were kept overnight at 4ºC in medium supplemented with 
10% of bovine fetal serum, by magnetic sorting (Miltenyi Biotec). CD4+CD25- T cells were 
labeled with 0.1 μM of CFSE (Invitrogen) and co-cultured with autologous mDC cultured with 
media or TL, at a ratio of 1:10 for 5 days in round-bottom 96-well plates with at least 5 x 104 
CD4+CD25- T cells. Proliferation was measured by dilution of CFSE. CD4+CD25+ Treg were 
isolated by magnetic sorting as described above. Treg were added at 1:5 ratio versus 
CD4+CD25- T cells, and co-cultured for 5 days. Treg were labeled with CellTrace Violet 
(Invitrogen) in order to be excluded from proliferating T cells. Furthermore, after co-culture T 
cells were re-stimulated by PMA (40ng/mL) and ionomycin (1μg/mL) for 5 hours in the 
presence of Brefeldin (Sigma, 5μg/mL) during the last 4 hours. Proliferation and cytokine 
production were analyzed by flow cytometry and reported as fold increase of specific T cell 
proliferation or cytokine production, calculated by dividing the percentage of proliferation or 
cytokine production (TNFα or IFN) in the TL condition by that in the control condition (media 
cultured DC). In all three experiments soluble GITRL (R and D systems, 10 μg/mL), 
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neutralizing anti-CTLA-4 (BNI3, Beckman Coulter, 10 μg/mL) or isotype control (IgG2a, 
Biolegend, 10 μg/mL) antibodies were added to the co-cultures.  
Statistical analysis 
All data set distributions were analyzed for normality using the Shapiro-Wilk normality test. 
The differences between paired groups of data were analyzed according to their distribution 
by either paired t-test or Wilcoxon matched pairs test using GraphPad Prism Software 
(version 5.0). P-values less than 0.05 were considered statistically significant (*P<0.05; 
**P<0.01; ***P<0.001). 
 
Table 1: Patient characteristics 
  
 
  
  
    
HCC (n=10) LM-CRC (n=18) 
Sex (male/female) 8 / 2 12 / 6 
Age (years) 55.1 ± 6.8 67.4 ± 1.9 
Race (Caucasian/Asian/African) 9 / 0 / 1 18 / 0 / 0 
ALT (units/L) 48.2 ± 8.6 27.9 ± 3.6 
Bilirubin (µmol/L) 14.0 ± 4.5 8.7 ± 3.4 
Prothrombin time (INR) 1.2 ± 0.03 1.0 ± 0.01 
Liver fibrosis (metavir score)  
9 / 0 / 1 18 / 0 / 0 
F0-F1 / F2 / F3-F4-cirrhosis 
Stage of disease (TNM) 
St I n=7  
St IVa n=18 
St II n=3 
 
Etiology of liver disease in HCC patients: 6 no known liver disease, 1 hemochromatosis, 1 
porphyria, 1 hepatitis B virus, 1 cirrhosis ECI 
INR= international normalized ratio 
  Where applicable: mean ±SEM 
   
 
Chapter 2 
- 32 - 
 
Figure legends 
Figure 1. Tumor-infiltrating Treg are potent suppressors of T cell responses, and they 
are characterized by the expression of higher levels of CTLA-4 and GITR. (A) The 
proportions of Treg (CD3+CD4+CD25+FoxP3+) among CD4 T cells were analyzed by flow 
cytometry in tumor, tumor-free liver tissue (TFL) and peripheral blood from patients with HCC 
or LM-CRC. Differences were analyzed by Wilcoxon matched pairs test. (B) CFSE-labeled 
CD4+CD25- T cells from PB were stimulated with autologous CMV-activated mDC (CMV-
DC) for 5 days. Autologous blood or tumor derived Treg from HCC-patients or LM-CRC 
patients were added in a ratio 1:5. Inhibition of T cell proliferation by Treg was determined by 
flow cytometry and reported as percentage of suppression of T cell proliferation. Data 
analyzed by paired t-test. (C) Differential expression of surface GITR and intracellular CTLA-
4 was measured on Treg present in blood, TFL and tumor tissue. Differences were analyzed 
by Wilcoxon matched pairs test for GITR and by paired t-test for CTLA-4. (D) FACS analysis 
of the co-expression of CTLA-4 and GITR by Treg from blood, TFL and tumor tissue. One 
representative patient and the collective data analyzed by Wilcoxon matched pairs test. HCC 
(closed symbols) or LM-CRC (open symbols). Values are also depicted as means ± SEM. *p 
< 0.05, **p < 0.01, ***p< 0.001. 
Figure 2. GITR engagement partially abrogates suppression mediated by tumor-
infiltrating Treg. CD4+CD25- effector T cells were isolated from peripheral blood and 
labeled with CFSE, and co-cultured during 5 days with autologous mDC activated with CMV 
antigens. Autologous tumor Treg from HCC-patients (closed symbols) or LM-CRC patients 
(open symbols) were added in the absence or presence of different concentrations of soluble 
GITRL (sGITRL). T cell proliferation (A) and cytokine (IFNγ and TNFα) production by 
proliferating cells (B) were measured by flow cytometry after re-stimulation with CMV-
activated Mo-DC. Values are also depicted as means ± SEM, *p < 0.05, **p < 0.01, ***p< 
0.001. Differences were analyzed by paired t-test. 
Figure 3. CTLA-4 blockage decreases T cell suppression mediated by tumor-
infiltrating Treg in a dose dependent manner. CFSE-labeled CD4+CD25- T cells isolated 
from PB were stimulated with autologous CMV-DC and cultured with autologous tumor 
derived Tregs from HCC-patients (closed symbols) or LM-CRC (open symbols) in the 
absence or presence of 10 or 20 ug/ml of blocking anti-CTLA-4 mAb or an irrelevant isotype 
control antibody. Cell proliferation (A) and cytokine production by proliferating cells (B) were 
analyzed by flow cytometry after re-stimulation with CMV-activated Mo-DC. Values are also 
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depicted as means ± SEM, *p < 0.05, **p < 0.01, ***p< 0.001. All data were analyzed by 
paired t-test. 
Figure 4. High doses of anti-CTLA-4 mAb can completely abrogate T cell suppression 
mediated by tumor-infiltrating Treg. The effect of higher doses of anti-CTLA-4 mAb on 
Treg-mediated suppression was tested using lymphocytes isolated from three different LM-
CRC patients. T cell proliferation analysis revealed that higher doses of the neutralizing anti-
CTLA-4 antibody are able to completely abolish the suppression mediated by tumor-
infiltrating Treg.  
Figure 5. GITRL and CTLA-4 blockage additively abolish T cell suppressive capacity of 
tumor-infiltrating Treg. Blood-derived CFSE-labeled CD4+CD25- T cells from HCC-patients 
or LM-CRC patients were co-cultured with autologous CMV-DC for 5 days. Autologous tumor 
derived Treg were added in a ratio 1:5. Cells were treated with 10 µg/ml of anti-CTLA-4 mAb 
or GITRL or a combination of both. Cell proliferation and cytokine production were analyzed 
by flow cytometry after re-stimulation with CMV-activated Mo-DC. (A) Depicts a 
representative experiment showing T cell proliferation, IFNγ and TNFα production after co-
culture and re-stimulation. (B) Collective data of five patients tested (three LM-CRC and two 
HCC) showing the relative T cell proliferation or cytokine production (IFNγ and TNFα) by 
proliferating cells. Values are means ± SEM, *p < 0.05, **p < 0.01, ***p< 0.001. Comparison 
between groups was made by paired t-test. 
Figure 6. Treatment with GITRL and anti-CTLA-4 antibody can recover ex vivo anti-
tumor T-cell immunity. Blood mDC activated with autologous TL were used to stimulate 
CFSE-labeled autologous peripheral CD4+CD25- T cells for one week. In some cultures 
autologous Ti-Treg were added and cells were treated with 10 µg/ml of an isotype control 
antibody or with a mixture of 10 µg/ml of GITRL and 10 µg/ml of anti-CTLA-4 antibody. T cell 
proliferation and cytokine production were analyzed by flow cytometry after re-stimulation 
with PMA and ionomycin. Proliferation and cytokine production are reported as fold increase 
of specific T cell proliferation or cytokine production, calculated by dividing the percentage of 
proliferation or cytokine production (TNFα or IFN) in the mDC + TL condition by that in the 
control condition without TL (medium DC). (A) A representative analysis from one patient and 
(B) Collective data from three different patients tested. HCC (closed symbols) or LM-CRC 
(open symbols). 
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Figure 3.   
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ABSTRACT 
CD4+ type 1 T regulatory (Tr1) cells have a crucial role in inducing tolerance. Immune-
regulation by these cells is mainly mediated through the secretion of high amounts of IL-10. 
Several studies have suggested that this regulatory population may be involved in tumor-
mediated immune-suppression. However, direct evidence of a role for Tr1 cells in human 
solid tumors is lacking. Using ex vivo isolated cells from individuals with hepatocellular 
carcinoma (HCC; n=39) or liver metastases from colorectal cancer (LM-CRC; n=60) we 
identify a CD4+FoxP3-IL-13-IL-10+ T cell population in tumors of individuals with primary or 
secondary liver cancer that is characterized as Tr1 cells by the expression of CD49b and the 
lymphocyte activation gene 3 (LAG-3) and strong suppression activity of T cell responses in 
an IL-10 dependent manner. Importantly, the presence of tumor-infiltrating Tr1 cells is 
correlated with tumor infiltration of plasmacytoid dendritic cells (pDCs). pDCs exposed to 
tumor-derived factors enhance IL-10 production by Tr1 cells through up-regulation of the 
inducible co-stimulatory ligand (ICOS-L). These findings suggest a role for pDCs and ICOS-L 
in promoting intra-tumoral immunosuppression by Tr1 cells in human liver cancer, which may 
foster tumor progression and which might interfere with attempts of immunotherapeutic 
intervention.  
Keywords: Hepatocellular carcinoma; colorectal cancer liver metastasis; ICOS-L; IL-10; 
Immunotherapy, Tr1 cells.  
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Introduction 
The two most common types of cancer affecting the liver are HCC and LM-CRC. 1, 2 For the 
majority of patients curative treatments are not available and alternative treatments like 
immunotherapy have so far shown limited efficacy. 3, 4 One of the main obstacles for 
immunotherapy is the immunosuppressive environment within tumors. 5, 6 In support of this, 
we recently described the accumulation of CD4+FoxP3+ regulatory T cells (Tregs) that are 
potent suppressors of anti-tumor immunity at the tumor site of patients with liver cancer. 7, 8 
However, other types of inhibitory T cells may also be involved in local immunosuppression 
inside the tumor. 
Tr1 cells were initially described in individuals who developed long-term tolerance after 
allogenic transplantation. 9 Since then Tr1 cells have proven to be important in promoting and 
maintaining tolerance in autoimmunity, allergy and transplantation. 10 There is experimental 
evidence suggesting a putative role for Tr1 cells in tumor escape from immune surveillance. 
11, 12 However, the absence of a defined cell surface signature and the reliance on a cytokine 
profile to distinguish Tr1 cells from other T cell subsets complicated their identification and 
study. 9 It was shown that exposure of dendritic cells to tumor-derived factors favors the 
induction of Tr1-like cells from naïve CD4+ T cells. 13 Additionally, tumor-infiltrating 
lymphocytes (TILs) of patients with head and neck squamous cell carcinoma were shown to 
contain more Tr1 precursors than peripheral blood. 14 These findings suggest that this 
regulatory T cell population could be involved in tumor-mediated immune-suppression. 
However, direct evidence for the presence of Tr1 cells and their role in solid tumor 
development remained elusive. Now, using recently described surface markers for the 
identification of Tr1 cells, 15  we report that TILs in patients with liver cancer contain a subset 
of suppressive CD4+Foxp3- T cells with the phenotypic and functional characteristics of Tr1 
cells. In addition, we provide evidence suggesting that intra-tumoral immunosuppression by 
Tr1 cells is promoted by tumor-infiltrating pDCs. 
Results  
IL-10 producing CD4+Foxp3- T cells accumulate in human liver tumors 
In order to characterize the CD4+ T cell subsets present in liver tumors we compared pair 
wise the cytokine profile of CD4+ TILs isolated from individuals with HCC or liver metastasis 
from CRC (LM-CRC) to the cytokines produced by CD4+ T cells from the tumor-free area of 
the liver (TFL) and peripheral blood (Figure 1 and Supplementary Figure 1). Freshly isolated 
single cell suspensions were activated with PMA and Ionomycin in the presence of protein 
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transporter inhibitors and analyzed by flow cytometry. Compared to TFL and blood, CD4+ 
TILs contained significantly higher frequencies of IL-10-producing cells in both groups of 
patients (Figure 1A). In contrast, the frequencies of IFN, TNF and IL-13 producing CD4+ T 
cells were similar in TFL and tumors.  
To further characterize these IL-10-producing CD4+ T cells, we analyzed their expression of 
IL-13 and FoxP3, and we observed that the majority of IL-10+ cells did not produce IL-13 nor 
expressed FoxP3 (Figure 1B, C and D). These cells were also negative for IL-4 
(Supplementary Figure 1B). Therefore, only a minor proportion of tumor-infiltrating IL-10-
producing CD4+ T cells correspond to FoxP3+ Tregs or Th2 cells. Instead, the large majority 
of IL10-producing CD4+ T cells are FoxP3-negative and IL-13-negative, and these cells are 
enriched at the tumor site (Figure 1E). Moreover, an important proportion of these cells 
produced IFN without significant differences between blood, TFL and tumor (Supplementary 
Figure 1C). 
Tumor-infiltrating CD4+FoxP3-IL-10+ T cells are potent suppressors of T cell function in 
an IL-10 dependent mechanism 
To investigate the functional properties of tumor-infiltrating CD4+FoxP3-IL-13-IL-4-IL-10+ 
cells, we isolated CD4+CD25- T cells, which are FoxP3- (Supplementary Figure 2A), from 
TILs and activated them with antibodies to CD3 and CD46 16 or ICOS 17, two co-stimulatory 
molecules that have been described to stimulate IL-10 production (Supplementary Figure 
2B). Importantly, we activated these cells for only 24-48 hours to prevent de novo generation 
of IL10-producing cells from naïve T cells. Similar to what we had observed upon short-term 
stimulation with PMA and ionomycin, this stimulation also revealed higher proportions of 
IL10-producing CD4+ cells in tumor tissue than in TFL or blood, (Supplementary Figures 2C-
D). After activation IL-10+ cells were enriched by magnetic sorting (Supplementary figure 3). 
We investigated the immunosuppressive potential of tumor-infiltrating IL-10 producing 
CD4+CD25- T cells by assessing their capacity to suppress T-cell proliferation and cytokine 
production in vitro (Figure 2A, B). CFSE-labeled PBMCs from healthy donors were 
stimulated with PHA and co-cultured in the presence of the IL-10+ enriched fraction (IL-
10high) or the remaining fraction (IL-10low). Notably, both cell fractions suppressed proliferation 
and cytokine production of responder CD3+ T cells (Figure 2A, B), but the degree of 
suppression differed considerably. Whereas the IL-10low fraction suppressed moderately 
(20.4 ± 5.5 %; mean ± SE), the IL-10high fraction strongly suppressed T cell proliferation (60.2 
± 9.2 %, p=0.005). No difference in suppression between cells stimulated with CD46 or anti-
ICOS antibodies was observed (Supplementary Figure 3B). Similar findings were observed 
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in the setting of CMV-specific CD4+ T cell responses (Supplementary Figure 4). To 
investigate whether the suppression was mediated by IL-10, we administered a neutralizing 
anti-IL-10R antibody to the co-cultures. As expected, suppression by the high IL10 producing 
CD4+ T cells was prevented when IL-10R was blocked, in all patients tested (Figure 2C). 
Thus, these data show that liver tumors are infiltrated by IL-10 producing CD4+FoxP3- T 
cells which are potent suppressors of T cell responses in an IL-10 dependent manner. The 
limited suppression observed when the IL-10low fraction was added to the T-cell culture is 
likely a consequence of IL-10 producing cells remaining in this fraction after enrichment of 
the IL-10high fraction by magnetic sorting (Supplementary Figure 5A), and could also be 
blocked by neutralizing anti-IL-10R antibodies (data not shown). In support of this 
explanation, there is a positive correlation (p = 0.023) between the frequencies of IL-10+ 
cells present in the IL-10 high or low fractions obtained after magnetic sorting and their 
degree of T cell suppression observed in the co-cultures (Supplementary Figure 5B).  
Tumor-infiltrating CD4+FoxP3-IL-10+ T cells display phenotypic characteristics 
corresponding to Tr1 cells 
A recent study has identified that CD49b and LAG-3 are stably and selectively co-expressed 
on Tr1 cells. 15 Because Tr1 cells are functionally characterized by the production of high 
levels of IL-10 and T-cell suppressive capacity, we examined the expression of these 
markers on the tumor-infiltrating IL-10+CD4+ T cells that we described above. Notably, the 
liver tumor-infiltrating CD4+FoxP3- T cells that produced the highest amounts of IL-10 co-
expressed CD49b and Lag-3 (Figure 2D) and we observed that CD4+FoxP3-CD49b+LAG-3+ 
T cells were selectively enriched in the tumor bed in both types of liver tumors (Figure 2 E 
and F). Therefore, taken together we conclude that the majority of the CD4+FoxP3-IL-10 
producing cells infiltrating liver tumors correspond to Tr1 cells and that they are strongly 
immunosuppressive in an IL-10-dependent manner.  
Tumor-exposed pDCs promote immune suppression through activation of Tr1 cells 
Given that pDCs have been reported to prime CD4+IL-10-producing T regulatory cells 
through ICOSL, 18 and in ovarian 19, 20 and breast cancer 21 expand CD4+FoxP3+ Tregs, as 
well as stimulate production of IL-10 in these cells, we explored tumor infiltration of pDCs in 
our patients. We observed that pDCs infiltrate liver tumors (Figure 3A and supplementary 
figure 6A), and in both groups of patients liver tumors contained higher frequencies 
compared to TFL. We hypothesized that in liver tumors infiltrating pDCs may promote the 
differentiation and/or activation of tumor-infiltrating Tr1 cells, as has been observed for 
CD4+FoxP3+ Tregs. 22 Supporting this hypothesis, the frequencies of tumor-infiltrating pDCs 
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and those of Tr1 cells as determined by flow cytometry, showed a highly significant positive 
correlation (Figure 3B). Also, by immunohistochemistry analysis we observed co-localization 
of CD303+ pDCs and LAG-3+ cells in the tumor milieu of both types of liver tumors (Figure 
3C, D) which was substantiated by a significant positive correlation in co-localization 
(Pearson r = 0.78; p = 0.03) after counting multiple microscopic fields (200x magnifications, 2 
independent observers). Such correlation was absent in TFL (r = -0.2; p= 0.49), and 
moreover less LAG-3+ and CD303+ cells were detected by immunohistochemistry in TFL 
than in tumors (per microscopic field of 200x magnification: LAG-3+ cells 3.4 ± 1.0 versus 
6.6±1.9 (mean ± SEM); and CD303+ cells 1.2 ± 0.4 versus 5.3 ± 1.6). Furthermore, analysis 
of the expression of ICOS-L in total cell suspensions obtained from tumors of HCC and LM-
CRC patients demonstrated that the main cell population expressing this molecule 
corresponded to CD123+ pDCs (Figure 3E), while Tr1 in tumors express high levels of ICOS 
(Figure 2D). We therefore hypothesized that pDCs in liver tumors may induce or activate Tr1 
cells trough ICOSL in liver tumors. 
To test this hypothesis, pDCs isolated from blood of healthy donors were exposed to lysates 
of tumor or TFL and then used to stimulate autologous naïve CD4+ T cells. pDCs exposed to 
tumor lysates (TL-pDCS) up-regulated ICOS-L expression (Figure 4A), whereas TFL lysates 
(TFLL) induced a significant down-regulation of ICOS-L. In contrast, exposure of pDCs to 
tumor lysate or TFL lysate did not affect expression of the co-stimulatory molecule CD83 and 
CD86 was up-regulated only in TL-pDCs (supplementary figure 6B). pDCs induced Tr1 from 
naïve CD4+ T cells and stimulated IL-10 production in these cells (Figures 4B, C). 
Interestingly, in parallel with their increased expression of ICOS-L, TL-pDCs induced higher 
numbers of IL-10 producing CD4+FoxP3-CD49+LAG-3+ Tr1 cells from naïve CD4+ T cells 
compared to pDCs treated with TFL lysate (TFLL-pDCs)(Figure 4B), but their capacity to 
induce CD49b and LAG-3 expression did not differ significantly (Figure 4C). The ability of TL-
pDCs to promote IL-10 production by Tr1 cells was dependent on ICOS-ICOS-L co-
stimulation, as it was blocked by addition of a neutralizing antibody against ICOS-L (Figure 
4B). Furthermore, there is a positive correlation (r= 0.75, p = 0.006) between the level of 
expression of ICOS-L on pDCs after exposure to medium, TFLL or tumor lysate, and the 
frequency of IL-10-producing Tr1 cells induced in the co-culture (Figure 4D). In contrast, the 
expression of CD49b and LAG-3 was not affected by ICOS-L blocking (Figure 4C). Thus, 
ICOS-ICOSL signaling seems to be unnecessary for the induction of the Tr1 phenotype by 
pDCs, but it is critical for the production of IL-10.  
Discussion  
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At the time of diagnosis the majority of HCC patients are not candidates for curative therapy, 
and in CRC patients with liver metastasis there is a high rate of recurrence after treatment. 1, 
2 For these groups of patients immunotherapy aimed at stimulating the local anti-tumor 
immune response might present an attractive alternative. However, immunotherapeutic 
attempts have so far shown poor clinical responses and this might be related to the inhibition 
of tumor-specific immunity by immune regulatory mechanism present in the tumor 
microenvironment. 3, 8 Detailed insight into the complex nature of intra-tumoral immune 
regulation is essential for the design of immunotherapeutic strategies, and the findings of this 
study may contribute to development of such strategies. 
TILs in liver tumors are composed mainly of CD4+ T cells that are hypo-responsive to tumor 
antigens. 7 We previously showed that an important fraction of the CD4+ T cells in these 
tumors correspond to CD4+FoxP3+ Tregs that are potent suppressors of anti-tumor 
immunity. 7, 8 There is accumulating evidence for the role of CD4+Foxp3+ Tregs in the 
development and progression of cancer. 23, 24 Several studies have shown that the presence 
of increased numbers of these cells in different tumors contributes to the suppression of 
antitumor immunity and correlates to decreased survival. 23-26 Over the years, several types 
of Tregs have been identified (reviewed in 9). Whereas CD4+FoxP3+ Tregs are probably the 
best characterized Treg type, Tr1 cells were until recently a subset of T cells that lacked a 
defined cell surface signature, and could therefore only be characterized by the production of 
high levels of IL-10, low levels of IL-2, variable levels of IFN and the absence of IL-4 and 
absence of high and constitutive expression of FoxP3. 9 The reliance on a cytokine profile to 
distinguish Tr1 cells complicated their identification and study, since these cells are not the 
only T cell subset that secretes IL-10. Still, experimental evidence suggested that exposure 
of dendritic cells to tumor derived factors favors the induction of Tr1-like cells from naïve T 
cells, 13 arguing for a role of Tr1 cells in cancer immunology. Later on, in head and neck 
carcinoma a suppressive role for in vitro generated CD4+CD25-FoxP3lowIL-10+TGFb+ cells 
was described. 27 Moreover, in Hodgkin lymphoma the presence of CD4+CD25-IL-10+ 
regulatory T cells has been described 12 and more recently a study described the presence of 
CD4+FoxP3-CD127- regulatory T cells in blood and tumors from HCC patients. Although 
they did not show regulatory functionality of the tumor-infiltrating CD4+FoxP3-CD127- cells, 
the circulating phenotypically counterpart suppressed T cell responses through an IL-10-
dependent mechanism, 11 suggesting a Tr1-like cell type.  
However, until now direct evidence for a role of Tr1 cells in human solid tumors is lacking. 
The recent description of co-expression of CD49b and LAG-3 as markers that can 
specifically identify this population of cells, 15 enabled us to show that the majority of liver 
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tumor-infiltrating IL-10 producing CD4+ T cells consists of Tr1 cells and only a minor 
proportion corresponded to Th2 cells or FoxP3+ Tregs. Compared to TFL, higher numbers of 
these Tr1 cells are present in the liver tumors of both HCC-patients and metastatic CRC-
patients, indicating selective accumulation in the tumor tissues. In functional assays the 
tumor-infiltrating Tr1 cells demonstrated a potent suppressive activity mediated by IL-10. 
Therefore, these cells represent a suppressive population in the tumor environment 
potentially contributing to the impaired anti-tumor immunity observed in patients with liver 
cancer.  
Our data suggest that tumor-infiltrating Tr1 cells may be activated by pDCs present in the 
tumor microenvironment. Using immunohistochemistry analysis pDCs could be identified in 
the vicinity of Lag3+ cells. Lag3 may also be expressed on CD4+Foxp3+ Tregs 9, but by 
flow-cytometry we observed that on the average only  6% of HCC or LM-CRC-derived 
CD4+Foxp3+ Tregs express Lag3 (data not shown). Therefore, this co-localization, together 
with the correlation between the frequencies of tumor-infiltrating pDCs and Tr1 cells 
observed in flow cytometric analysis (Figure 3B), suggests a possible interaction between 
both cell types, but further experiments are needed to confirm this in situ interaction. 
Furthermore, the main population expressing ICOSL in tumor tissues are CD123+ pDCs. In 
vitro exposure of immature pDCs to tumor lysates, but not lysates of normal liver tissue, 
conditioned pDCs to up-regulate the expression of ICOS-L and induce the production of IL-
10 by Tr1 cells in a mechanism mediated by ICOS-ICOS-L signaling. There is substantial 
evidence suggesting that pDCs have a specialized role in the induction of peripheral 
tolerance by inducing IL-10-production by Tregs through ICOS-L-ICOS signaling. 18, 28 Both in 
breast and in ovarian cancer stimulation of CD4+FoxP3+ Tregs to produce IL-10 by pDCs 
has been described. 19, 22 Our results are consistent with a role for pDCs to stimulate IL10 
production by Tr1 cells in the tumor microenvironment of patients with liver cancer. 
Altogether these data suggest that ICOS co-stimulation represents a potential target for 
immunotherapeutic intervention, affecting tumor-specific immunosuppression mediated by 
both CD4+Foxp3+ Tregs and Tr1 cells.  
In summary, in patients with primary and secondary liver cancer we identified a population of 
tumor-infiltrating Tr1 cells that contributes to local immune suppression in an IL-10 
dependent manner. pDCs may drive intra-tumoral immunosuppression by these Tr1 cells by 
stimulating IL-10 production via ICOS-ICOS-L signaling. Consequently, as has been shown 
for CD4+FoxP3+ Tregs, 7, 29 Tr1 cells may inhibit anti-tumor immunity at the tumor site in liver 
cancer and thereby promote tumor development. This knowledge is critical for the design of 
new immunotherapeutic interventions for patients with liver cancer and other solid cancers in 
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which IL-10 producing CD4+ T cells are present, and blockade of the engagement of ICOS-
ICOS-L may provide alleviation of this intra-tumoral immunosuppressive mechanism. 
Patients and Methods 
Patients 
Between September 2009 and July 2013 a total of 99 individuals who were eligible for 
surgical resection of HCC (n=39) or LM-CRC (n=60) were enrolled. Paired samples of fresh 
liver tumor tissue and tumor-free liver tissue (TFL) obtained at the maximum distance (at 
least 1 cm) from the tumor, were used for isolating TILs and intra-hepatic lymphocytes. In 
addition, peripheral blood was collected. None of the patients was treated with chemotherapy 
or radiation prior to resection. The clinical characteristics of the patients are summarized in 
Table 1. The study was approved by the local ethics committee and all patients in the study 
gave informed consent before tissue donation. 
Cell preparation, flow cytometric analysis, antigen-specific T-cell activation, 
immunohistochemistry 
Detailed descriptions of these methods are provided in the Supplementary Information. 
Activation and isolation of IL-10-producing cells 
CD4+CD25- T cells were isolated from TILs of patients with liver cancer by magnetic sorting 
as previously reported. 7 Briefly, the non-CD4+ cells were removed by a magnetically labeled 
cocktail of antibodies followed by depletion of CD25+ cells (Cat. 130-091-301, Miltenyi 
Biotec). CD4+CD25- T cells were stimulated with Dynabeads that were coupled to anti-CD3 
(OKT-3, Cat. 314304, Biolegend) alone or in combination with anti-CD46 (TRA-2-10, 
Cat.352404, Biolegend) or anti-ICOS (ISA-3; Cat. 16-9948-82, ebiosciences) antibodies 
using the Dynabeads antibody coupling kit (Cat. 143.11D, Invitrogen). The bead to cell ratio 
was 0.5:1. Cells were cultured in the presence of 250 U/mL IL-2 (Cat. 130-097, Miltenyi 
Biotec) for 24-48 hrs. Then, cells were magnetically sorted into IL-10low and IL-10high fractions 
using the secretion assay-cell enrichment kit from Miltenyi (Supplementary Figure 2).  
Suppression assays 
The suppressive effect of IL-10 producing CD4+ T cells was assessed by co-culture with 
PBMCs from healthy donors that were labeled with 0.1 µM of carboxyfluorescein diacetate 
succinimidyl ester (CFSE, C34554, Invitrogen), and activated with 6 µg/mL of 
phytohemagglutinin (PHA, Remel-Thermo Fisher Scientific) for 5 days. The ratio of cells was 
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1:10 (Tr1:PBMCs) with at least 5 x 104 responder cells. Proliferation and cytokine production 
were measured by flow cytometry after re-stimulation with PMA/Ionomycin. Inhibition of T cell 
proliferation or cytokine production was determined by comparison with culture conditions 
without IL-10 producing CD4+ T cells, and reported as percentage of suppression of T cell 
proliferation or cytokine production. To analyze the role of IL-10 in the suppressive capacity 
of Tr1 cells, 30 ug/ml of neutralizing anti-IL-10R antibody (3F9 Cat. 308806) or isotype-
matched control antibody (both from Biolegend) were added to some co-cultures. 
In vitro activation and co-culture of pDCs and naïve T cells 
pDCs were enriched from PBMCs of healthy donors by positive immunomagnetic selection 
using anti-BDCA-4 antibodies (Cat. 130-090-532, Miltenyi Biotec). Purity of pDCs as 
determined by CD123 labeling was 92 ± 2.5 %. pDCs were seeded at 105 cells/well in 200 µl 
of sRPMI medium (details can be found in Supplementary Methods) with 10% human AB 
serum in the presence of 10 ng/ml of IL-3 (Cat. 130-093, Miltenyi Biotec). pDCs were 
cultured with medium alone or in the presence of liver tissue lysates (200 µg/ml of total 
protein). After 18 hrs pDCs were harvested and washed. Then pDCs were stained for 
phenotypic analysis or co-cultured in a ratio 1:5 with autologous naïve CD4+ T cells, which 
were purified with the naïve CD4 T cell enrichment kit from Stemcell technologies (Cat. 
19155). Cells were co-cultured for 7 days. Thereafter the cells were washed and re-
stimulated 5 hrs with PMA and Ionomycin. The immunophenotype of CD4+ T cells and their 
cytokine profile were measured by flow cytometry. Tissue lysates were prepared from freshly 
dissected paired TFL and tumor tissues by 5 cycles of freezing and thawing in PBS, followed 
by filtration (0.2 µm). The total protein level was determined by BCA assay (Thermo 
Scientific), and the lysates were stored at -80° C before use. To determine involvement of 
ICOS-L in activation of Tr1, 50 µg/ml neutralizing anti-ICOS-L antibody (MIH12, Cat. 16-
5889) or isotype-matched control antibody (both from e-Biosciences) were added to the co-
cultures. 
Statistical analysis 
The differences between paired groups of data were analyzed according to their distribution 
by either t-test or Wilcoxon matched pairs test. Differences between different groups of 
patients were analyzed by either t-test or Mann Whitney test, using GraphPad Prism 
Software (version 5.0). P-values less than 0.05 were considered statistically significant 
(*P<0.05; **P<0.01; ***P<0.001). 
   
Chapter 3 
- 53 - 
 
 
 
Chapter 3 
- 54 - 
 
Figure legends 
Figure 1. Accumulation of IL-10-producing CD4+FoxP3- T cells in liver tumors. PBMCs 
or MNCs isolated from tissues of HCC (n= 8-9) and LM-CRC (n= 5-14) patients were 
stimulated in vitro for 5 hours with PMA/Ionomycin in the presence of protein transport 
inhibitors. IFN, TNF, IL-13 and IL-10 were measured by intracellular staining by flow 
cytometry. (A) The percentages of cytokine-producing cells among total CD3+CD4+ T cells 
in blood, tumor-free area of the liver (TFL) and tumor. (B) IL-13 expression in viable tumor-
derived CD3+CD4+IL-10+ T cells of HCC and LM-CRC patients stimulated with 
PMA/Ionomycin. FoxP3 and IL-10 expression in CD3+CD4+ T cells isolated from HCC (C) or 
LM-CRC tumors (D). (E) Frequencies of CD4+CD3+IL-13-FoxP3-IL-10+ T cells among CD4+ T 
cells. Red dots correspond to HCC and blue open dots are for LM-CRC (displayed as LMC in 
graphs). Values are means ± SEM, *p < 0.05, **p < 0.01, ***p< 0.001.  
Figure 2. Tumor-infiltrating CD4+FoxP3-IL-10+ T cells are potent suppressors of T cell 
function and their phenotype corresponds to Tr1 cells. Tumor-infiltrating CD4+CD25- T 
cells were activated with anti-CD3/CD46 or anti-CD3/ICOS antibodies for 24-48 hrs, then 
stained for IL-10 and magnetically sorted into IL-10low and IL-10high fractions, which were both 
co-cultured at a 1:10 ratio with CFSE-labeled PBMCs from healthy donors stimulated with 
phytohemagglutinin (PHA) for 5 days. (A) T cell proliferation and TNF production measured 
by flow cytometry in PHA-stimulated PBMCs cultured alone or in the presence of IL-10low or 
IL-10high fractions of tumor infiltrating CD4+CD25- T cells. (B) Collective analysis of the 
percentages of suppression of T cell proliferation and TNF production from 8 patients. (C) 
Effect of blocking IL-10R on the suppressive capacity of CD4+IL-10high cells. Cells were 
cultured as described above in the presence of 30 g/ml of neutralizing anti-IL-10R antibody 
or an irrelevant isotype control antibody. (D) Expression of CD49b and LAG-3 on tumor-
infiltrating CD4+ T cells activated with antibodies to CD3 and ICOS for 24 hrs. Cells were 
gated on viable CD3+CD4+ T cells and FoxP3+CD127- Tregs were excluded from the 
analysis. Histograms show the expression of IL-10 and ICOS in different populations based 
on the expression of CD49b and LAG-3. (E) CD49b and LAG-3 expression in blood, TFL and 
TILs isolated from a representative patient with HCC. Cells were gated on viable 
CD3+CD4+FoxP3- T cells. (F) Collective percentages of CD49b+LAG-3+ cells within 
CD4+Foxp3- T cells in 21 patients analyzed (HCC n= 8 and LM-CRC n= 13). HCC (red dots) 
and LM-CRC (blue open dots).  
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Figure 3. Plasmacytoid DCs are enriched at the tumor site and correlate with the 
frequencies of Tr1 cells. (A) Percentages of pDCs (CD123+HLA-DR+LIN-) among CD45+ 
leukocytes from paired samples of TFL and tumor tissue from 78 patients tested (HCC = 27 
and LM-CRC = 51). Tumor leukocytes contain significantly higher numbers of pDCs than TFL 
(on the average 0.74 ± 0.6 % pDCs in HCC tumors and 1.01 ± 0.9 % in LM-CRC tumors, 
compared to 0.45 % and 0.75 ± 0.6 % in TFL, respectively). (B) Pearson correlation analysis 
between the frequencies of tumor-infiltrating pDCs and CD4+FoxP3-CD49b+LAG-3+ Tr1 
cells in liver tumors (n = 15). Red dots are HCC and blue open dots represent LM-CRC. (C, 
D) Immunohistochemistry analysis shows co-localization of CD303+ pDCs (red brown) and 
LAG-3+ cells (blue) in LM-CRC (C) and HCC (D) tumors. Magnification 200x. An insert at 
higher magnification showing the close localization of CD303+ and Lag-3+ cells in HCC is 
displayed in D. (E) Expression of ICOSL and CD123 analyzed by flow cytometry in total cell 
suspensions from liver tumors.  
Figure 4. Tumor-derived pDCs induce the production of IL-10 by Tr1 cells through 
ICOS-ligand-ICOS signaling. (A) Blood pDCs isolated from healthy donors after overnight 
culture in the presence of lysates from TFL (TFLL-pDCs) or tumor tissue (TL-pDCs) were 
analyzed for the expression of ICOS-L. pDCs exposed to tissue lysates were used to 
stimulate autologous naïve CD4+ T cells. The expression of IL-10 (B) and CD49b and Lag-3 
(C) were analyzed on CD4+ T cells after co-culture with pDCs and re-stimulation with 
PMA/Ionomycin. IL-10 production was analyzed in CD3+CD4+FoxP3-CD49b+LAG-3+ T cells. 
To evaluate the impact of ICOS-ICOS-L signaling, cells were co-cultured in the presence of 
50 ug/ml of control isotype antibody or anti-ICOS-L neutralizing antibody. Values are means 
± SEM, *p < 0.05, **p < 0.01. Red dots represent HCC lysates and blue open dots LM-CRC 
lysates. (D) Pearson correlation analysis of the expression of ICOSL on pDCs cultured with 
medium, TFLL or TL, and the percentage of IL-10+ Tr1 cells detected after co-culture.  
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Figure 4.    
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Supplementary Figure 1.    
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Supplementary Figure 2.    
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Supplementary Figure 3.    
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Supplementary Figure 4.    
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Supplementary Figure 5.    
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Supplementary Figure 6.    
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ABSTRACT 
Background & Aims: Ligand binding to inhibitory receptors on immune cells, such as 
programmed cell death 1 (PD-1) and cytotoxic T-lymphocyte associated protein 4 (CTLA4), 
downregulates the T-cell–mediated immune response (called immune checkpoints). 
Antibodies that block these receptors increase anti-tumor immunity in patients with 
melanoma, non-small cell lung cancer, and renal cell cancer. Tumor-infiltrating CD4+ and 
CD8+ T cells in patients with hepatocellular carcinoma (HCC) have been found to be 
functionally compromised. We analyzed HCC samples from patients to determine if these 
inhibitory pathways prevent T-cell responses in HCCs and to find ways to restore their anti-
tumor functions. 
Methods: We collected HCC samples from 59 patients who underwent surgical resection 
from November 2013 through May 2017, along with tumor-free liver tissues (control tissues) 
and peripheral blood samples. We isolated tumor-infiltrating lymphocytes (TIL) and intra-
hepatic lymphocytes. We used flow cytometry to quantify expression of the inhibitory 
receptors PD-1, hepatitis A virus cellular receptor 2 (TIM3), lymphocyte activating 3 (LAG3), 
and CTLA4 on CD8+ and CD4+ T cells from tumor, control tissue, and blood; we studied the 
effects of antibodies that block these pathways in T-cell activation assays. 
Results: Expression of PD-1, TIM3, LAG3, and CTLA4 was significantly higher on CD8+ and 
CD4+ T cells isolated from HCC tissue than control tissue or blood. Dendritic cells, 
monocytes, and B cells in HCC tumors expressed ligands for these receptors. Expression of 
PD-1, TIM3, and LAG3 was higher on tumor-associated antigen (TAA)-specific CD8+ TIL, 
compared with other CD8+ TIL. Compared to TIL that did not express these inhibitory 
receptors, CD8+ and CD4+ TIL that did express these receptors had higher levels of markers 
of activation, but similar or decreased levels of granzyme B and effector cytokines. 
Antibodies against CD274 (PD-L1), TIM3, or LAG3 increased proliferation of CD8+ and CD4+ 
TIL and cytokine production in response to stimulation with polyclonal antigens or TAA. 
Importantly, combining antibody against PD-L1 with antibodies against TIM3, LAG3, or 
CTLA4 further increased TIL functions. 
Conclusions: The immune checkpoint inhibitory molecules PD-1, TIM3, and LAG3 are up-
regulated on TAA-specific T cells isolated from human HCC tissues, compared to T cells 
from tumor-free liver tissues or blood. Antibodies against PD-L1, TIM3, or LAG3 restore 
responses of HCC-derived T cells to tumor antigens, and combinations of the antibodies 
have additive effects. Strategies to block PD-L1, TIM3, and LAG3 might be developed for 
treatment of primary liver cancer. 
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Introduction 
Liver cancer represents the second most common cause of cancer-related mortality 
worldwide, and hepatocellular carcinoma (HCC) is the most prevalent primary liver cancer.1, 2 
The current treatment options for HCC, such as surgical resection, liver transplantation and 
radiofrequency ablation, are curative only for patients with early stage disease. 
Unfortunately, the majority of HCC patients are not eligible for curative procedures because 
of late diagnosis and thus have poor prognosis.3 HCC is highly resistant to chemotherapy, 
but immunotherapy may be an attractive therapeutic option for HCC, since an inflammatory 
tumor microenvironment is associated with improved survival.4, 5 As reported in our earlier 
studies, intra-tumoral accumulation of activated regulatory T cells (Treg) is one of the 
suppressive mechanisms that contribute to HCC immune evasion.6-8 However, inhibitory 
receptor-ligand pathways (called immune checkpoints) may additionally contribute to 
suppression of anti-tumor immunity in the tumor microenvironment.  
There is evidence that tumor-infiltrating T cells upon chronic stimulation by tumor antigens 
lose their effector functions and their ability to kill tumor cells, which is accompanied by a 
progressive increase in the diversity and amount of inhibitory receptors expressed on them, 
including PD-1, TIM3, LAG3, CD244, CD160, CTLA4 and BTLA.9-12 Upon interaction with 
their respective ligands expressed on tumor cells and tumor-infiltrating antigen-presenting 
cells (APC), these receptors suppress T cell responses to tumor antigens. Blocking the 
interactions of PD-1 and CTLA4 with their respective ligands has been shown to be a 
promising novel therapeutic approach for several types of human malignancies such as 
advanced melanoma, non-small cell lung cancer and renal cell cancer, which improved anti-
tumor T cell responses and provided unprecedented clinical benefits for patients.13-18        
We and others have observed that tumor-infiltrating CD4+ T helper cells (Th) and CD8+ 
cytotoxic T cells (CTL) of HCC patients are functionally compromised.6, 19 Recent studies 
have shown that the PD-1/PD-L1 inhibitory interaction mediates suppression of CD8+ tumor-
infiltrating lymphocytes (TIL),20-22 while the TIM3/galectin-9 (GAL-9) interaction mediates 
CD4+ TIL dysfunction23 in HCC patients. Nevertheless, the expression of these and other 
inhibitory receptors on tumor-infiltrating T cells, and their functional relevance to both helper 
and cytotoxic T cell responses to tumor antigens in the HCC microenvironment have not 
been studied thoroughly. It is also unclear whether combined blockade of inhibitory pathways 
can additively increase the effector function of HCC-specific T cells. 
In this study, we aimed to systematically determine which inhibitory pathways participate in 
the suppression of T cell responses in the HCC microenvironment. We used paired samples 
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of leukocytes isolated from resected tumors, tumor-free liver tissues (TFL) and peripheral 
blood of HCC patients, to measure the expression of five inhibitory receptors on CD4+ Th and 
CD8+ CTL. We also performed ex vivo functional assays to determine whether blockade of 
inhibitory interactions can invigorate the functionality of tumor-infiltrating T cells. We found 
that inhibitory receptors PD-1, TIM3, LAG3 and CTLA4 were up-regulated on tumor-
infiltrating T cells; and interestingly, PD-1, TIM3 and LAG3 were selectively increased on 
tumor-associated antigen (TAA)-specific CD8+ TIL. Blocking PD-L1, TIM3 or LAG3 enhanced 
ex vivo proliferation of CD4+ and CD8+ TIL and effector cytokine production, and combined 
blockade of PD-L1 with TIM3, LAG3 or CTLA4 further enhanced ex vivo TIL responses to 
polyclonal stimuli and TAA.   
Patients and Methods 
Patients  
Fifty-nine patients who were eligible for surgical resection of HCC were enrolled in the study 
from November 2013 to May 2017. Paired fresh tissue samples from tumors and surrounding 
(minimum 1cm distance from the tumor) TFL were obtained, and tumor-infiltrating leukocytes 
and intra-hepatic leukocytes were isolated respectively. Peripheral blood from the same 
patients was also collected on the day of resection. None of the patients received 
chemotherapy or immunosuppressive treatment at least three months before surgery. The 
clinical characteristics of the patients are summarized in Supplementary Table 1. Eighty-five 
percent of patients included in the study are Caucasians. The study was approved by the 
local ethics committee, and all the patients signed the informed consent before tissue and 
blood donation.    
Cell preparation 
Peripheral blood mononuclear cells (PBMC) were isolated by Ficoll density gradient 
centrifugation. Single cell suspensions from tumors and TFL were obtained by tissue 
digestion as described previously.6-8 Briefly, fresh tissues were cut into small pieces and 
digested with 0.5 mg/mL of collagenase IV (Sigma-Aldrich, St. Louis, MO) and 0.2 mg/mL of 
DNAse I (Roche, Indianapolis, IN) for 20-30 minutes at 37 °C. Cell suspensions were filtered 
through 100 µm pore cell strainers (BD Biosciences, Erembodegem, Belgium) and 
mononuclear leukocytes were obtained by Ficoll density gradient centrifugation. Viability was 
determined by trypan blue exclusion. 
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Ex vivo mRNA-encoded full-length tumor antigen-specific T cell stimulation assay 
PBMC or TIL of HCC patients were labeled with 0.1 µM carboxyfluorescein diacetate 
succinimidyl ester (CFSE, Invitrogen), after which 100,000 cells in RPMI medium 
supplemented with 10% human AB serum, 2mM L-glutamine, 50 mM Hepes Buffer, 1% 
penicillin-streptomycin, 5mM Sodium Pyruvate and 1% minimum essential medium non-
essential amino acids (MEM NEAA) were transferred to each well of 96-well round-bottom 
culture plate. Glypican-3 (GPC3) mRNA-, MAGEC2 mRNA- or (as negative controls) eGFP 
mRNA-transfected or mock-electroporated autologous CD40-activated B cells (B cell blasts) 
in the same medium were added at a PBMC/TIL : B cell ratio of 1:1. TIL were co-cultured 
with B cell blasts (200 µl/ well) in the presence or absence of 10 μg/ml neutralizing 
monoclonal antibodies against human PD-L1, TIM3, LAG3 or CTLA4, or combinations of 
these antibodies, or isotype control antibodies. After seven days, CFSE-labeled cells were 
harvested, and stained with CD8, CD4, CD3 antibodies. Dead cells were excluded by using 
the LIVE/DEAD fixable dead cell stain kit with aqua fluorescent reactive dye, and T cell 
proliferation was determined based on CFSE dilution by flow cytometry analysis.  
Detailed description of other methods is provided in the Supplementary Information. 
Results 
Increased expression of inhibitory receptors on tumor-infiltrating CD4+ T helper cells 
and CD8+ cytotoxic T cells from HCC patients.  
We first compared the expression levels of five inhibitory receptors (PD-1, TIM3, LAG3, 
CTLA4 and BTLA) on CD4+ Th and CD8+ CTL, in paired samples of leukocytes freshly 
isolated from surgically resected tumors, TFL and peripheral blood from HCC patients. We 
excluded Foxp3+ Treg from CD4+ T cells because we focused on anti-tumor effector T cell 
populations. PD-1, TIM3 and CTLA4 were expressed on significantly higher proportions of Th 
and CTL in tumors than in TFL and blood, whereas LAG3 was expressed on significantly 
higher proportions of CTL in tumors than in TFL and blood (Fig. 1A-C). Compared to the 
other investigated inhibitory receptors PD-1 was expressed by most tumor-infiltrating Th and 
CTL and with highest median fluorescence intensity (MFI) (Supplementary Fig. 1). BTLA was 
expressed at negligible levels, and we did not observe any significant difference between its 
expression in the tumor and that in TFL. Therefore, we focused on the other four receptors in 
the rest of our study.  
Since PD-1 was the highest expressed receptor on TIL, we analyzed co-expression of PD-1 
and the other three receptors on TIL. Interestingly, we observed co-expression of TIM3, 
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LAG3 or CTLA4 with PD-1 on tumor-infiltrating Th and CTL, but there were also tumor-
infiltrating Th and CTL expressing only TIM3, LAG3 or CTLA4 but not PD-1 (Fig. 1D, E). In 
addition, Supplementary Fig. 2 illustrates that there were significant, although weak, positive 
correlations between the percentages of PD-1, TIM3, LAG3 or CTLA4 positive Th in tumors 
and those in blood, and between the percentages of LAG3 or CTLA4 positive CTL in tumors 
and those in blood. These data indicate that the expression of inhibitory receptors on TIL is 
partially reflected by their expression on circulating T cells in HCC patients.  
Increased expression of PD-1, TIM3 and LAG3 on TAA-specific CD8+ TIL. 
To study the expression of these inhibitory receptors on TAA-specific CTL, we used HLA-
A*0201 dextramers loaded with GPC3 and MAGEC2 peptides (Fig. 2A). These TAA are 
among the most frequently expressed TAA in HCC tumors in the Western-European area.24 
TAA dextramer-binding CTL were detectable in tumors from seven out of thirteen HLA-A2+ 
patients, and in blood from three out of twelve patients (Supplementary Table 3). The 
resected tumors of the patients with TAA dextramer-binding CTL expressed the 
corresponding TAA (confirmed by immunohistochemistry staining, data not shown). Fig. 2B 
presents the percentages of CTL binding to the dominant epitope-HLA-A*0201-dextramer 
complex of these patients, which ranged from 0.11%–8.0% in tumors and from 0.23%-0.87% 
in blood. Representative histograms of the expression of inhibitory receptors on TAA 
dextramer-binding versus TAA dextramer negative CD8+ TIL are presented in Fig. 2C; and 
Fig. 2D summarizes the comparison of the expression of inhibitory receptors between CTL 
that did and did not recognize the dominant TAA epitope in each patient. Interestingly, 
expression of PD-1, TIM3 and LAG3, but not CTLA4, was significantly increased on TAA-
specific CD8+ TIL, compared to TAA dextramer negative CD8+ TIL (MFI data are shown in 
Supplementary Fig. 3). Likewise, CD8+ TIL that recognized non-dominant peptides 
demonstrated enhanced expression of inhibitory receptors in the same patients (data not 
shown).   
Tumor-infiltrating antigen-presenting cells from HCC patients express inhibitory 
ligands.  
We further analyzed the expression levels of inhibitory ligands PD-L1 (for PD-1), GAL-9 (for 
TIM3), MHC-II (for LAG3), CD86 and CD80 (for CTLA4) on APC subsets within tumor tissues 
by flow cytometry. The major human APC subsets, CD45+BDCA1+CD19- myeloid dendritic 
cells (mDC), CD45+CD14+ monocytes and CD45+CD19+ B cells, were all found in HCC 
tumors. The percentages of mDC and B cells were higher in tumor-infiltrating CD45+ 
leukocytes than in TFL-infiltrating CD45+ leukocytes, but cell numbers isolated per gram of 
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tissue did not differ (Fig. 3A, B). All five ligands were found to be expressed on tumor-
infiltrating APC (Fig. 3C, D). The MFI of PD-L1 and GAL-9 on mDC and monocytes, and 
MHC-II on monocytes were significantly higher in the tumor than in TFL (Supplementary Fig. 
4). In a separate study using immunohistochemistry, we found that PD-L1 and GAL-9 were 
also expressed on tumor cells in HCC tissues.25 Together, these data suggest the 
suppression of tumor-infiltrating T cells by these inhibitory interactions in tumors of HCC 
patients.       
Tumor-infiltrating T cells expressing inhibitory receptors display an activated status. 
Given the increased expression of inhibitory receptors, tumor-infiltrating T cells in human 
HCC may be dysfunctional. Alternatively, expression of inhibitory receptors can be the 
consequence of local T cell activation. To study these two possibilities, we examined the 
activation status, cytotoxic effector molecule expression and cytokine production profile of 
tumor-infiltrating T cells expressing inhibitory receptors. We first compared the ex vivo 
activation status of tumor-infiltrating Th and CTL that do or do not express inhibitory 
receptors, using the activation markers HLA-DR and CD69. PD-1+ cells were significantly 
more activated than PD-1- cells in both T cell populations (Fig. 4A). So were TIM3+, LAG3+ 
and CTLA4+ cells compared with TIM3-, LAG3- or CTLA4- cells, respectively. Despite their 
activated status, the expression of cytotoxic effector molecule granzyme B was comparable 
or reduced in inhibitory receptor positive CD8+ TIL compared with respective receptor 
negative cells (Fig. 4B).  
Furthermore, we stimulated TIL with PMA and ionomycin in order to assess effector cytokine 
production. After exposure to PMA and ionomycin for five hours, PD-1, TIM3, LAG3 and 
CTLA4 were not distinctly up-regulated on TIL (data not shown). The percentages of IFN-γ 
and TNF-α producing cells in inhibitory receptor positive cells were comparable or reduced 
compared with those in respective receptor negative cells, in both CD4+ Th and CD8+ CTL 
(Fig. 4C). Together, these data indicate that tumor-infiltrating T cells that express inhibitory 
receptors are activated but do not have enhanced functionality.   
PD-L1, TIM3 or LAG3 blockade increases ex vivo proliferation and effector cytokine 
production of tumor-infiltrating T cells. 
Given that the inhibitory receptors PD-1, TIM3, LAG3 and CTLA4 are up-regulated on HCC 
tumor-infiltrating T cells and their respective ligands are expressed on tumor-infiltrating APC 
subsets, we tested whether blocking the PD-1/PD-L1, TIM3/GAL-9, LAG3/MHC-II or 
CTLA4/CD80/CD86 pathways can enhance the functionality of tumor-infiltrating T cells. We 
first stimulated CFSE-labeled total tumor-infiltrating mononuclear leukocytes with CD3/CD28 
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beads, in the presence or absence of 10 μg/ml neutralizing antibodies against human PD-L1, 
TIM3, LAG3, CTLA4, or combinations of these neutralizing antibodies, or isotype control 
antibodies (mIgG1 and mIgG2a). After four days, T cell proliferation was measured by flow 
cytometry (Fig. 5A), and IFN-γ secretion in culture supernatant was quantified by ELISA. 
Compared with the control condition without neutralizing antibody, treatment with anti-PD-L1, 
anti-TIM3 or anti-LAG3 significantly enhanced the proliferation of CD4+ and CD8+ TIL (Fig. 
5B); these three antibodies also significantly increased IFN-γ secretion (Fig. 5C). Treatment 
with anti-CTLA4 significantly enhanced CD4+ TIL proliferation. Interestingly, combined 
blockade of PD-L1 with CTLA4 further enhanced the proliferation of CD4+ and CD8+ TIL, 
while PD-L1 blockade together with LAG3 blockade further enhanced CD8+ TIL proliferation 
and IFN-γ secretion, and combining PD-L1 blockade with TIM3 blockade further enhanced all 
three types of function compared to single PD-L1 blockade (Fig. 5D, E).  
Combining PD-L1 blockade with TIM3, LAG3 or CTLA4 blockade additively increases 
ex vivo responses of tumor-infiltrating T cells to HCC tumor antigens. 
To test the effects of blocking these four inhibitory pathways on tumor-specific T cell 
immunity, we used two tumor antigen-specific T cell stimulation assays.  
In the first assay, we stimulated TIL with pooled HLA-A*0201-restricted GPC3 and MAGEC2 
peptides, in the presence or absence of antibody blocking inhibitory pathway or combinations 
of blocking antibodies. After seven days, expression levels of intracellular IFN-γ, TNF-α, 
activation-induced CD137 (an accepted marker for detection of antigen-specific T cell 
responses26) and surface CD107a (as a measure for cytotoxic degranulation) in CD8+ TIL 
were analyzed after re-stimulation with pooled GPC3 and MAGEC2 peptides (Fig. 6A). 
Compared to the stimulation with control peptide, seven HLA-A2+ patients showed specific 
CD8+ TIL responses to pooled GPC3 and MAGEC2 peptides. A summary of data (Fig. 6B) 
illustrates that blocking PD-L1, TIM3, LAG3 or CTLA4 increased tumor-specific CD137, 
CD107a expression, IFN-γ and/or TNF-α production of CD8+ TIL, but large variations 
between individual patients were observed, ranging from no effect to higher than two-fold 
increases of CD8+ TIL responses. Interestingly, PD-L1 blockade in combination with TIM3, 
LAG3 or CTLA4 blockade further enhanced tumor-specific CD8+ TIL responses compared to 
single PD-L1 blockade in part of the patients. 
In the second assay, autologous B cell blasts expanded from patient PBMC by three-week 
culture in the presence of trimeric CD40 ligand and rhIL-4 and then transfected with mRNA 
encoding GPC3 or MAGEC2 by electroporation, served as APC. B cell blasts expressed 
MHC-II, CD80, CD86,27 PD-L1 and GAL-9 (data not shown). To enable antigen presentation 
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to CD4+ T cells, the mRNA constructs we used encode these TAA fused to the 
transmembrane and luminal regions of dendritic cell lysosome-associated membrane protein 
(DCLamp), which is a targeting signal for the endo-lysosomal compartment, resulting in 
peptide loading in MHC-II in addition to MHC-I.28 To validate this assay, we first co-cultured 
an HLA-A*0201-restricted GPC3-specific CD8+ T cell clone29 or human T cells transfected 
with a human T cell receptor (TCR) recognizing MAGEC2 presented by HLA-A*0201,30 with 
GPC3 mRNA- or MAGEC2 mRNA-transfected B cell blasts expanded from PBMC of an 
HLA-A2+ healthy donor. B cell blasts pulsed with the GPC3 FVGEFFTDV peptide or the 
MAGEC2 ALKVDVEERV peptide served as positive controls. Fig. 7A reveals clear IFN-γ 
response of the GPC3-specific CD8+ T cell clone to GPC3 mRNA-transfected B cell blasts 
and GPC3 peptide, and clear IFN-γ response of MAGEC2-specific human T cells to 
MAGEC2 mRNA-transfected B cell blasts and MAGEC2 peptide, but the T cells did not 
respond to eGFP mRNA-transfected or mock-electroporated B cell blasts (negative controls) 
or to non-cognate antigens. 
Next, we co-cultured CFSE-labeled PBMC from an HCC patient whose resected tumor 
expressed GPC3 strongly and MAGEC2 weakly (confirmed by immunohistochemistry 
staining), with GPC3 mRNA-, MAGEC2 mRNA-, eGFP mRNA-transfected or mock-
electroporated autologous B cell blasts, and measured T cell proliferation after seven days. 
Fig. 7B reveals evident specific responses of CD4+ and CD8+ T cells to GPC3, and weaker 
responses to MAGEC2, but not to eGFP. These results confirm that TAA-specific CD4+ and 
CD8+ T cell responses can be accurately detected and quantified using this T cell stimulation 
assay.    
We co-cultured CFSE-labeled TIL with GPC3 mRNA-, MAGEC2 mRNA-, eGFP mRNA-
transfected or mock-electroporated autologous B cell blasts, in the presence or absence of 
antibody blocking inhibitory pathway or combinations of blocking antibodies, and measured T 
cell proliferation after seven days. Representative proliferation data of CD4+ and CD8+ TIL 
from one patient whose resected tumor expressed MAGEC2 (confirmed by 
immunohistochemistry staining) are presented in Fig. 7C. In six patients both GPC3- and 
MAGEC2-specific TIL proliferative responses were observed, and in three patients either 
GPC3- or MAGEC2-specific responses were observed. In these nine patients, 6.6% ± 3.8% 
(mean ± SEM) of CD4+ and 3.9% ± 1.5% (mean ± SEM) of CD8+ proliferating TIL were 
observed in response to these TAA. A summary of data from these nine patients (Fig. 7D) 
demonstrates that blocking PD-L1, TIM3, LAG3 or CTLA4 increased tumor-specific 
proliferation of CD4+ and CD8+ TIL in most but not all patients. Furthermore, PD-L1 blockade 
in combination with TIM3, LAG3 or CTLA4 blockade enhanced proliferation of both CD8+ and 
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CD4+ TIL in more patients and further enhanced TIL proliferation compared to single PD-L1 
blockade.  
Discussion 
The purpose of this study was to determine whether inhibitory pathways lead to suppression 
of T cell responses in the HCC microenvironment, and to examine whether blocking these 
inhibitory pathways can restore the functions of tumor-infiltrating T cells. Overall, the results 
of our study demonstrate that inhibitory pathways involving the receptors PD-1, TIM3, LAG3 
and CTLA4 participate in intra-tumoral suppression of CD4+ Th and CD8+ CTL in HCC. 
Single blockade of PD-L1, TIM3, LAG3, or CTLA4 could recover TIL responses to tumor 
antigens, but large differences in effects were observed between individual patients. 
Importantly, combining PD-L1 blockade with TIM3, LAG3 or CTLA4 blockade further 
enhanced the responsiveness of TIL and was effective in more patients.    
Previous studies have revealed increased expression of PD-1,20, 21, 31 TIM323 and LAG332 on 
either CD4+ or CD8+ TIL in HCC patients, but to our knowledge expression of CTLA4 and 
BTLA as well as co-expression of all these inhibitory receptors on both CD4+ and CD8+ TIL in 
HCC patients have not been studied before. Here, we demonstrate that tumor-infiltrating Th 
have significantly increased PD-1, TIM3 and CTLA4 expression; whereas CTL have 
significantly increased PD-1, TIM3, LAG3 and CTLA4 expression, compared with their 
counterparts in TFL and blood (Fig. 1C). Similar to melanoma,33 BTLA was not up-regulated 
on tumor-infiltrating T cells. A previous study suggested that HBV positive HCC patients had 
more intra-tumoral TIM3+ T cells compared to HBV negative HCC patients,23 but we did not 
find any difference in the expression of inhibitory receptors between HCC patients with HBV 
or HCV infection or other etiologies for HCC (e.g. alcoholic liver disease). There was also no 
difference between patients with cirrhotic or non-cirrhotic liver (data not shown). Using HLA-
A*0201 dextramers loaded with GPC3 or MAGEC2 peptides, we are the first to demonstrate 
that PD-1, TIM3 and LAG3 are selectively up-regulated on tumor-infiltrating TAA-specific 
CD8+ T cells from HCC patients (Fig. 2D, supplementary Fig. 3). Similarly, we observed that 
circulating TAA-specific CD8+ T cells express relatively high levels of the same inhibitory 
receptors, which extends previous observation showing high PD-1 expression on circulating 
TAA-specific CD8+ T cells in HCC patients.34, 35 The selectively increased expression of these 
inhibitory receptors on TAA-specific TIL together with the expression of their respective 
ligands on tumor-infiltrating APC suggests that they may be involved in the regulation of 
tumor antigen-specific responsiveness of tumor-infiltrating T cells.            
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Given that expression of individual inhibitory receptor on T cells can be induced by T cell 
activation,36, 37 but expression of increasing numbers of inhibitory receptors often coincides 
with gradual loss of T cell functions,9, 38, 39 we investigated the activation status, cytotoxic 
effector molecule expression and cytokine production profile of tumor-infiltrating T cells in 
relation to the expression inhibitory receptors. Interestingly, CD4+ Th and CD8+ CTL 
expressing either inhibitory receptor displayed a more activated status (Fig. 4A); however, 
they displayed comparable or reduced levels of granzyme B, IFN-γ and TNF-α (Fig. 4B,C). 
Together with our data showing selectively enhanced expression of inhibitory receptors on 
TAA-specific TIL, these findings indicate that, in accordance with recent studies in other 
human cancers,11, 33, 39 HCC tumor-infiltrating T cells that express inhibitory receptors are 
probably tumor-reactive T cells, which may continue to up-regulate the expression of 
inhibitory receptors in response to chronic stimulation by tumor antigens to prevent further 
over activation. Of note, PD1+TIM3+ T cells displayed the lowest level of granzyme B, IFN-γ 
and TNF-α, which suggests that PD-1 and TIM3 play an important role in T cell suppression 
in HCC microenvironment.    
We performed polyclonal and tumor-specific functional assays to test the effect of blocking 
these inhibitory pathways on the functions of tumor-infiltrating T cells ex vivo. Because we 
were interested in and measured the net effect of blocking antibody intervention on CD4+ and 
CD8+ TIL function in a context that reflected the tumor microenvironment as much as 
possible, we used total tumor-infiltrating mononuclear leukocytes in all our functional assays 
which contained both T cells expressing inhibitory receptors and APC subsets expressing 
inhibitory ligands. As a consequence, tumor-infiltrating Treg and probably other types of 
suppressor cells were also present. Our data indicate that the ex vivo proliferative function of 
both CD4+ and CD8+ TIL and IFN-γ secretion in response to polyclonal stimuli were 
enhanced significantly by blocking PD-L1, TIM3 or LAG3, while blocking CTLA4 only 
significantly enhanced CD4+ TIL proliferation (Fig. 5B,C). Similar effects of blocking the PD-
1/PD-L1 pathway on CD8+ TIL and blocking the TIM3/GAL-9 pathway on CD4+ TIL in HCC 
patients have been shown before,20, 21, 23, 31 but we are the first to demonstrate that blocking 
PD-L1, LAG3 or TIM3 can enhance the functional responsiveness of both CD4+ and CD8+ 
TIL in HCC patients. Even more importantly, we found that combining anti-PD-L1 antibody 
with anti-TIM-3, anti-LAG-3 or anti-CTLA-4 antibody further enhanced the functionality of 
CD4+ or CD8+ TIL compared to single PD-L1 blockade (Fig. 5D,E).  
The effects of inhibitory receptor-ligand blockade on responses of tumor-infiltrating T cells to 
tumor antigens were studied in two different assays. In the first TAA peptide assay, 
activation-induced CD137, cytotoxic degranulation marker CD107a, and effector cytokine 
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IFN-γ and TNF-α levels were variably increased in CD8+ TIL in the presence of single anti-
PD-L1, anti-TIM3, anti-LAG3 or anti-CTLA4 antibody (Fig. 6B). Importantly, combined 
blocking treatments further enhanced these effects in part of the patients compared to single 
anti-PD-L1 antibody. In the second assay, we used autologous CD40-activated B cell blasts 
transfected with mRNA encoding full-length GPC3 or MAGEC2 to measure responses of 
CD4+ and CD8+ TIL to the natural repertoire of TAA-derived peptides irrespective of patient 
HLA typing.40 Tumor antigen-specific proliferation of CD8+ and CD4+ TIL was increased up to 
four-fold in the presence of single anti-PD-L1, anti-TIM3, anti-LAG3 or anti-CTLA4 antibody, 
but the responses to single blockade were also variable between individual patients (Fig. 
7D). Combined treatments of anti-PD-L1 with either anti-TIM3, anti-LAG3 or anti-CTLA4 
antibody enhanced proliferation of both CD8+ and CD4+ TIL in more patients compared to 
single PD-L1 blockade. A recent phase 1 clinical trial of tremelimumab (CTLA4 blockade) 
has reported a manageable safety profile and a response rate of 17.6% in 17 HCV-related 
advanced HCC patients.41 Very recently in a phase 1/2 clinical trial, nivolumab (PD-1 
blockade) has demonstrated an objective response rate of 20%, disease control with stable 
disease for ≥6 months in 37%, and encouraging overall survival in 214 advanced HCC 
patients in the dose-expansion phase regardless of HCC etiology. In addition, liver toxicity 
was limited and manageable in the majority of patients, while symptomatic treatment-related 
adverse events were comparable in patients with and without HCV or HBV infection.42 These 
studies are the first to show safety and efficacy of immune checkpoint blockade in HCC 
patients. Further clinical trials should be performed to verify whether blockade of TIM3 and 
LAG3 has clinical efficacy in HCC patients, and whether combined targeting of inhibitory 
pathways improves clinical responses.  
In some of the patients we could isolate sufficient TIL to determine the expression of 
inhibitory receptors directly ex vivo in addition to performing the ex vivo polyclonal or mRNA-
encoded TAA-specific functional assays. In both assays, the high-responding tumor-
infiltrating T cells (those with > median % increase of TIL responses in the presence of PD-
L1, TIM3, LAG3 or CTLA4 blockade) displayed higher frequencies of PD-1, TIM3 or LAG3-
expressing cells than low or non-responding tumor-infiltrating T cells (those with < median % 
increase of TIL responses), respectively (Supplementary Fig. 5 & 6), suggesting that the 
inter-individual variations in TIL responses to single immune checkpoint blockade may be 
related to the differences in the expression levels of the corresponding inhibitory receptor on 
TIL. Interestingly, the expression levels of several investigated inhibitory receptors on tumor-
infiltrating T cells correlated with those on circulating T cells (Supplementary Fig. 2). 
Although correlations were weak, these findings support the idea that the expression of 
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inhibitory receptor on circulating T cells may become useful as biomarkers to predict clinical 
response of individual HCC patient to checkpoint blockade therapy.      
Our study has several limitations: 1) the effects of immune checkpoint blockade on tumor 
antigen-specific responses have been studied in limited numbers of patients, because patient 
samples are limited and these assays comparing many conditions require large numbers of 
TIL; 2) in some types of experiments, not all the conditions could be performed in every 
patient sample, due to limited numbers of isolated cells; 3) we included only two TAA (GPC3 
and MAGEC2) in our study, but these antigens are among the most prevalent HCC-specific 
antigens,24 they are selectively expressed on tumor cells and have been proven to be 
immunogenic;29, 43 4) our patients all underwent liver resection, and therefore are not 
representative for the whole HCC patient population; 5) in our patient cohort, there are more 
non-viral hepatitis patients than viral hepatitis patients, which is different from Asian HCC 
patient cohorts. 
In summary, we conclude that PD-1, TIM3 and LAG3 are up-regulated on TAA-specific TIL in 
HCC patients. While blocking individual inhibitory pathway has variable effects, combining 
PD-L1 blockade with TIM3, LAG3 or CTLA4 blockade revitalizes ex vivo tumor-specific TIL 
responses in most patients and additively enhances the effects compared to single PD-L1 
blockade. Therefore, our study provides evidence that PD-1/PD-L1, TIM3 and LAG3 are 
promising immunotherapeutic targets for the most common primary liver cancer, and 
suggests that the aforementioned combined targeting of immune checkpoints may result in 
superior clinical responses in more patients than targeting a single checkpoint. 
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Figure legends  
Figure 1. Expression of inhibitory receptors on CD4+ Th and CD8+ CTL in tumors, TFL, 
and blood. PBMC and mononuclear leukocytes isolated from tumors and TFL were stained 
with antibodies against PD-1, TIM3, LAG3, CTLA4 and BTLA. (A) Representative dot plots of 
inhibitory receptor expression and appropriate isotype controls on CD3+CD4+Foxp3- TIL and 
(B) CD3+CD8+ TIL. (C) The percentages of inhibitory receptor positive cells among CD4+ Th 
or CD8+ CTL in tumors, TFL and blood. Values of individual patients are depicted, and lines 
show medians; * p < 0.05, ** p < 0.01, *** p < 0.001. (D) Representative dot plots of co-
expression of inhibitory receptors on CD4+Foxp3- TIL and CD8+ TIL. (E) The mean 
percentages of co-expression of inhibitory receptors among CD4+Foxp3- TIL (n=12) or CD8+ 
TIL (n=22).  
Figure 2. Expression of PD-1, TIM3 and LAG3 is increased on TAA-specific CD8+ TIL. 
PBMC and TIL of HLA-A2+ patients were stained with HLA-A*0201 dextramers loaded with 
GPC3 FVGEFFTDV, GPC3 FLAELAYDL, MAGEC2 ALKVDVEERV, or MAGEC2 
LLFGLALIEV peptides. (A) Representative dot plots of TAA dextramer staining compared to 
negative control. CD8+ and CD8-CD4+ TIL were gated within CD56-CD14-CD19- viable cells. 
(B) The percentages of dextramer-binding CD8+ T cells in tumors of seven patients and in 
blood of three patients with detectable dextramer-binding CD8+ T cells. Lines show medians. 
For each patient, the value of either the only or the dominant dextramer-binding population is 
depicted. (C) Representative histograms of inhibitory receptor expression on GPC3 
FVGEFFTDV dextramer positive (blue line) versus dextramer negative (red line) CD8+ TIL. 
(D) The percentages of PD-1, TIM3, LAG3 or CTLA4 positive cells in TAA dextramer positive 
versus TAA dextramer negative CD8+ T cells in tumors and blood. For each patient, the 
value of either the only or the dominant dextramer-binding population is depicted. * p < 0.05, 
** p < 0.01. (B)(D) Blue symbols: GPC3 FVGEFFTDV positive; green symbol: GPC3 
FLAELAYDL positive; red symbols: MAGEC2 LLFGLALIEV positive.  
Figure 3. Tumor-infiltrating antigen-presenting cells express inhibitory ligands. 
Expression of inhibitory ligands PD-L1, GAL-9, MHC-II, CD86 and CD80 was measured by 
flow cytometry. (A) The percentages of B cells, mDC and monocytes within CD45+ cells 
gated from tumors, TFL and blood. Lines depict medians; * p < 0.05, ** p < 0.01, *** p < 
0.001. (B) The absolute numbers of B cells, mDC and monocytes isolated per gram of tumor 
and TFL tissues. Values of individual patients are presented, lines depict medians. (C) 
Representative histograms of inhibitory ligand expression on tumor-infiltrating B cells, mDC 
and monocytes. Upper panel: ligand staining, lower panel: isotype control. (D) The 
Chapter 5 
- 88 - 
 
percentages of inhibitory ligand positive cells within tumor-infiltrating B cells, mDC or 
monocytes in individual patients are presented; lines depict medians.  
Figure 4. Tumor-infiltrating T cells expressing inhibitory receptors display a more 
activated status. TIL were stained ex vivo with antibodies against surface activation 
markers HLA-DR and CD69 and stained with an antibody against the cytotoxic effector 
molecule Granzyme B intracellularly. (A) The percentages of HLA-DR+ or CD69+ cells in 
CD3+CD4+Foxp3- TIL or CD3+CD8+ TIL which do or do not express PD-1, TIM3, LAG3 or 
CTLA4 are presented. (B) The percentages of Granzyme B+ cells in CD8+ TIL which do or do 
not express inhibitory receptors. (C) TIL were exposed to PMA and ionomycin at 37°C for 
five hours, in the presence of protein transport inhibitor brefeldin during the last four hours, 
followed by intracellular cytokine staining. The percentages of cytokine-producing cells in TIL 
which do or do not express inhibitory receptors are presented. Values of individual patients 
are depicted, and lines show means. * p < 0.05, ** p < 0.01, *** p < 0.001. 
Figure 5. PD-L1, TIM3 or LAG3 blockade increases ex vivo proliferation and cytokine 
production of CD4+ and CD8+ TIL in response to polyclonal stimuli. CFSE-labeled TIL 
were stimulated with CD3/CD28 beads, in the presence or absence of 10 μg/ml neutralizing 
antibodies. (A) Dot plots show the proliferation (CFSE-low) of CD3+CD4+ and CD3+CD8+ TIL 
after stimulation with CD3/CD28 beads, without addition of neutralizing antibody. Scatter plot 
shows the percentages of the proliferating (CFSE-low) CD4+ and CD8+ TIL of individual 
patients, without addition of neutralizing antibody. (B) (D) Effects of blocking inhibitory 
interactions on CD4+ and CD8+ TIL proliferation (n=10). Since the proliferation differed 
between patients, the results are reported as relative proliferation percentages calculated by 
dividing the percentages of proliferating (CFSE-low) T cells in the conditions with neutralizing 
antibody or with combinations of antibodies or with isotype controls, by the percentages in 
the condition with only CD3/CD28 beads. Values are depicted as means with SEM, * p < 
0.05, ** p < 0.01. (C) (E) IFN-γ accumulation in culture supernatant was quantified by ELISA. 
Values are depicted as medians with interquartile range (n=10). 
Figure 6. Combining PD-L1 blockade with TIM3, LAG3 or CTLA4 blockade additively 
increases ex vivo responses of CD8+ TIL to TAA peptide stimulation. TIL of HLA-A2+ 
patients were stimulated with pooled GPC3 FVGEFFTDV, GPC3 FLAELAYDL, MAGEC2 
ALKVDVEERV and MAGEC2 LLFGLALIEV peptides (1 μg/ml of each), in the presence or 
absence of 10 μg/ml neutralizing antibodies. Intracellular cytokine production, CD137 and 
surface CD107a expression were analyzed after restimulation with pooled HCC peptides. 
Restimulation with HCV antigen peptide served as negative control for HCV negative 
Chapter 5 
- 89 - 
 
patients (including patients negative for both HCV and HBV), while restimulation with HBV 
antigen peptide served as negative control for HBV negative patients. (A) Representative dot 
plots of CD137, CD107a, IFN-γ and TNF-α expression in CD3+CD8+ TIL. (B) CD8+ TIL 
responses to TAA peptides of seven patients, which are reported as fold increase calculated 
by dividing the percentages of CD137+, CD107a+, IFN-γ+ or TNF-α+ cells in the conditions 
with neutralizing antibody or with combinations of antibodies, by the percentages in the 
condition with only pooled HCC peptides. Not all four read-outs were detectable in every 
patient, therefore results of four to seven patients are presented for each type of response. 
Each line and each color represent one patient. 
Figure 7. Combining PD-L1 blockade with TIM3, LAG3 or CTLA4 blockade additively 
increases ex vivo proliferation of CD4+ and CD8+ TIL in response to TAA presented by 
mRNA-transfected autologous B cell blasts. (A) HLA-A*0201-restricted GPC3 
FVGEFFTDV-specific CD8+ T cell clone or human T cells transfected with a TCR recognizing 
MAGEC2 ALKVDVEERV were co-cultured with HLA-A2+ B cell blasts transfected with GPC3 
mRNA or MAGEC2 mRNA. EGFP mRNA- or mock- (without mRNA) electroporated B cell 
blasts served as negative controls, while HLA-A2+ B cell blasts pulsed with 1 µg/ml 
FVGEFFTDV peptide or ALKVDVEERV peptide served as positive controls. IFN-γ 
accumulation in culture supernatant was quantified by ELISA after 24 hours. (B) CFSE-
labeled PBMC from an HCC patient were co-cultured with GPC3 mRNA-, MAGEC2 mRNA-, 
eGFP mRNA- or mock-electroporated autologous B cell blasts. CD4+ and CD8+ T cell 
proliferation was measured by flow cytometry. (C) (D) CFSE-labeled TIL were co-cultured 
with GPC3 mRNA-, MAGEC2 mRNA-, eGFP mRNA- or mock-electroporated autologous B 
cell blasts, in the presence or absence of 10 μg/ml neutralizing antibodies. (C) 
Representative dot plots of CD4+ and CD8+ T cell proliferation in response to eGFP mRNA-
transfected (negative control) and MAGEC2 mRNA-transfected autologous B cell blasts in 
the absence or presence of neutralizing antibody. (D) Proliferation of CD4+ and CD8+ TIL of 
nine patients in response to GPC3 and/or MAGEC2. For each patient, the data of either the 
only or the average antigen-induced TIL response are presented. Since the proliferative 
responses to TAA differed between patients, the results are reported as fold increase of 
antigen-specific T cell proliferation calculated by dividing the percentages of proliferating 
(CFSE-low) T cells in response to GPC3 or MAGEC2 in the conditions with neutralizing 
antibody or with combinations of antibodies, by the percentages in the condition without 
neutralizing antibody. 
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Figure 3.  
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Figure 4.  
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Figure 6.  
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Supplementary figure legends 
Supplementary Figure 1. Expression of inhibitory receptors on CD4+ Th and CD8+ CTL 
in the tumor, TFL, and blood. Median fluorescence intensity of inhibitory receptors PD-1, 
TIM3, LAG3, CTLA4 and BTLA within (A) CD4+ Th and (B) CD8+ CTL from the tumor, TFL 
and blood. Values of individual patients are depicted, and lines show medians; * p < 0.05, ** 
p < 0.01, *** p < 0.001. 
Supplementary Figure 2. Correlation of the expression of inhibitory receptors on T 
cells between the tumor and the blood. Spearman correlation analysis demonstrates (A) 
positive correlations of the percentages of PD-1, TIM3, LAG3 or CTLA4 positive cells in CD4+ 
Th between the tumor and the blood, and (B) positive correlations of the percentages of 
LAG3 or CTLA4 positive cells in CD8+ CTL between the tumor and the blood. 
Supplementary Figure 3. Expression of PD-1, TIM3 and LAG3 is increased on HCC 
TAA-specific CD8+ TIL. Median fluorescence intensity of PD-1, TIM3, LAG3 and CTLA4 in 
TAA dextramer positive versus TAA dextramer negative CD8+ T cells in the tumor and the 
blood. For each patient, the value of either the only or the dominant dextramer-binding 
population is depicted; * p < 0.05. Blue symbols: GPC-3 FVGEFFTDV positive; green 
symbols: GPC-3 FLAELAYDL positive; red symbols: MAGE-C2 LLFGLALIEV positive. 
Supplementary Figure 4. Expression of inhibitory ligands on antigen-presenting cells 
in the tumor, TFL and blood. (A) Median fluorescence intensity of inhibitory ligands PD-L1, 
MHC-II, GAL-9, CD80 and CD86 and (B) the percentages of cells expressing inhibitory 
ligands within B cells, myeloid dendritic cells (mDC) and monocytes from the tumor, TFL and 
blood. Values of individual patients are shown; lines depict (A) means or (B) medians; * p < 
0.05, ** p < 0.01. 
Supplementary Figure 5. Association between the expression of inhibitory receptor 
and the effect of blocking antibody on TIL proliferation in polyclonal T cell activation 
assay. The percentages of inhibitory receptor positive CD3+CD4+Foxp3- TIL or CD3+CD8+ 
TIL are shown, comparing high-responding TIL (n=4) and low or non-responding TIL (n=4) in 
the four conditions with neutralizing antibody. High-responding TIL are those whose relative 
% increase of TIL proliferation in the presence of a neutralizing antibody is above the median 
% increase of all the patients, and low or non-responding TIL are those whose relative % 
increase of TIL proliferation is below the median level. Values are depicted as means with 
SEM, * p < 0.05.      
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Supplementary Figure 6. Association between the expression of inhibitory receptor 
and the effect of blocking antibody on TIL proliferation in mRNA-encoded full-length 
tumor antigen-specific T cell stimulation assay. The percentages of inhibitory receptor 
positive CD3+CD4+Foxp3- TIL or CD3+CD8+ TIL are shown, comparing high-responding TIL 
(n=3) and low or non-responding TIL (n=4) in the four conditions with neutralizing antibody. 
High-responding TIL are those whose fold increase of TIL proliferation in the presence of a 
neutralizing antibody is above the median fold increase of all the patients, and low or non-
responding TIL are those whose fold increase of TIL proliferation is below the median level. 
Values are depicted as means with SEM.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Chapter 5 
- 99 - 
 
Supplementary Figure 1.  
  
Chapter 5 
- 100 - 
 
Supplementary Figure 2.  
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Supplementary Figure 3.  
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Supplementary Figure 4.  
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Supplementary Table 1. Patient characteristics 
  HCC (n=59) 
Sex (male/female) 46 / 13 
Age (years)** 64.8 ± 1.8 
Race 
(Caucasian/Asian/African) 
50 / 5 / 4 
ALT (units/L)** 58.7 ± 6.4 
Bilirubin (µmol/L)** 16.4 ± 5.7 
Protrombin time (INR)** 1.1 ± 0.02 
Liver fibrosis (metavir score)      
F0-F1 / F2 / F3-F4-cirrhosis  
28 / 4 / 27 
AFP (µg/L)** 
<20/ 20-400/ >400/ unknown 
45 / 1 / 10 / 3 
Stage of disease (TNM) 
St I n=28, St II n=26,  
St IIIa n=4, unknown 
n=1  
 
Abbreviations: INR, international normalized ratio; AFP, alpha fetoprotein; TNM, tumor-node-
metastasis.  
Etiology of liver disease: no known liver disease (n = 23), HBV/HCV (n =10/6), alcohol-
related liver disease (n = 6), HBV/HCV + alcohol (n = 3), non-alcoholic steatohepatitis 
(NASH)/non-alcoholic fatty liver disease (NAFLD) (n = 4/4), HBV + NASH (n = 1), porphyria 
(n = 1), abernathy (n=1). 
**Mean ± SEM. 
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Supplementary Table 2. Anti-human antibodies used in flow cytometry (FACS) 
 
Antibody Clone Supplier Antibody Clone Supplier 
CD69 APC L78 BD Biosciences mIgG1-PE P3.6.2.8.1 eBioscience 
IFN-gamma-FITC 25723.11 BD Biosciences HLA-DR-APC LN3 eBioscience 
HLA-A2-APC BB7.2 BD Biosciences HLA-DR-PE LN3 eBioscience 
CD19-
HorizonV500 HIB19 BD Biosciences 
HLA-DR-PerCP-
Cy5.5 LN3 eBioscience 
mIgG2a-PerCP X39 BD Biosciences CD14 PE-Cy7 61D3 eBioscience 
CD3 PerCP-
Cy5.5 UCHT1 BD Biosciences CD3 PE-Cy7 UCHT1 eBioscience 
HLA-A2-FITC BB7.2 BD Biosciences CD8-APC okt-08 eBioscience 
mIgG2b-FITC 27-35 BD Biosciences CD14-eFlour450 61D3 eBioscience 
mIgG1-PB MOPC-21 BD Biosciences 
IFN-gamma-Pe-
Cy7 4S.B3 eBioscience 
mIgG2b-PE 27-35 BD Biosciences 
HLA-DR-APC-
eFluor780 LN3 eBioscience 
mIgG1-PerCP X40 BD Biosciences CD14-FITC 61D3 eBioscience 
mIgG1-FITC MOPC-21 BD Biosciences 
CD279 (PD1)-
PE-Cy7 J105 eBioscience 
mIgG1-pacific 
blue MOPC-21 BD Biosciences CD8-efluor450 RPA-T8 eBioscience 
GranzymeB-V450 GB11 BD Biosciences 
CD274(B7-H1)-
PE-Cy7 MIH1 eBioscience 
CD137 (4-1BB)-
APC 4B4-1 BD Biosciences 
CD270 (HVEM)-
PE 
eBioHVEM-
122 eBioscience 
CD19 PE J4.119 Beckman 
CD4-APC-
eFluor780 OKT4 eBioscience 
CD69-PE TP1.55.3 Beckman 
CD3-APC-
eFluor780 SK7 eBioscience 
CD3 FITC UCHT1 Beckman FoxP3-eFluor450 236A/E7 eBioscience 
mIgG2a-PE U7.27 Beckman CD45 efluor 450 HI30 eBioscience 
CD152 (CTLA4)-
APC L3D10 Biolegend 
CD19-APC-
eFluor780 HIB19 eBioscience 
CD272 (BTLA)-
APC MIH26 Biolegend 
CD8a-PerCp-
Cy5.5 RPA-T8 eBioscience 
CD3 PE UCHT1 Biolegend TNFα APC MAb11 eBioscience 
CD86-PB IT2.2 Biolegend 
CD223(LAG3)-
PE 3DS223H eBioscience 
anti-TNF-α-
PerCP-Cy5.5 Mab11 Biolegend 
CD223(LAG3)-
PerCP-eF710 3DS223H eBioscience 
TIM3-Brilliant-
Vio421 F38-2E2 Biolegend CD8-FITC SK1 eBioscience 
Galectin-9 PE 9M1-3 Biolegend rat IgG2a-APC eBR2a eBioscience 
CD80-PE-Cy7 2D10 Biolegend mIgG1-FITC P3 eBioscience 
CD14-BV510 M5E2 Biolegend mIgG2a-APC eBM2a eBioscience 
CD56-BV510 HCD56 Biolegend rat IgG2b-APC eB149/10H5 eBioscience 
HLA-DR, DP, DQ-
FITC Tü39 Biolegend CD8-PE RPA-T8 eBioscience 
mIgG1-Pe-Cy7 MOPC-21 Biolegend CD107a PE H4A3 eBioscience 
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 rat IgG2a-PE  RTK2758 Biolegend TIM3-PE 344823 
R&D 
systems 
mIgG2a-FITC MOPC-173 Biolegend BDCA1-APC AD5-8E7 Miltenyi 
mIgG1-APC MOPC-21 Biolegend    
 
 
Supplementary Table 3. The percentages of CD8+ T cells binding to different TAA-
peptide-HLA-A*0201-dextramer complexes in tumors of 13 HLA-A2+ HCC patients and 
in blood of 12 HLA-A2+ HCC patients    
Epitope FVG FLA ALK LLF FVG FLA ALK LLF 
TAA 
GPC-
3 
GPC-
3 
MAGE-
C2 
MAGE-
C2 
GPC-3 GPC-3 
MAGE-
C2 
MAGE-C2 
Patient TIL TIL TIL TIL PBMC PBMC PBMC PBMC 
1 0.36% 0.32% 
 
0.35% 
    2 
    
0.8% 0.61% 
 
0.64% 
3 
   
0.56% 
   
0.23% 
4 
    
0.87% 
   5 0.26% 0.15% 
      6 
        7 
   
0.11% 
    8 
   
2.72% 
    9 
    
NT NT NT NT 
10 8.00% 
       11 
        12 
        13  0.13%       
 
Abbreviations: TAA, tumor-associated antigen; NT, not tested; FVG, GPC3 peptide 
FVGEFFTDV; FLA, GPC3 peptide FLAELAYDL; ALK, MAGEC2 peptide ALKVDVEERV; 
LLF, MAGEC2 peptide LLFGLALIEV; TIL, tumor-infiltrating lymphocytes; PBMC, peripheral 
blood mononuclear cells.  
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Supplementary Materials and Methods 
Flow cytometric analysis 
Fresh PBMC and mononuclear leukocytes isolated from tumor and TFL were analyzed for 
expression of surface and intracellular markers using specific antibodies (Supplementary 
Table 2). Cell surface staining with fluorochrome-conjugated antibodies was performed in the 
dark at 4°C for 30 minutes, then cells were washed and resuspended in PBS with 0.2 mM 
EDTA and 0.5% human serum. For Foxp3, Granzyme B and CTLA4 staining, cells were 
fixed and permeabilized using the Foxp3 staining buffer set from eBioscience (Vienna, 
Austria). For intracellular cytokine staining, cells were exposed to 40 ng/mL PMA (Sigma, 
Zwijndrecht, The Netherlands) and 1 µg/mL ionomycin (Sigma) at 37°C for five hours in the 
presence of 5 µg/mL brefeldin (Sigma) during the last four hours, followed by staining of IFN-
γ and TNF-α upon fixation and permeabilization using the Foxp3 staining buffer set. To 
identify TAA-specific T cells, PBMC and TIL of HLA-A2+ HCC patients (as determined by flow 
cytometric analysis of binding to anti-HLA-A2 antibody) were pre-treated with protein tyrosine 
kinase inhibitor (PKI) dasatinib at a final concentration of 50 nM in PBS at 37°C for 30 
minutes.1-3 Cells were then stained with PE-labeled HLA-A*0201/GPC3 144-152 
(FVGEFFTDV), HLA-A*0201/GPC3 522-530 (FLAELAYDL), HLA-A*0201/MAGEC2 336-344 
(ALKVDVEERV), HLA-A*0201/MAGEC2 191-200 (LLFGLALIEV) (Immudex, Copenhagen, 
Denmark) or no dextramer (as a negative control) at room temperature for 10 minutes. 
Subsequently, cells were stained with CD8 (clone SK1), CD4, PD-1, TIM3, LAG3, CD56, 
CD19, CD14 antibodies at 4°C for 20 minutes and then CTLA4 antibody intracellularly using 
the Foxp3 staining buffer set. Dead cells were excluded by using a LIVE/DEAD fixable dead 
cell stain kit with aqua fluorescent reactive dye (Invitrogen, Paisley, UK). Cells were 
measured by a FACSCanto II flow cytometer (BD Biosciences, San Diego, USA) and 
analyzed using FlowJo software. Appropriate isotype control antibodies (Supplementary 
Table 2) were used for gating purposes.  
Ex vivo polyclonal T cell activation assay 
All TIL cultures were performed in RPMI 1640 (Lonza, Breda, The Netherlands) 
supplemented with 10% human AB serum (Invitrogen), 2mM L-glutamine (Invitrogen), 50 mM 
Hepes Buffer (Lonza), 1% penicillin-streptomycin (Life Technologies), 5mM Sodium Pyruvate 
(Gibco) and 1% MEM NEAA at 37°C. TIL were labeled with 0.1 µM CFSE (Invitrogen); 
afterwards 100,000 cells in 200 µl medium were cultured in each well of a 96-well round-
bottom culture plate and stimulated with anti-human CD3/CD28 dynabeads (Gibco-Life 
Technologies AS, Norway) at a cell : bead ratio of 10:1, in the presence or absence of 10 
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μg/ml neutralizing monoclonal antibodies against human PD-L1 (clone 5H14), TIM3 (clone 
F38-2E2, Biolegend, San Diego, USA5, 6), LAG3 (clone 17B4, AdipoGen, Liestal, 
Switzerland7) or CTLA4 (clone BNI3, Beckman Coulter, Marseille, France8), or combinations 
of these antibodies, or isotype-matched control antibodies (mIgG1 and mIgG2a, Biolegend, 
London, UK). In preliminary experiments a cell : CD3/CD28 bead ratio of 10:1 was 
established to provide sub-optimal stimulation of T cell proliferation. After four days, culture 
supernatant was collected and secretion of IFN-γ was quantified by ELISA (Ready-SET-Go!, 
eBioscience). CFSE-labeled cells were harvested and stained with CD8, CD4, CD3 
antibodies. Dead cells were excluded by using the LIVE/DEAD fixable dead cell stain kit with 
aqua fluorescent reactive dye, and T cell proliferation was determined based on CFSE 
dilution by flow cytometry analysis.  
Ex vivo tumor antigen peptide stimulation assay 
TIL of HLA-A2+ HCC patients were stimulated with pooled HCC TAA peptides (GPC3 peptide 
FVGEFFTDV,9 GPC3 peptide FLAELAYDL,10, 11 MAGEC2 peptide ALKVDVEERV and 
MAGEC2 peptide LLFGLALIEV,12 which are published immunogenic epitopes restricted by 
HLA-A*0201 (1 μg/ml of each peptide), in the presence or absence of 10 μg/ml neutralizing 
monoclonal antibodies against human PD-L1, TIM3, LAG3 or CTLA4, or combinations of 
these antibodies, or isotype control antibodies. 100,000 cells in 200 µl RPMI medium 
supplemented with 10% human AB serum, 2mM L-glutamine, 50 mM Hepes Buffer, 1% 
penicillin-streptomycin, 5mM Sodium Pyruvate and 1% MEM NEAA were cultured in each 
well of a 96-well round-bottom culture plate. Fresh medium containing 20 IU/ml recombinant 
human interleukin-2 (rhIL-2, Roche) was added after two days. After seven days, cells were 
re-stimulated with pooled HCC TAA peptides or (as negative controls) HCV nonstructural 
protein 5B peptide 2594-2602 (ALYDVVTKL) or HBV core protein peptide 18-27 
(FLPSDFFPSV) kindly provided by Gertine W. van Oord and Yingying Dou in our laboratory 
for six hours in the presence of CD107a antibody, and brefeldin (5 µg/mL, Sigma) was 
present during the final five hours. Re-stimulation with HCV antigen peptide served as 
negative control for HCV negative patients (including patients negative for both HCV and 
HBV), HBV antigen peptide served as negative control for HBV negative patients. Cells were 
then stained with CD8, CD4, CD3 antibodies, followed by staining of IFN-γ, TNF-α and 
CD137 upon fixation and permeabilization according to the manufacturer’s instructions 
(eBioscience A&B fixation/permeabilization kit). Dead cells were excluded by using the 
LIVE/DEAD fixable dead cell stain kit with aqua fluorescent reactive dye.  
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Expansion of human B cells by stimulation with trimeric CD40 ligand and IL-4 
Blood from HLA-A2+ healthy blood bank donors or HCC patients was collected (1-2 months 
before surgery for HCC patients) for isolating PBMC and expanding B cells. PBMC were 
seeded in 6-well plates (Costar, Cambridge, USA) at a concentration of 2-3×106 cells/ml in 
IMDM (Lonza, Breda, The Netherlands) with 10% heat inactivated human AB serum, 1% 
penicillin-streptomycin, 1% insulin-transferrin-selenium solution (Gibco-Invitrogen, Breda, the 
Netherlands), 40 IU/ml recombinant human interleukin-4 (rhIL-4, Strathmann Bioscience, 
Germany) and 1 µg/ml soluble human trimeric CD40 ligand (sCD40L, kindly provided by 
Celldex Therapeutics, Hampton, NJ, USA). During the first seven days of culture, 1 ng/ml 
cyclosporine A (CsA, Novartis, Basel, Switzerland) was added to prevent T cell expansion. 
Residual CD3+ cells were depleted by magnetic cell sorting using CD3 microbeads (Miltenyi 
Biotec, Bergisch Gladbach, Germany) after seven days. Since then cells were passed every 
3-4 days at a concentration of 0.5×106 CD19+ cells/ml in the presence of rhIL-4 and sCD40L 
but without CsA, and after three weeks expanded B cells were cryopreserved. B cells 
expanded using rhIL-4 and sCD40L become B cell blasts with efficient antigen-presenting 
capacity13, 14 and are well-suited for presentation of antigens encoded by transfected mRNA 
to T cells.15 The purity of CD40-activated B cells (B cell blasts) was checked after staining 
with CD19 and CD3 antibodies and was at least 95% before freezing.13 
In vitro generation of eGFP, GPC3 and MAGEC2 messenger RNA 
Messenger RNA (mRNA) encoding for GPC3, MAGEC2 or eGFP were synthesized by in 
vitro transcription. The back bone vector pEtheRNA was constructed in order to maximize 
the level and duration of protein expression. The plasmid contains a 5’ translation enhancer, 
a 3’ RNA stabilizing sequence and a 124 residue long poly A tail. GPC3 and MAGEC2 genes 
were ligated into this construct and are directly followed by a sequence encoding the 
transmembrane and luminal regions of DCLamp, which is a targeting signal for the 
endolysosomal compartment, resulting in peptide loading in MHC-II. The eGFP gene was 
ligated into the vector without additional targeting sequences. Prior to in vitro transcription, 
the DNA plasmids were linearized with BfuAI. RNA synthesis was performed by eTheRNA 
immunotherapies NV, Niel, Belgium. During transcription a cap analog was incorporated in 
the mRNA. The quality of the in vitro transcribed mRNA was confirmed by capillary gel 
electrophoresis and the mRNA concentration was measured by spectrophotometry. The 
obtained mRNA were stored in small aliquots at -80°C till use. 
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Messenger RNA electroporation 
B cell blasts were thawed and washed twice, first with serum-free IMDM and subsequently 
with Opti-MEM (Life technologies, Bleiswijk, The Netherlands). 5-10×106 B cell blasts were 
resuspended in a final volume of 200 µL of Opti-MEM containing 20 µg of mRNA. 
Electroporation was performed in a 4 mm gap cuvette using a Gene Pulser XcellTM 
electroporation system (Bio-Rad Laboratories, Hercules, CA). We used a square wave pulse 
of 600 V in a pulse time of 0.6 ms in all experiments, which we found optimal for antigen 
presentation to T cells. Immediately after electroporation, B cell blasts were transferred into 
IMDM without phenol red (Life Technologies) with 10% heat-inactivated human AB serum, 
1% penicillin-streptomycin and 1% insulin-transferrin-selenium solution and incubated at 
37°C. Two hours after electroporation, cells were harvested for further experiments. 
GPC3-specific CD8+ T cell clone and MAGEC2-specific human T cells 
A previously described HLA-A*0201-restricted GPC3 (FVGEFFTDV) specific CD8+ T cell 
clone was kindly provided by Dr. Tetsuya Nakatsura, Kashiwa, Japan.9 Human T cells 
retrovirally transduced with a TCR that specifically recognizes MAGEC2 peptide 
(ALKVDVEERV) in HLA-A*0201 as described by Straetemans T et al.,16 were kindly provided 
by Dr. Reno Debets, Department of Internal Oncology, Erasmus MC. These T cells were 
used as responder cells for testing presentation of GPC3 and MAGEC2 by mRNA-
transfected B cell blasts. GPC3-specific T cells were expanded by non-specific stimulation 
with 5 µg/ml PHA and irradiated allogeneic PBMC as feeder cells, in AIM-V medium (Gibco) 
supplemented with 10% human AB serum, 100 IU/ml rhIL-2 and 10 ng/ml recombinant 
human interleukin-15. Every 3-4 days T cells were further expanded by splitting the cultures 
and replenishing fresh culture medium without feeder cells or PHA. After14 days, cells were 
harvested for experiments or cryopreserved till further use. 
Statistical analysis 
All data set distributions were analyzed for normality by the Shapiro-Wilk normality test. 
Differences between paired groups of data were analyzed according to their distribution by 
either paired t test or Wilcoxon matched pairs test. Differences between different groups of 
patients were analyzed according to their distribution by either unpaired t test or Mann-
Whitney test. Correlation was analyzed according to the distribution by either Pearson or 
Spearman correlation test. The statistical analysis was performed using GraphPad Prism 
Software (version 5.0). P values less than 0.05 were considered statistically significant (* 
P<0.05; ** P<0.01; *** P<0.001). 
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ABSTRACT 
Purpose: Liver metastasis develops in >50% of patients with colorectal cancer (CRC), and is 
a leading cause of CRC-related mortality. We aimed to identify which inhibitory immune 
checkpoint pathways can be targeted to enhance functionality of intra-tumoral T-cells in 
mismatch repair-proficient liver metastases of colorectal cancer (LM-CRC).  
Methodology: Intra-tumoral expression of multiple inhibitory molecules was compared 
among mismatch repair-proficient LM-CRC, peritoneal metastases of colorectal cancer (PM-
CRC) and primary CRC. Expression of inhibitory molecules was also analyzed on leukocytes 
isolated from paired resected metastatic liver tumors, tumor-free liver tissues, and blood of 
patients with mismatch repair-proficient LM-CRC. The effects of blocking inhibitory pathways 
on tumor-infiltrating T-cell responses were studied in ex vivo functional assays.  
Results: Mismatch repair-proficient LM-CRC showed higher expression of inhibitory 
receptors on intra-tumoral T-cells and contained higher proportions of CD8+ T-cells, dendritic 
cells and monocytes than mismatch repair-proficient primary CRC and/or PM-CRC. Inhibitory 
receptors LAG3, PD-1, TIM3 and CTLA4 were higher expressed on CD8+ T-cells, CD4+ T-
helper and/or regulatory T-cells in LM-CRC tumors compared with tumor-free liver and blood. 
Antibody blockade of LAG3 or PD-L1 increased proliferation and effector cytokine production 
of intra-tumoral T-cells isolated from LM-CRC in response to both polyclonal and autologous 
tumor-specific stimulations. Higher LAG3 expression on intra-tumoral CD8+ T-cells 
associated with longer progression-free survival of LM-CRC patients.  
Conclusion: Mismatch repair-proficient LM-CRC may be more sensitive to immune 
checkpoint inhibitors than mismatch repair-proficient primary CRC. Blocking LAG3 enhances 
tumor-infiltrating T-cell responses of mismatch repair-proficient LM-CRC, and therefore may 
be a new promising immunotherapeutic target for LM-CRC. 
Keywords: immunotherapy; immune checkpoint inhibitor; tumor-infiltrating lymphocyte; liver 
metastasis; colorectal cancer; peritoneal metastasis; LAG3; PD-1; T cell; mismatch repair 
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INTRODUCTION 
Colorectal cancer (CRC) is the third most common cause of cancer-related mortality 
worldwide.(1-3) More than 50% of CRC patients develop metastatic disease to their liver 
over the course of their life,(4) and liver metastasis is a leading cause of death from CRC.(5-
7) Unfortunately, surgical resection of isolated liver metastases of CRC (LM-CRC) is curative 
in only 20%-30% of patients,(8, 9) and systemic therapy provides limited survival benefit.(10) 
Patients with unresectable LM-CRC have a poor prognosis with a median survival of only two 
years.(11) Therefore, there is a pressing need for more effective therapeutic strategies for 
LM-CRC. 
The immune system plays a crucial role in cancer surveillance and elimination, and antibody 
blockade of inhibitory immune checkpoint pathways that suppress anti-tumor T-cell immunity 
and assist tumor immune evasion,(12-16) has recently emerged as an attractive treatment 
option for multiple types of malignancies.(17-21) Targeting the PD-1/PD-L1 inhibitory 
pathway has resulted in objective responses in 17%-28% of advanced melanoma patients, 
12%-27% of renal cell cancer patients, 10%-18% of non-small cell lung cancer patients and 
20% of advanced hepatocellular carcinoma patients.(22-25) In contrast, CRC patients hardly 
respond to PD-1 and PD-L1 blocking antibodies(23-26), except for the minority of patients 
who are with mismatch repair (MMR)-deficient CRC.(27, 28) A defective MMR enzyme 
system occurs in 10%-20% of CRC tumors and results in microsatellite instability, which is 
used as a molecular marker of MMR-deficiency.(29) It has been hypothesized that the 
observed difference in responsiveness to PD-1/PD-L1 blockade between MMR-deficient and 
MMR-proficient CRC is related to the higher numbers of somatic mutations in MMR-deficient 
tumors, due to the reduced ability to repair DNA damage. The increased mutation rate may 
result in the presence of more mutation-encoded neo-antigens in the tumors, which elicit 
stronger anti-tumor T cell responses.(27) Indeed, MMR-deficient CRC tumors are 
characterized by denser CD8+ T cell infiltration.(30) They also have higher expression levels 
of inhibitory checkpoint molecules, probably to resist immune-mediated tumor 
elimination.(31) Together, enhanced immune cell infiltration and upregulation of inhibitory 
immune checkpoints may render MMR-deficient CRC more sensitive to PD-1/PD-L1 
blockade than MMR-proficient CRC.  
In LM-CRC the incidence of MMR deficiency is low,(32) and it may therefore be expected 
that LM-CRC poorly respond to immune checkpoint inhibitors. Nevertheless, these tumors 
contain immune infiltrates, and increased numbers of tumor-infiltrating CD8+ T cells are 
positively associated with overall survival and response to chemotherapy,(33, 34) indicating 
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that intra-tumoral T cell immunity is an important determinant of LM-CRC progression. In 
addition, MMR-proficient LM-CRC are immunologically distinct from primary CRC in terms of 
immune infiltration.(35) Moreover, the unique immune environment in the liver(36) favors 
immunological tolerance,(36) and one of the mechanisms used by the liver to resist immune 
responses is the induction of expression of inhibitory receptors on hepatic T cells(37, 38) and 
their ligands on hepatocytes and other liver tissue cells.(39) Previously we have observed 
that intra-tumoral CD8+ cytotoxic T cells (CTL) and CD4+ T helper cells (Th) are functionally 
compromised in LM-CRC,(40) and we also demonstrated that the suppression mediated by 
intra-tumoral regulatory T cells (Treg) in LM-CRC can be alleviated by blocking the inhibitory 
receptor CTLA4 and activating the stimulatory receptor GITR.(41) However, the expression 
and functional roles of inhibitory receptor-ligand pathways in regulating tumor-infiltrating 
effector T cell responses have not been studied yet in LM-CRC. 
Therefore, the aim of this study was to determine whether inhibitory immune checkpoint 
pathways can be targeted to enhance the functionality of tumor-infiltrating lymphocytes (TIL) 
in MMR-proficient LM-CRC. We measured the expression of inhibitory receptors and their 
ligands on leukocytes isolated from paired resected metastatic liver tumors, tumor-free liver 
tissues (TFL) and blood of patients with LM-CRC, and compared their expression levels with 
those on leukocytes isolated from peritoneal metastasis of CRC (PM-CRC) and primary 
CRC. In addition, we studied the effects of antibody blockade of inhibitory pathways on TIL 
responses of LM-CRC in ex vivo functional assays.  
RESULTS 
Comparison of immune infiltrates and expression of inhibitory molecules among 
MMR-proficient liver metastases, peritoneal metastases and primary CRC. 
To speculate whether TIL in CRC tumors at different anatomical sites may differ in sensitivity 
to checkpoint inhibitors, we first compared frequencies of T cell and antigen-presenting cell 
(APC) subsets, as well as their expression of inhibitory molecules, between MMR-proficient 
LM-CRC, primary CRC, and metastases outside the liver. Two in all LM-CRC tumors and 
three out of twelve primary CRC tumors that we collected were MMR-deficient, whereas all 
eleven PM-CRC tumors were MMR-proficient (Table 1 and Supplementary Table S1). The 
data of the five patients with MMR-deficient tumors are shown in Supplementary Fig. S1.  
We observed several interesting differences among MMR-proficient tumors from different 
anatomical locations. Firstly, both LM-CRC and PM-CRC contained significantly higher 
frequencies of CD8+ CTL and significantly lower frequencies of CD4+Foxp3- Th than primary 
CRC, while frequencies of Treg were similar in CRC tumors at all three sites (Fig. 1A). 
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Secondly, CD8+ CTL in LM-CRC displayed a higher frequency of PD1+ cells than those in 
primary CRC, and also contained higher frequencies of TIM3+ and LAG3+ cells than those in 
PM-CRC, while CD4+ Th in LM-CRC displayed a higher frequency of LAG3+ cells than those 
in PM-CRC (Fig. 1B). Thirdly, CD4+Foxp3+ Treg in LM-CRC contained higher frequencies of 
PD-1+ and TIM3+ cells than those in primary CRC and PM-CRC, and also displayed a higher 
frequency of LAG3+ cells than those in PM-CRC (Fig. 1B). Finally, LM-CRC contained 
significantly higher frequencies of myeloid dendritic cells (mDC) and monocytes than primary 
CRC (Fig. 1C), which not only can present tumor antigens to T cells but also express the 
inhibitory ligands PD-L1 (for PD-1), galectin 9 (for TIM3), MHC class II molecules (for LAG3), 
CD86 and CD80 (for CTLA4) (Fig. 1D). Hierarchical clustering analysis showed that the 
immunological data of most LM-CRC patients clustered together as did the data of most 
primary CRC patients (Supplementary Fig. S2). Together, these data indicate that the CD8+ 
CTL:Treg ratio, which is critical for immunological tumor control in primary as well as 
metastasized CRC,(42) is more favorable in CRC metastases compared to primary CRC. In 
addition, the increased expression of PD-1 on TIL suggests that TIL of LM-CRC may be 
more sensitive to blockade of the PD-1/PD-L1 pathway than TIL of primary CRC.      
Elevated expression of inhibitory receptors on CD8+ cytotoxic T cells, CD4+ T helper 
cells and regulatory T cells in MMR-proficient LM-CRC tumors.  
We isolated leukocytes from surgically resected metastatic liver tumors, TFL and blood of 
LM-CRC patients, and compared the expression levels of five inhibitory receptors (PD-1, 
TIM3, LAG3, CTLA4 and BTLA) on CD8+ CTL, CD4+Foxp3- Th and CD4+Foxp3+ Treg. When 
compared to TFL and blood, significantly higher proportions of CD8+ CTL, Th and Treg in TIL 
expressed PD-1 and TIM-3. In addition, TIL contained higher frequencies of CTLA4+ CTL 
and CTLA4+ Th, while LAG3 was overexpressed on CD8+ CTL in TIL when compared to TFL 
and blood (Fig. 2). Interestingly, the highest expression of CTLA4, which is functionally 
involved in the suppressive capacity of Treg,(43) and also of PD-1 and TIM3 was found on 
tumor-infiltrating Treg. In contrast, frequencies of BTLA+ cells in intra-tumoral T cells were 
low, and they did not differ significantly from those in TFL and blood (Supplementary Fig. 
S3). Therefore, we focused on the other four receptors in the rest of this study. To investigate 
whether the expression of inhibitory receptors on circulating T cells had a relation with the 
expression on intra-tumoral T cells, we performed correlation analysis, as illustrated in 
Supplementary Fig. S4. There were significant positive correlations between the frequencies 
of PD-1+ CTL and PD-1+ Treg in the tumor and those in the blood, between the frequency of 
LAG3+ Th in the tumor and that in the blood, and between the frequencies of CTLA4+ Th and 
CTLA4+ Treg in the tumor and those in the blood. These results indicate that the expression 
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of inhibitory receptors on circulating T cells partly reflects their expression on intra-tumoral T 
cells. 
Intra-tumoral antigen-presenting cells express inhibitory ligands.  
To study the expression of inhibitory ligands PD-L1, galectin 9, MHC-II molecules, CD86 and 
CD80 on APC in LM-CRC tissues, we measured these molecules by flow cytometry. Three 
major APC subsets BDCA-1+CD19- mDC, CD14+ monocytes and CD19+ B cells were found 
in all tumors. The frequency of B cells was higher in tumors than in TFL, and the frequency of 
mDC was higher in tumors and TFL than in the blood, whereas the frequency of monocytes 
was lower in tumors than in the blood (Fig. 3A). The three different tumor-infiltrating APC 
populations expressed the five ligands at different levels and considerable variations 
between individual patients were observed (Fig. 3B, C). Intra-tumoral mDC and monocytes 
contained higher proportions of PD-L1+ and MHC-II+ cells than intra-tumoral B cells. The 
median fluorescence intensities of five ligands in APC subsets in the tumor, TFL and blood 
are presented in Fig. 3D, showing that the expression of inhibitory ligands is generally not 
increased on tumor-infiltrating APC compared to APC in TFL. Together, the abovementioned 
data suggest that inhibitory interactions between T cells and APC in MMR-proficient LM-CRC 
are possible.       
Intra-tumoral T cells expressing inhibitory receptors show increased levels of 
activation markers. 
Considering that increased expression of inhibitory receptors on T cells can be induced by 
recent activation, or by chronic stimulation that may lead to T cell dysfunctionality, we 
examined the ex vivo activation status and in vitro effector cytokine production of effector T 
cells derived from MMR-proficient LM-CRC. First we compared the expression of activation 
markers HLA-DR and CD69 on intra-tumoral T cells that do or do not express inhibitory 
receptors. Interestingly, PD-1+, TIM3+, LAG3+ or CTLA4+ CTL and Th showed a more 
activated status than PD-1-, TIM3-, LAG3- or CTLA4- CTL and Th, respectively (Fig. 4A, B). 
Subsequently, we assessed effector cytokine production of tumor-derived T cells after short-
term PMA and ionomycin stimulation. Despite the activated status, the frequencies of 
inhibitory receptor positive CTL and Th cells that produced IFN-γ and TNF-α were reduced or 
similar to those in the respective receptor negative T cells (Fig. 4C, D). Interestingly, LAG3+ 
CTL and Th cells did not show reduction in cytokine production. Because among all studied 
inhibitory receptors, tumor-infiltrating CTL and Th showed the highest expression of PD-1 
(Fig. 2C, D), we analyzed co-expression of PD-1 and the other three receptors. Co-
expression of PD-1 and either TIM3, LAG3 or CTLA4 was found, especially in CD8+ CTL, but 
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expression of TIM3, LAG3 or CTLA4 without PD-1 was also observed (Supplementary Fig. 
S5). Similar to single receptor positive CTL and Th, double receptor positive CTL and Th 
showed reduced or comparable frequencies of IFN-γ and TNF-α producing cells to double 
receptor negative cells, while LAG3+PD-1+ CTL and Th did not show significant reduction in 
cytokine production (Fig. 4C, D). These data demonstrate that in general intra-tumoral T cells 
that express inhibitory receptors do not produce more effector cytokines, despite the 
activated status.  
Antibody blockade of LAG3 or PD-L1 boosts ex vivo proliferation and effector cytokine 
production of T cells derived from MMR-proficient LM-CRC.  
Because PD-1, TIM3, LAG3 and CTLA4 are upregulated on T cells in MMR-proficient LM-
CRC tumors, we tested whether blockade of the PD-1/PD-L1, TIM3/galectin 9, LAG3/MHC-II 
or CTLA4/CD80/CD86 pathways could enhance the effector functions of tumor-derived T 
cells. We stimulated CFSE-labeled total tumor-infiltrating mononuclear leukocytes with 
CD3/CD28 beads, in the presence or absence of antagonistic antibodies against human PD-
L1, TIM3, LAG3, CTLA4 or isotype controls (mIgG1 or mIgG2a). After four days of culture, T 
cell proliferation was measured by flow cytometry (Fig. 5A), and effector cytokine secretion in 
the culture supernatants was quantified by enzyme-linked immunosorbent assay. Fig. 5B 
illustrates that the baseline proliferation of CD8+ and CD4+ T cells derived from tumors was 
significantly lower than that of T cells from the blood of the same patients, indicating the 
proliferative function of intra-tumoral T cells is impaired compared to circulating T cells of 
patients with MMR-proficient LM-CRC. Interestingly, treatment with anti-LAG3 antibody or 
anti-PD-L1 antibody significantly increased the proliferation of both CD8+ and CD4+ TIL 
compared with the control condition without antagonistic antibody (Fig. 5C). These two 
antibodies also significantly increased IFN-γ and TNF-α secretion (Fig. 5D).  
Antibody blockade of LAG3 or PD-L1 boosts ex vivo responses of T cells derived from 
MMR-proficient LM-CRC to autologous tumor antigens.  
To investigate whether blockade of the aforementioned inhibitory pathways can enhance 
tumor-specific anti-tumor T cell responses, we stimulated CFSE-labeled total tumor-
infiltrating mononuclear leukocytes with autologous blood-derived mDC preloaded with 
autologous tumor lysates, in the presence or absence of antagonistic antibodies, and 
measured CD8+ and CD4+ T cell proliferation after six days. Increased TIL proliferation 
against mDC loaded with tumor lysates compared with mDC without tissue lysates was 
observed in all five tested patients, while loading of mDC with normal liver lysates did not 
increase or minimally increased TIL proliferative responses (Fig. 6A, C). Addition of anti-PD-
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L1 antibody enhanced proliferative responses of TIL in all four tested patients, while 
treatment with anti-LAG3 antibody increased both CD8+ and CD4+ TIL proliferation in four out 
of five patients. In three out of four patients anti-LAG3 antibody boosted CD8+ and/or CD4+ 
TIL responses to higher levels than anti-PD-L1 antibody (Fig. 6A, C). After five hours of 
restimulation, intracellular expression of IFN-γ and TNF-α in proliferating T cells was 
analyzed, and was found to be enhanced by both anti-LAG3 and anti-PD-L1 antibodies in 
most patients (Fig. 6B, D, E). Like in CD3/CD28 stimulations, anti-TIM3 and anti-CTLA4 
antibodies boosted TIL responses less strongly and also in less patients.  
Higher LAG3 expression on intra-tumoral CD8+ T cells is associated with longer 
progression-free survival of patients with MMR-proficient LM-CRC.    
In a subset of patients, we could analyze associations between the frequencies of inhibitory 
receptor positive TIL and patient progression-free survival after the LM-CRC resection. In 
survival analysis higher expression of LAG3 on CD8+ TIL, CD4+ Th and Treg was associated 
with longer time to recurrence (Fig. 7), whereas higher expression of PD-1 or TIM3 on CD8+ 
TIL was associated with shorter time to recurrence (data not shown). In multivariable 
analysis only LAG3 expression on CD8+ TIL was demonstrated to be an independent 
predictor of progression-free survival (Table 2), which supports its functional relevance to 
anti-cancer immunity in TIL of LM-CRC. We hypothesize that LAG3+CD8+ TIL may be highly 
activated T cells (Fig. 4A) stimulated by tumor antigens, but subsequently inhibited by 
increased and continuous expression of LAG3 and interaction with its ligands on APC and 
tumor cells, yet with preserved effector functions (Fig. 4C), which may control tumor growth. 
Because the sample size is small, these results need conformation in an independent study. 
In one fourth of the patients we only have data of LAG3 expression on CD8+ TIL but not on 
CD4+ Th or Treg, so we did not include the latter T cell subsets in the multivariable analysis. 
The death events were too few to analyze overall survival of LM-CRC patients.     
DISCUSSION 
Checkpoint inhibitors have recently emerged as attractive treatments for several types of 
solid cancers. However, PD-1 and PD-L1 blocking antibodies were proven unsuccessful in 
CRC, with the exception of MMR-deficient CRC.(23-25, 27, 28) The first aim of this study 
was to investigate whether the composition of the immune infiltrates and the intra-tumoral 
expression levels of inhibitory molecules in CRC metastases in the liver environment differ 
from those in primary CRC tumors and metastases outside the liver, which would suggest 
potential differences in sensitivity to checkpoint inhibitors among CRC tumors at different 
anatomical locations. The second objective was to determine whether targeting of inhibitory 
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checkpoint pathways by antagonistic antibodies can enhance the functionality and anti-tumor 
responses of tumor-infiltrating T cells in LM-CRC. Because the incidence of MMR deficiency 
in LM-CRC is low, we focused on MMR-proficient tumors. 
This study is the first to investigate the expression levels of inhibitory receptors on TIL in LM-
CRC. Similar to what we reported in hepatocellular carcinoma,(44) intra-tumoral CD8+ CTL 
and CD4+ Th in MMR-proficient LM-CRC displayed increased expression of PD-1, TIM3, 
CTLA4 and/or LAG3 compared to their counterparts in TFL and blood. In addition, we found 
selectively enhanced expression of PD-1 and TIM3 on intra-tumoral Treg (Fig. 2C-E). The 
elevated frequencies of inhibitory receptor positive cells in TIL together with the expression of 
their ligands on tumor-infiltrating APC (Fig. 3B-D) suggest that these inhibitory checkpoint 
pathways may be involved in intra-tumoral suppression of T cells in MMR-proficient LM-CRC.  
Interestingly, we observed higher expression of PD-1 and/or TIM3 on CD8+ CTL and Treg in 
LM-CRC than in primary CRC, while expression of LAG3, TIM3 and/or PD-1 on CD8+ CTL, 
Th and Treg was higher in LM-CRC than in PM-CRC (Fig. 1B). We hypothesize that these 
differences are due to the unique tolerogenic properties of the liver environment, which 
induces expression of inhibitory receptors on hepatic T cells both in diseased and healthy 
conditions.(37, 38) Furthermore, we found increased proportions of CD8+ CTL in LM-CRC 
and PM-CRC compared with primary CRC (Fig. 1A). The observed differences between 
MMR-proficient LM-CRC and MMR-proficient primary CRC are to some extent reminiscent of 
those found between MMR-deficient primary CRC and MMR-proficient primary CRC by Llosa 
et al. (31) They demonstrated that MMR-deficient primary CRC displayed higher infiltration 
with CD8+ CTL as well as upregulated expression of PD-1, PD-L1, CTLA4 and LAG3 
compared to MMR-proficient primary CRC, and suggested that these differences contributed 
to the enhanced clinical responsiveness to anti-PD-1 therapy of microsatellite instable CRC 
compared with microsatellite stable CRC.(31) In addition, we found that LM-CRC contained 
increased frequencies of professional APC subsets (mDC and monocytes) (Fig. 1C), which 
may result in improved presentation of tumor antigens to intra-tumoral T cells as well as 
more PD-L1 and MHC-II expression in LM-CRC compared with primary CRC, because in 
LM-CRC mDC and monocytes expressed more PD-L1 and MHC-II than B cells (Fig. 3C). 
Hierarchical clustering analysis showed that the immune phenotypical data of most LM-CRC 
tumors clustered together as did the data of most primary CRC tumors (Supplementary Fig. 
S2). These data confirm those of Halama et al., who demonstrated similar heterogeneity in 
composition of immune infiltrates between paired primary CRC tumors and liver metastases 
derived from the same patients.(35) We extracted and statistically analyzed their paired data 
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of primary CRC and LM-CRC from 16 patients and found a higher CD8+ cell density in LM-
CRC than in primary CRC (Supplementary Fig. S6).  
Moreover, discrepancies in somatic mutations, copy number alterations, genetic and 
epigenetic molecular alterations between primary CRC tumors and matched liver metastases 
were revealed in up to a half of the cases, which may lead to higher mutational load and 
thereby more neo-epitopes in LM-CRC.(45-48) Together, these findings indicate major 
differences between liver metastases and primary CRC as well as peritoneal metastases, 
including differences in immune cell infiltration and inhibitory molecule expression, which 
may be at least partly induced by the liver environment. We therefore suggest that TIL of 
MMR-proficient LM-CRC may be more sensitive to PD-1/PD-L1 blockade and other 
checkpoint inhibitors than TIL of MMR-proficient primary CRC and CRC metastases at other 
anatomical locations. Nevertheless, to precisely compare the effects of checkpoint inhibitors 
on TIL of primary CRC and LM-CRC, experiments with TIL from paired tissues might be 
needed but were unfortunately not available in the current study. 
To determine whether TIL expressing inhibitory receptors represent T cells that are recently 
activated upon recognition of tumor antigens, or are dysfunctional due to chronic antigenic 
stimulation, we studied their ex vivo activation status and in vitro effector cytokine production. 
Similar to what we reported in hepatocellular carcinoma,(44) intra-tumoral CD4+ Th and CD8+ 
CTL expressing any of the four inhibitory receptors showed a more activated status but 
produced reduced or similar levels of effector cytokines than their counterparts not 
expressing the corresponding inhibitory receptor (Fig. 4). However, in our ex vivo cultures, 
tumor cells that may express inhibitory ligands are lacking, so the TIL might be less 
functional in vivo and need checkpoint inhibitors. Nevertheless, proliferative responses of 
tumor-derived T cells to CD3/CD28 stimulation were lower than those of circulating T cells 
(Fig. 5B). Consistent with what others reported on IFN-γ production by CD8+ TIL in primary 
CRC patients,(49, 50) our results demonstrate a certain degree of dysfunctionality of intra-
tumoral CD4+ Th and CD8+ CTL in MMR-proficient LM-CRC, which may be at least partly 
due to inhibitory checkpoint interactions between T cells and APC subsets in the TIL 
cultures, but not complete dysfunctionality.  
This study is also the first to investigate the effects of antibody blockade of four inhibitory 
checkpoint pathways on responses of TIL isolated from MMR-proficient LM-CRC. In both 
polyclonal T cell activation and tumor-specific TIL stimulation assays, increased proliferation 
of TIL and increased production of effector cytokines were observed upon the addition of 
anti-LAG3 antibody or anti-PD-L1 antibody (Fig. 5 and Fig. 6) In some patients ex vivo anti-
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tumor responses of TIL were more robustly enhanced by anti-LAG3 antibody than by anti-
PD-L1 antibody (Fig. 6), suggesting that LAG3 might be the most promising target for 
immunotherapy of LM-CRC among all four checkpoint pathways tested in this study. 
However, these data need confirmation using TIL from a larger number of patients. The 
superiority of LAG3 blockade compared to PD-L1 blockade was more seen in tumor antigen-
specific stimulation than in polyclonal stimulation. We hypothesize that the small proportion 
of LAG3+ TIL is strongly enriched with tumor antigen-reactive T cells, which are known to 
constitute only a small proportion of all tumor-infiltrating T cells. In addition, we propose that 
PD-1 is expressed on a larger fraction of TIL which contains more non-tumor antigen-specific 
T cells. Although TIM3 blockade was reported to reduce T cell apoptosis and inhibit tumor 
growth in a mouse CT26 colon tumor model,(51) little effect was observed in our experiments 
using TIL derived from human LM-CRC. This result also contrasts to our recent observation 
that ex vivo responses of TIL isolated from hepatocellular carcinomas can be invigorated by 
TIM3 blockade.(44) This difference may relate to the lower expression of galectin 9 on APC 
subsets in LM-CRC compared to hepatocellular carcinomas.  
Because we were interested in the net effects of checkpoint inhibitors on TIL responses in a 
context that reflected the LM-CRC tumor microenvironment as much as possible, we used 
total tumor-infiltrating mononuclear leukocytes in our functional assays, which contained both 
T cells expressing inhibitory receptors and APC expressing inhibitory ligands. As a 
consequence, tumor-infiltrating Treg,(40, 41) type 1 regulatory T cells(52) and probably other 
types of immune suppressor cells were also present in these assays. Therefore, the reported 
functional effects of checkpoint inhibitors on effector T cells in these assays may be partly 
indirect, mediated by effects of these antibodies on suppressor cells. The effects of 
checkpoint inhibitor on effector T cells in our assays might even be counteracted by its 
effects on suppressor cells. We found that half of Treg in LM-CRC tumors expressed PD-1, 
and blocking PD-1/PD-L1 interaction was shown to enhance the suppressive function of Treg 
isolated from liver tissues of patients with chronic hepatitis C infection.(53)  
Interestingly, higher expression of LAG3 on CD8+ TIL was associated with longer time to 
recurrence of patients with LM-CRC. We hypothesize that LAG3+CD8+ TIL are cells which 
have recently been activated (Fig. 4A) by recognition of antigens in the tumor, and 
upregulate LAG3 expression in response to activation but still have functional capacity to 
exert effector functions and delay tumor growth (Fig. 4C). LAG3 expression is upregulated on 
T cells after activation and differentiation,(54, 55) and intra-tumoral T cells that recognize 
tumor antigens are characterized by expression of LAG3 and other inhibitory receptors.(56) 
Although chronic tumor antigen stimulation in the tumor microenvironment can induce T cell 
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exhaustion with simultaneous induction of high expression of multiple inhibitory receptors, 
this does not mean that all CD8+ TIL which express one or more inhibitory receptors at any 
level are functionally exhausted. Indeed, a recent mouse study showed that tumor antigen-
specific TIL which expressed LAG3 or PD-1 produced IFN-γ in situ and had cytolytic 
potential.(57) Likewise, in the current study we observed that LAG3+CD8+ TIL in LM-CRC 
were not functionally impaired (Fig. 4C). Nevertheless, they could be functionally invigorated 
upon antibody blockade of LAG3 (Fig. 5 and Fig. 6), indicating that interaction of LAG3 with 
its ligands serves as an extrinsic mechanism in the tumor microenvironment which inhibits 
their functionality.  
Our study has several limitations: 1) Due to the finite numbers of isolated TIL, the tumor-
specific stimulation assay could only be performed in a limited number of LM-CRC patients 
(Supplementary Table S1), neither could all the conditions be tested in every functional 
assay, nor could the relation between the expression of inhibitory molecules on TIL and the 
effects of checkpoint inhibitors on TIL responses be well analyzed. 2) We could not study 
paired LM-CRC, primary CRC and PM-CRC tumors from the same patients because primary 
and metastatic CRC tumors were resected at different time points and in different hospitals. 
3) MMR-deficient tumors could not be studied well, because we received fresh tissues from 
only a few MMR-deficient tumors during our study. 
In conclusion, increased frequencies of CD8+ CTL, mDC and monocytes as well as 
increased inhibitory receptor expression on intra-tumoral T cells in MMR-proficient LM-CRC 
suggest that TIL of MMR-proficient LM-CRC may be more sensitive to immune checkpoint 
inhibitors than TIL of MMR-proficient primary CRC. Blockade of LAG3 and PD-L1 can both 
enhance ex vivo functions of tumor-infiltrating T cells from MMR-proficient LM-CRC. 
Therefore, these two inhibitory pathways may be potential immunotherapeutic targets for the 
most prevalent metastatic liver cancer, despite the lack of MMR deficiency. Clinical studies 
focusing on responses of LM-CRC to anti-LAG3 and combination with anti-PD-L1 or anti-PD-
1 antibodies(12, 58) are required to conclude whether this prediction based on our preclinical 
study is correct. 
PATIENTS AND METHODS 
Patients and specimens  
Fifty three patients who were eligible for surgical resection of LM-CRC were enrolled in the 
study from November 2013 to March 2017. Another twelve patients who received surgical 
resection of primary CRC and another eleven patients whose PM-CRC were surgically 
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resected before hyperthermic intraperitoneal chemotherapy were enrolled in the study from 
February 2016 to December 2016. Fresh tissue samples from hepatic tumors, tumor-free 
liver tissues as distant as possible from the tumor (minimum 1cm distance), colorectal tumors 
and peritoneal tumors were obtained. Peripheral blood from LM-CRC patients was also 
collected on the day of resection. None of the patients received chemotherapy or 
immunosuppressive therapy at least three months before surgery. The clinical characteristics 
of the patients are summarized in Table 1. The study was approved by the local ethics 
committee, and signed informed consent from all patients was obtained before tissue and 
blood donation. 
Cell preparation 
Peripheral blood mononuclear cells (PBMC) were isolated by Ficoll density gradient 
centrifugation. Single cell suspensions from tumors and tumor-free liver were obtained by 
tissue digestion. Briefly, fresh tissues were first cut into small pieces and then digested with 
0.125 mg/mL collagenase IV (Sigma-Aldrich, St. Louis, MO) and 0.2 mg/mL DNAse I (Roche, 
Indianapolis, IN) in Hanks' Balanced Salt solution with Ca2+ and Mg2+ (Sigma, Zwijndrecht, 
The Netherlands) for 30 minutes at 37 °C with interrupted gently swirling. Cell suspensions 
were filtered through 100 µm pore cell strainers (BD Biosciences, Erembodegem, Belgium) 
and mononuclear leukocytes were obtained by Ficoll density gradient centrifugation. Viability 
was determined by trypan blue exclusion. 
Flow cytometric analysis 
Fresh peripheral blood mononuclear cells (PBMC) and leukocytes isolated from tissues were 
analyzed for expression of surface and intracellular markers using specific antibodies 
(Supplementary Table S2). Cell surface staining with fluorochrome-conjugated antibodies 
was performed in the dark at 4°C for 30 minutes, then cells were washed and resuspended 
in phosphate buffered saline with 0.2 mM EDTA and 0.5% human serum. For Foxp3 and 
CTLA4 staining, cells were fixed and permeabilized using the Foxp3 staining buffer set 
(eBioscience, Vienna, Austria). For intracellular cytokine staining, cells were stimulated with 
40 ng/mL PMA (Sigma, Zwijndrecht, The Netherlands) and 1 µg/mL ionomycin (Sigma) at 
37°C for five hours in the presence of 5 µg/mL brefeldin (Sigma) for the last four hours, 
followed by staining of IFN-γ and TNF-α upon fixation and permeabilization using the Foxp3 
staining buffer set. Dead cells were excluded by using a LIVE/DEAD fixable dead cell stain 
kit with aqua fluorescent reactive dye (Invitrogen, Paisley, UK). Cells were measured using a 
FACS Canto II flow cytometer (BD Biosciences, San Diego, USA) and analyzed using 
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FlowJo software (version 10.0, LLC). Appropriate isotype control antibodies were used for 
gating purposes (Supplementary Table S2).  
Ex vivo polyclonal T cell activation assay 
All LM-CRC cell cultures were performed in complete medium RPMI 1640 (Lonza, Breda, 
The Netherlands) supplemented with 10% human AB serum (Invitrogen), 2mM L-glutamine 
(Invitrogen), 50 mM Hepes Buffer (Lonza), 1% penicillin-streptomycin (Life Technologies), 
5mM Sodium Pyruvate (Gibco) and 1% minimum essential medium non-essential amino 
acids), at 37°C. TIL and PBMC from LM-CRC were labeled with 0.1 µM carboxyfluorescein 
diacetate succinimidyl ester (CFSE, Invitrogen); afterwards 105 TIL or PBMC were cultured in 
200 µl complete medium in each well of a 96-well round-bottom culture plate and stimulated 
with anti-human CD3/CD28 dynabeads (Gibco-Life Technologies AS, Norway) at a cell : 
bead ratio of 10:1, in the presence or absence of 10 μg/ml antagonistic monoclonal 
antibodies against human PD-L1 (clone 5H1, kindly provided by Dr. Haidong Dong, Mayo 
Clinic College of Medicine(59)), TIM3 (clone F38-2E2, Biolegend, San Diego, USA(60, 61)), 
LAG3 (clone 17B4, AdipoGen, Liestal, Switzerland(62)) or CTLA4 (clone BNI3, Beckman 
Coulter, Marseille, France(63)), or isotype-matched control antibodies (mIgG1 and mIgG2a, 
Biolegend, London, UK). In preliminary experiments a cell : bead ratio of 10:1 was 
established to provide sub-optimal stimulation of T cell proliferation. After four days, culture 
supernatant was collected and frozen at -20°C until secretion of IFN-γ and TNF-α was 
quantified by enzyme-linked immunosorbent assay (ELISA, Ready-SET-Go!, eBioscience). 
CFSE-labeled cells were harvested and stained with CD8, CD4 and CD3 antibodies. Dead 
cells were excluded by using the LIVE/DEAD fixable dead cell stain kit with aqua fluorescent 
reactive dye, and T cell proliferation was determined based on CFSE dilution by flow 
cytometric analysis.  
Ex vivo tumor-specific T cell stimulation assay 
Tumor lysates and normal liver lysates were generated from a small piece of freshly resected 
metastatic liver tumor or TFL by five cycles of freezing and thawing in phosphate buffered 
saline, followed by filtration (0.2 μm syringe filter), as previously described.(40, 41) Myeloid 
dendritic cells (mDC) were isolated from patient autologous PBMC by depletion of CD19+ B 
cells followed by positive selection for BDCA-1 (BDCA-1 DC isolation kit, Miltenyi Biotec). 
mDC were cultured overnight with or without 20 µg/mL autologous tumor lysates or normal 
liver lysates, in the presence of 10 ng/mL granulocyte-macrophage colony-stimulating factor 
(Miltenyi Biotec) and 0.5 µg/mL polyinosinic : polycytidylic acid (InvivoGen, San Diego, CA). 
Simultaneously TIL isolated from LM-CRC were kept at 4°C in complete medium overnight. 
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Thereafter TIL were labeled with 0.1 µM carboxyfluorescein diacetate succinimidyl ester 
(CFSE, Invitrogen), and 105 TIL were co-cultured with autologous mDC preloaded with or 
without tumor lysates or normal liver lysates at an mDC : TIL ratio of 1:5, in the presence or 
absence of 10 μg/ml antagonistic monoclonal antibodies against human PD-L1 (clone 5H1, 
kindly provided by Dr. Haidong Dong, Mayo Clinic College of Medicine(59)), TIM3 (clone 
F38-2E2, Biolegend, San Diego, USA(44)), LAG3 (clone 17B4, AdipoGen, Liestal, 
Switzerland(44)) or CTLA4 (clone BNI3, Beckman Coulter, Marseille, France(63)), in 200 µl 
complete medium in each well of a 96-well round-bottom culture plate. After six days, cells 
were restimulated with PMA (40 ng/mL) and ionomycin (1 µg/mL) for five hours in the 
presence of 5 µg/mL brefeldin for the last four hours. Cells were then stained with CD8, CD4 
and CD3 antibodies, followed by intracellular staining of IFN-γ and TNF-α upon fixation and 
permeabilization according to the manufacturer’s instructions (eBioscience A&B 
fixation/permeabilization kit). Dead cells were excluded by using the LIVE/DEAD fixable dead 
cell stain kit with aqua fluorescent reactive dye, and T cell proliferation was determined 
based on CFSE dilution by flow cytometric analysis.  
Determination of mismatch repair status by immunohistochemistry 
Immunostainings were performed on formalin-fixed paraffin-embedded whole tissue sections 
(4 μm thick) using the Benchmark Ultra autoimmunostainer (Ventana Medical Systems Inc, 
Roche Group, Tucson, USA) according to the manufacturer’s protocols and instructions. 
Briefly, deparaffinization was followed by heat-induced epitope retrieval in Ultra CC1 pre-
diluted buffer for 48-60 minutes at 100°C. Primary antibodies anti-MLH1 (Novocastra; Leica 
Microsystems B.V., Amsterdam, The Netherlands; clone ES05; dilution 1:75), anti-PMS2 
(Cell Marque, Rocklin, USA; clone EPR3947, ready to use), anti-MSH2 (Cell Marque, clone 
G219-1129; ready to use) and anti-MSH6 (Dako, Glosturp, Denmark; clone EP49; dilution 
1:75) were applied and followed by incubation (from 40 minutes to 1 hour and 32 minutes). 
Upon antibody incubation Ventana standard signal amplification was performed, followed by 
ultraWash counter-staining with one drop of Hematoxylin (for 20 minutes) and one drop of 
bluing reagent (for 4 minutes). Then slides were removed from the stainer, washed in water 
with a drop of dishwashing detergent and mounted. These immunohistochemical stainings 
detected the presence or absence of the protein products of the MMR genes MLH1, PMS2, 
MSH2 and MSH6. The pattern of their loss provides information about which gene is not 
functioning properly. IHC staining was evaluated under a light microscope as follows: nuclear 
expression of all MMR proteins indicates an MMR-proficient tumor status, loss of nuclear 
expression of any of the proteins indicates an MMR-deficient tumor status. 
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Statistical analysis 
The distributions of all continuous data set were analyzed for normality by the Shapiro-Wilk 
normality test. Differences between paired groups of data were analyzed by either paired t 
test or Wilcoxon matched pairs test according to their distribution. Differences between 
different groups of patients were analyzed by either unpaired t test or Mann-Whitney test 
according to their distributions. Correlation was analyzed by either Pearson or Spearman 
correlation test according to their distributions. These statistical analyses were performed 
using GraphPad Prism 5 (GraphPad Software). Hierarchical clustering was analyzed by one 
minus Pearson correlation using GENE-E (Broad Institute). Progression-free survival (time to 
recurrence) was calculated from the date of LM-CRC surgery to the date of event (LM-CRC 
recurrence), or the date of last follow-up. Patients lost to follow-up were censored as of the 
last day of follow-up. Survival curves were estimated by the Kaplan-Meier mothed. The 
Breslow test was used to assess differences between survival curves of different groups. For 
multivariable analysis, the Cox proportional Hazard regression analysis was used. These 
statistical analyses were performed using SPSS Statistics 21 (IBM). P values less than 0.05 
were considered statistically significant (* p < 0.05; ** p < 0.01; *** p < 0.001). 
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 Table 1. Patient characteristics 
 
Abbreviations: CRC, colorectal cancer; LM-CRC, liver metastasis of CRC; PM-CRC, 
peritoneal metastasis of CRC; TNM, tumor-node-metastasis; MMR, mismatch repair.  
**Mean ± standard error of the mean. 
 
 
Table 2. Multivariable Cox proportional Hazard regression analysis of progression-free 
survival of patients with MMR-proficient LM-CRC     
Variables  
 P 
value HR 
95% CI for HR 
Lower Upper 
PD-1 on CD8+ TIL .160 2.418 .706 8.283 
TIM3 on CD8+ TIL .774 1.183 .375 3.732 
LAG3 on CD8+ TIL .032 .351 .135 .912 
  
Abbreviations: TIL, tumor-infiltrating lymphocytes; HR, hazard ratio; CI, confidence interval.  
The hazard ratio is interpreted as the chance of recurrence occurring in the “> median” group 
to the chance of recurrence occurring in the “< median” group. 
 
  LM-CRC (n=53) PM-CRC (n=11) primary CRC (n=12) 
Gender 
(female/male) 
16 / 37 4 / 7 5 / 7 
Age (years)** 66.3 ± 3.3 56.9 ± 3.8 63.4 ± 3.4 
Stage of disease 
(TNM) 
Stage IV n=53 Stage IV n=11 
Stage I n=3, Stage II 
n=4, Stage III n=4, 
Stage IV n=1 
Tumor MMR 
status  
MMR-deficient n=2, 
MMR-proficient n=51 
MMR-deficient n=0, 
MMR-proficient n=11 
MMR-deficient n=3, 
MMR-proficient n=9 
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Figure legends 
Figure 1. Comparison of immune infiltrates and inhibitory molecule expression among 
MMR-proficient liver metastases (LM), peritoneal metastases (PM) and primary CRC. 
(A) The frequencies of CD8+ CTL, CD4+Foxp3- Th and CD4+Foxp3+ Treg within CD3+ TIL 
from LM-CRC, primary CRC and PM-CRC. (B) The frequencies of inhibitory receptor positive 
cells within CD8+ CTL, Th and Treg in LM-CRC, primary CRC and PM-CRC. (C) The 
frequencies of B cells, mDC and monocytes (Mono) within CD45+ cells from LM-CRC, 
primary CRC and PM-CRC. (D) The frequencies of inhibitory ligand positive cells within 
tumor-infiltrating B cells, mDC and monocytes from LM-CRC, primary CRC and PM-CRC. 
Values of individual patients are shown, and lines depict medians. Differences were analyzed 
by unpaired t test or Mann-Whitney test; * p < 0.05, ** p < 0.01, *** p < 0.001.  
Figure 2. Expression of inhibitory receptors on CD8+ CTL, CD4+ Th and CD4+ Treg in 
the tumor, TFL and blood of MMR-proficient LM-CRC. PBMC and leukocytes isolated 
from LM-CRC tumors and TFL were stained with antibodies against PD-1, LAG3, TIM3 and 
CTLA4. (A) (B) Representative dot plots of inhibitory receptor expression on (A) CD3+CD8+ 
CTL and (B) CD3+CD4+Foxp3- Th in the tumor, TFL and blood; the gates were made 
according to appropriate isotype controls. (C) (D) (E) The frequencies of inhibitory receptor 
positive cells within (C) CD8+ CTL, (D) CD4+Foxp3- Th and (E) CD4+Foxp3+ Treg in the 
tumor, TFL and blood. Values of individual patients are shown, and lines depict medians. 
Differences were analyzed by paired t test or Wilcoxon matched pairs test; * p < 0.05, ** p < 
0.01, *** p < 0.001.  
Figure 3. Intra-tumoral antigen-presenting cells of MMR-proficient LM-CRC express 
inhibitory ligands. Expression of inhibitory ligands PD-L1, galectin 9 (GAL-9), MHC-II, 
CD86 and CD80 was measured by flow cytometry. (A) The frequencies of CD19+ B cells, 
BDCA1+CD19- mDC and CD14+ monocytes (Mono) within CD45+ cells derived from tumors, 
TFL and blood. Values of individual patients are presented, lines depict medians. (B) 
Representative histograms of inhibitory ligand stainings and isotype controls on tumor-
infiltrating mDC, monocytes and B cells. (C) The frequencies of inhibitory ligand positive cells 
within tumor-infiltrating B cells, mDC and monocytes in individual patients are presented; 
lines depict medians. (D) The median fluorescence intensities (MFI) of inhibitory ligands on B 
cells, mDC and monocytes derived from tumors, TFL and blood of LM-CRC patients. Values 
of individual patients are shown, and lines depict medians. Differences were analyzed by 
paired t test or Wilcoxon matched pairs test; * p < 0.05, ** p < 0.01, *** p < 0.001. 
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Figure 4. Tumor-infiltrating T cells expressing inhibitory receptors show increased 
expression of activation markers. TIL from MMR-proficient LM-CRC were stained ex vivo 
with antibodies against surface activation markers HLA-DR and CD69. (A) (B) The 
frequencies of HLA-DR+ or CD69+ cells in (A) CD8+ CTL and (B) CD4+ Th that do or do not 
express PD-1, TIM3, LAG3, or CTLA4 are presented (n=9-11). Lines show medians, 
whiskers depict minimum to maximum. Differences were analyzed by paired t test or 
Wilcoxon matched pairs test. (C) (D) TIL from MMR-proficient LM-CRC were stimulated with 
PMA and ionomycin at 37°C for five hours, in the presence of protein transport inhibitor 
brefeldin for the last four hours, followed by intracellular cytokine staining. The frequencies of 
cytokine-producing cells in (C) CD8+ CTL and (D) CD4+ Th that do or do not express 
inhibitory receptors are presented (n=7-12). Lines show medians, whiskers depict Min to 
Max, boxes indicate the 25th to 75th percentiles. Differences were analyzed by paired t test or 
Wilcoxon matched pairs test; * p < 0.05, ** p < 0.01, *** p < 0.001. 
Figure 5. Antibody blockade of LAG3 or PD-L1 boosts ex vivo proliferation and 
cytokine production of intra-tumoral T cells from MMR-proficient LM-CRC in response 
to polyclonal stimuli. CFSE-labeled TIL from LM-CRC patients were stimulated with 
CD3/CD28 beads for four days, in the presence or absence of 10 μg/ml antagonistic 
antibodies. (A) Representative dot plots of CD3+CD8+ and CD3+CD4+ TIL proliferation in 
response to CD3/CD28 beads (a-CD3/CD28) in the presence or absence of antagonistic 
antibodies (a-) or isotype controls (iso ctrl). Dotplots indicated by “TIL” show proliferative 
responses in the absence of CD3/CD28 beads. In all other conditions, CD3/CD28 beads 
were added. (B) The percentages of proliferating cells (CFSE-low) within CD8+ and CD4+ T 
cells derived from the tumor or blood in response to CD3/CD28 beads without addition of any 
antagonistic antibody. Values of individual patients are presented. (C) Effects of antibody 
blockade of inhibitory interactions on CD8+ and CD4+ TIL proliferation (n=7-9). Because the 
proliferative responses differed between patients, the results are reported as relative 
proliferation in the presence of antibodies compared to baseline proliferation, which was 
calculated by dividing the percentages of proliferating (CFSE-low) T cells in the presence of 
antagonistic antibody or isotype control antibody by the percentages in the control condition 
with only CD3/CD28 beads. Values are depicted as means with standard error of the mean. 
(D) IFN-γ and TNF-α accumulation in culture supernatants was quantified at day four by 
enzyme-linked immunosorbent assay. Values are depicted as medians with interquartile 
range (n=10-11). Differences were analyzed by paired t test or Wilcoxon matched pairs test; 
* p < 0.05, ** p < 0.01. 
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Figure 6. Antibody blockade of LAG3 or PD-L1 boosts ex vivo responses of intra-
tumoral T cells from MMR-proficient LM-CRC to autologous tumor antigens. Blood 
mDC loaded with autologous tumor lysates were used to stimulate CFSE-labeled TIL, in the 
presence or absence of 10 μg/mL antagonistic antibodies. After six days T cell proliferation 
and intracellular cytokine production were analyzed after re-stimulation with PMA and 
ionomycin. (A) (B) Representative dot plots of T cell proliferation, IFN-γ and TNF-α 
expression in CD3+CD8+ and CD3+CD4+ TIL, in response to autologous mDC pre-loaded 
with tumor lysates (TIL+mDC+tumor lysate), in the presence or absence of antagonistic 
antibodies (a-). TIL responses to mDC that were not pre-loaded with tumor lysates 
(TIL+mDC) served as controls to determine non-antigen-specific TIL proliferation and 
cytokine production. (C) (D) (E) Collective data of five patients tested. Each line and each 
color represent one patient. The results are reported as net tumor-specific responses, 
calculated by subtracting the percentages of proliferating (CFSE-low) T cells or IFN-γ+ or 
TNF-α+ proliferating T cells in the control condition (mDC without tissue lysates) from the 
percentages in the conditions with tumor lysates (TL) in the absence or presence of 
antagonistic antibody. In two experiments an additional control was included, in which TIL 
were stimulated with blood mDC pre-loaded with normal liver lysates (NL), which did not lead 
to increased TIL responses.    
Figure 7. Kaplan-Meier curves of progression-free survival (time to recurrence) in 
relation to LAG3 expression on intra-tumoral T cells in MMR-proficient LM-CRC. The 
cutoff values to divide the patients into two groups are the median percentages of LAG3+ 
cells in tumor-infiltrating CD8+ CTL, CD4+Foxp3- Th or CD4+Foxp3+ Treg cells. For 
determination of the p values the Breslow test was used. 
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Supplementary figure legends 
Supplementary Figure S1. Immune infiltrates and inhibitory molecule expression in 
MMR-deficient liver metastases (LM) and primary CRC. (A) The frequencies of CD8+ 
CTL, CD4+Foxp3- Th and CD4+Foxp3+ Treg within CD3+ TIL from LM-CRC and primary 
CRC. (B) The frequencies of inhibitory receptor positive cells within CD8+ CTL, Th and Treg 
in LM-CRC and primary CRC. (C) The frequencies of B cells, mDC and monocytes (Mono) 
within CD45+ cells from primary CRC. (D) The frequencies of inhibitory ligand positive cells 
within tumor-infiltrating B cells, mDC and monocytes from primary CRC. Values of individual 
patients are shown, and lines depict medians.  
Supplementary Figure S2. Hierarchical clustering analysis of MMR-proficient liver 
metastases, peritoneal metastases and primary CRC. Heatmap illustrating the 
frequencies of CD8+ CTL, CD4+ Th and CD4+ Treg within CD3+ TIL, the frequencies of 
inhibitory receptor positive cells within CD8+ CTL, CD4+ Th and CD4+ Treg, the frequencies 
of B cells, mDC and monocytes within CD45+ cells, and the frequencies of inhibitory ligand 
positive cells within tumor-infiltrating B cells, mDC and monocytes, across LM-CRC, PM-
CRC and primary CRC tumors. Rows represent different parameters. Columns represent 
individual patients clustered by one minus pearson correlation (LM-CRC: n=5, primary CRC: 
n=6, PM-CRC: n=2). Due to limited numbers of TIL isolated from each tumor sample we 
could measure all the different phenotypic markers only in TIL isolated from limited numbers 
of tumors. (A) Absolute values: 0%-100%. (B) Relative values: row minimum (min) to row 
maximum (max). Grey: missing values. 
Supplementary Figure S3. Expression of BTLA on CD8+ CTL, CD4+ Th and CD4+ Treg 
in the tumor, TFL and blood of MMR-proficient LM-CRC. (A) (B) Representative dot plots 
of BTLA expression on CD3+CD8+ CTL and CD3+CD4+Foxp3- Th in the tumor, TFL and 
blood; the gates were made according to appropriate isotype controls. (C) (D) (E) The 
frequencies of BTLA positive cells within CD8+ CTL, CD4+ Foxp3- Th and CD4+ Foxp3+ Treg 
in the tumor, TFL and blood. Values of individual patients are shown, and lines depict 
medians. Differences were analyzed by paired t test or Wilcoxon matched pairs test; * p < 
0.05.  
Supplementary Figure S4. Correlation of inhibitory receptor expression on T cells 
between the tumor and the blood of patients with mismatch repair-proficient LM-CRC. 
Spearman correlation analysis demonstrates (A) positive correlation of the frequencies of 
PD-1+ cells in CD8+ CTL and CD4+ Treg between tumors and blood, (B) positive correlations 
of the frequencies of LAG3+ cells in CD4+ Th between tumors and blood, and (C) positive 
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correlations of the frequencies of CTLA4+ cells in CD4+ Th and CD4+ Treg between tumors 
and blood. Correlations were analyzed by Spearman correlation test. 
Supplementary Figure S5. Co-expression of inhibitory receptors on tumor-derived T 
cells in MMR-proficient LM-CRC. The mean frequencies of co-expression of PD-1 with 
TIM3, LAG3 or CTLA4 in CD8+ CTL (n=20) and CD4+ Th (n=10). 
Supplementary Figure S6. T cell densities in primary CRC tumors and liver 
metastases. CD3+, CD8+ and granzyme B+ cell densities in paired primary CRC and LM-
CRC of 16 patients. The data were reanalyzed after being extracted from Halama et al. Table 
1.(35) Values of individual patients are shown, and lines depict means. Differences were 
analyzed by paired t test or Wilcoxon matched pairs test; * p < 0.05. 
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Supplementary Table S1. Numbers of patient samples used in each type of 
experiments in the study 
Tumor type 
and number 
of samples 
MMR 
status and 
number of 
samples 
T cell or 
APC 
subsets 
Inhibitory 
receptors 
Inhibitory 
ligands 
Activation 
or 
cytokine 
Polyclonal 
T cell 
activation 
assay 
Tumor-specific 
T cell 
stimulation 
assay 
  
Figure 1 Figure 1, 
Figure 2 
Figure 1, 
Figure 3 
Figure 4 Figure 5 Figure 6 
53 LM-CRC 1 deficient 
      
 
1 deficient 
      
 
1 proficient 
      
 
1 proficient 
      
 
1 proficient 
      
 
1 proficient 
      
 
1 proficient 
      
 
1 proficient 
      
 
2 proficient 
      
 
2 proficient 
      
 
4 proficient 
      
 
5 proficient 
      
 
6 proficient 
      
 
11 
proficient 
      
 
15 
proficient 
      
        11 PM-CRC 2 proficient 
      
 
9 proficient 
      
        12 primary 
CRC 1 deficient 
      
 
2 deficient 
      
 
3 proficient 
      
 
6 proficient 
      Abbreviations: CRC, colorectal cancer; LM-CRC, liver metastasis of CRC; PM-CRC, 
peritoneal metastasis of CRC; MMR, mismatch repair. 
Supplementary Table S2. Antibodies used in flow cytometry 
Antibody Clone Supplier Antibody Clone Supplier 
CD69 APC L78 BD Biosciences CD8-PE RPA-T8 eBioscience 
IFN-gamma-FITC 25723.11 BD Biosciences HLA-DR-APC LN3 eBioscience 
CD137 (4-1BB)-APC 4B4-1 BD Biosciences HLA-DR-PE LN3 eBioscience 
CD14-PerCP MOP9 BD Biosciences HLA-DR-PerCP-Cy5.5 LN3 eBioscience 
CD3 PerCP-Cy5.5 UCHT1 BD Biosciences CD3 PE-Cy7 UCHT1 eBioscience 
CD19 APC-H7 SJ25C1 BD Biosciences CD8-APC okt-08 eBioscience 
mIgG2b-FITC 27-35 BD Biosciences IFN-gamma-Pe-Cy7 4S.B3 eBioscience 
mIgG1-PB 
MOPC-
21 BD Biosciences HLA-DR-APC-eFluor780 LN3 eBioscience 
mIgG2b-PE 27-35 BD Biosciences CD279 (PD1)-PE-Cy7 J105 eBioscience 
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mIgG1-PerCP X40 BD Biosciences CD8-efluor450 RPA-T8 eBioscience 
mIgG1-FITC 
MOPC-
21 BD Biosciences CD274(B7-H1)-PE-Cy7 MIH1 eBioscience 
mIgG1-pacific blue 
MOPC-
21 BD Biosciences CD270 (HVEM)-PE 
eBioHVEM-
122 eBioscience 
mIgG2a-PerCP X39 BD Biosciences CD4-APC-eFluor780 OKT4 eBioscience 
CD69-PE TP1.55.3 Beckman CD3-APC-eFluor780 SK7 eBioscience 
CD3 FITC UCHT1 Beckman FoxP3-eFluor450 236A/E7 eBioscience 
CD45 FITC J33 Beckman CD45 efluor 450 HI30 eBioscience 
mIgG2a-PE U7.27 Beckman CD8a-PerCp-Cy5.5 RPA-T8 eBioscience 
CD272 (BTLA)-APC MIH26 Biolegend CD223(LAG3)-PE 3DS223H eBioscience 
CD3 PE UCHT1 Biolegend 
CD223(LAG3)-PerCP-
eF710 3DS223H eBioscience 
CD86-PB IT2.2 Biolegend CD8-FITC SK1 eBioscience 
anti-TNF-α-PerCP-
Cy5.5 Mab11 Biolegend rat IgG2a-APC eBR2a eBioscience 
Galectin-9 PE 9M1-3 Biolegend mIgG1-FITC P3 eBioscience 
CD80-PE-Cy7 2D10 Biolegend mIgG2a-APC eBM2a eBioscience 
CD152 (CTLA4)-APC L3D10 Biolegend rat IgG2b-APC eB149/10H5 eBioscience 
HLA-DR, DP, DQ-
FITC Tü39 Biolegend mIgG1-PE P3.6.2.8.1 eBioscience 
mIgG1-Pe-Cy7 
MOPC-
21 Biolegend BDCA1-APC AD5-8E7 Miltenyi 
 rat IgG2a-PE 
 
RTK2758  Biolegend TIM3-PE 344823 
R&D 
systems 
mIgG2a-FITC 
MOPC-
173 Biolegend    
mIgG1-APC 
MOPC-
21 Biolegend    
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Liver cancer represents the second most common cause of cancer-related mortality 
worldwide. Hepatocellular carcinoma (HCC) is the most prevalent primary liver cancer, 
cholangiocarcinoma (CCA) second. Liver metastasis of colorectal cancer (LM-CRC) is the 
most common secondary liver cancer and a leading cause of death from CRC. The current 
therapeutic options for all three types of liver cancer are very limited. Hence, there is a 
pressing need for novel and effective treatments. The goals of this thesis are: 1) to determine 
whether regulatory T cells and co-inhibitory immune checkpoint pathways contribute to the 
immunosuppression within the tumor microenvironment in liver cancers, 2) and to identify 
potential promising targets to alleviate these immune suppressive mechanisms, thereby 
enhancing anti-tumor functions of tumor-infiltrating T cells in patients with liver cancer. In this 
chapter we will summarize and discuss the main findings in this thesis and propose 
suggestions for future research.  
In Chapter 1, we review the current knowledge on immune suppressive mechanisms in the 
tumor microenvironment of HCC, CCA and LM-CRC, summarize the results of clinical 
studies to overcome these immune suppressive mechanisms, suggest alternative therapeutic 
approaches to abrogate these mechanisms based on the described novel insights from 
preclinical studies, and point out the current gaps in our knowledge on immune suppressive 
mechanisms in the tumor microenvironment of liver cancer. We discuss 1) suppressive 
immune cell subsets such as conventional regulatory T cells and type 1 regulatory T cells 
that can supress effector T cell functions, 2) co-inhibitory pathways between T cells 
expressing co-inhibitory receptors and other immune cells and tumor cells expressing the 
ligands for these receptors, 3) intra-tumoral enzymes generating immune suppressive 
metabolites, 4) inhibition of migration of immune effector cells into the tumors, which leads to 
a paucity of immune cells inside liver cancers.   
Regulation of intra-tumoral suppressor T cells in liver cancers 
Part I focuses on conventional regulatory T cells (Treg) and type 1 regulatory T cells (Tr1). 
We have studied how to abrogate the immune suppression exerted by these cells in the 
tumor microenvironment (Figure 1).  
In Chapter 2, we show that treatment with a soluble form of the natural ligand of the co-
stimulatory receptor GITR, or a blocking antibody to co-inhibitory receptor CTLA4, reduced 
ex vivo suppression of effector CD4+ T cells mediated by CD4+Foxp3+ Treg isolated from 
HCC and LM-CRC tumors, thereby restoring effector T cell proliferation and cytokine 
production. Importantly, a combination of low doses of both treatments exhibited a stronger 
recovery of effector T cell function in the presence of tumor-derived Treg compared with 
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either treatment alone. Our data suggest that in patients with HCC or LM-CRC both GITR-
ligation and anti-CTLA-4 antibody can improve antigen-specific T cell responses in the 
tumors by decreasing tumor-infiltrating Treg-mediated suppression. However, as part of an 
immunotherapeutic strategy, combining low doses of both drugs may be at least as effective 
as monotherapy with higher doses of either drug.  
In Chapter 3, we identified a population of tumor-infiltrating Tr1 cells that contributes to local 
immune suppression in an IL-10 dependent manner in HCC and LM-CRC. Importantly, the 
presence of tumor-infiltrating Tr1 cells is correlated with tumor infiltration of plasmacytoid 
dendritic cells. Plasmacytoid dendritic cells may drive intra-tumoral immunosuppression by 
Tr1 cells through stimulating IL-10 production by Tr1 cells via ICOS/ICOS-ligand signaling. 
Therefore, Tr1 cells may inhibit anti-tumor immunity in HCC and LM-CRC and thereby foster 
tumor progression. Blockade of the engagement of ICOS on Tr1 cells and ICOS-ligand on 
plasmacytoid dendritic cells may provide alleviation of this intra-tumoral immunosuppressive 
mechanism, and provide a new potential immunotherapeutic approach for patients with solid 
cancers in which IL-10-producing CD4+ T cells are present, . 
In Chapter 4, we propose that CD25 is a less attractive target for cancer immunotherapy in 
humans than originally suggested by Arce Vargas et al.,(1) because CD25 is not solely 
expressed on conventional Treg, but also on CD4+Foxp3lowCD45RA- non-Treg in tumors, 
tumor-free tissues, lymph nodes and peripheral blood of HCC and CRC patients. CD25 
antibody-mediated depletion of these cells may counteract the enhancement of anti-tumor 
immunity by Treg depletion. In addition, based on the observed reduction of CD16 (FcγR III) 
expression on intra-tumoral NK cells in cancer patients, the capacity of antibody-dependent 
cell-mediated cytotoxicity (ADCC) to deplete immune cells in human tumors may be more 
limited than previously expected. Therefore, CD25-depleting antibodies might not be 
appropriate for intra-tumoral Treg depletion in humans. Future research to develop Treg-
depleting antibody therapies should focus on other targets than CD25. 
Higher frequencies of Treg have been observed in HCC and LM-CRC tumors compared to 
paired tumor-free liver tissues and blood in Part I, and the same finding is also described for 
CCA tumors in Part II of this thesis. In addition, lower frequencies of CD8+ cytotoxic T cells, 
natural killer T cells and natural killer cells as well as lower expression of the cytotoxic 
effector molecules perforin and granzyme B in CD8+ T cells in HCC and LM-CRC tumors 
have previously been reported by us,(2) and are reported in Part II of this thesis for CCA 
tumors. These data indicate that the composition of immune infiltrates in liver tumors has 
immunosuppressive properties. It has been reported that the composition of tumor-infiltrating 
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lymphocytes is associated with the prognosis of liver cancers, for instance increased 
numbers of intra-tumoral Treg are associated with disease progression and recurrence.(3-8) 
Moreover, higher number of intra-tumoral Treg has been associated with increased numbers 
of intra-tumoral macrophages, circulating myeloid-derived suppressor cells, and with a 
compromised intra-tumoral CD8+ T cell response.(9-13) Altogether these observations 
suggest that depletion or inhibition of intra-tumoral Treg and concomitant stimulation of 
immune effector cells may be effective to reduce tumor growth and recurrence as well as 
prolong survival of patients with liver cancer.        
Until recently direct evidence for a role of Tr1 cells in human solid tumors was lacking. The 
recent description of co-expression of CD49b and LAG3 as markers that can specifically 
identify this population of cells,(14) enabled us to show that the majority of liver tumor-
infiltrating IL-10-producing CD4+ T cells consists of Tr1 cells and only a minor proportion 
corresponds to Th2 cells or Foxp3+ Treg. Our data demonstrate a possible interaction 
between Tr1 cells and plasmacytoid dendritic cells by which tumor-infiltrating Tr1 cells may 
be activated by plasmacytoid dendritic cells present in the tumor microenvironment. The 
main population expressing ICOS-ligand in tumor tissues are CD123+ plasmacytoid dendritic 
cells. There is substantial evidence indicating that plasmacytoid dendritic cells have a 
specialized role in the induction of peripheral tolerance by inducing IL-10 production by 
conventional Treg through ICOS-ICOS-ligand signaling.(15, 16) Stimulation of conventional 
Treg to produce IL-10 by plasmacytoid dendritic cells has been described in breast cancer 
and ovarian cancer.(17, 18) Our results are consistent with a role for plasmacytoid dendritic 
cells to stimulate IL-10 production by Tr1 cells in the tumor microenvironment of patients with 
liver cancer. Altogether these data suggest that ICOS co-stimulation represents a potential 
target for immunotherapeutic intervention, affecting tumor-specific immunosuppression 
mediated by both Treg and Tr1 cells.  
In addition, other issues have already been discussed in the previous chapters. 
Regulation of intra-tumoral effector T cells in liver cancers 
Part II focuses on CD8+ cytotoxic T cells (CTL) and CD4+ T helper cells (Th). Here, we have 
studied how to invigorate effector functions of tumor-infiltrating T cells by targeting co-
inhibitory and co-stimulatory immune checkpoint pathways (Figure 1).  
In Chapter 5, we conclude that co-inhibitory receptors PD-1, TIM3 and LAG3 are 
upregulated on tumor antigen-specific CD8+ T cells isolated from patient HCC tumor tissues. 
Myeloid dendritic cells, monocytes and B cells in HCC tumors express ligands for these 
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receptors. Compared with tumor-infiltrating CD8+ CTL and CD4+ Th that did not express 
these co-inhibitory receptors, tumor-infiltrating CTL and Th that did express these receptors 
showed higher levels of activation markers, but similar or decreased levels of granzyme B 
and effector cytokines. While blocking a single co-inhibitory pathway had variable effects on 
ex vivo functional responses of HCC-derived T cells, combining antibody against PD-L1 with 
antibodies against TIM3, LAG3 or CTLA4 revitalized ex vivo tumor-specific responses of 
HCC-derived CD8+ and CD4+ T cells in most patients and additively enhanced these effects 
compared to single PD-L1 blockade. Overall, the aforementioned combined targeting of co-
inhibitory checkpoints is a promising immunotherapeutic strategy for HCC, and may result in 
superior clinical responses in more patients than targeting a single co-inhibitory checkpoint. 
In Chapter 6, we demonstrate higher proportions of CD8+ T cells, myeloid dendritic cells and 
monocytes  within immune cells isolated from mismatch repair (MMR)-proficient LM-CRC 
compared to immune cells derived from MMR-proficient primary CRC, suggesting an 
increased cytotoxic and antigen-presenting capacity of immune infiltrates in LM-CRC. In 
addition, we observed increased expression of co-inhibitory receptors on intra-tumoral T cells 
in MMR-proficient LM-CRC, which suggests that tumor-infiltrating T cells in MMR-proficient 
LM-CRC may be more sensitive to immune checkpoint inhibitors than tumor-infiltrating T 
cells in MMR-proficient primary CRC. Antibody blockade of LAG3 or PD-L1 enhanced ex vivo 
effector functions of CD8+ and CD4+ T cells derived from MMR-proficient LM-CRC, with 
LAG3 blockade showing the most robust effects on tumor-specific responses. In addition, 
higher LAG3 expression on intra-tumoral CD8+ T cells associated with longer progression-
free survival of LM-CRC patients. Overall, LAG3 may be a new promising immunotherapeutic 
target for LM-CRC, even for MMR-proficient tumor type. Clinical studies focusing on 
responses of LM-CRC to anti-LAG3 antibody treatment are recommended. 
In Chapter 7, we analyzed the composition and characteristics of intra-tumoral immune 
infiltrates in CCA. We found decreased numbers of cytotoxic lymphocytes and increased 
numbers of Treg in CCA tumors compared with paired tumor-free liver tissues. While Treg 
infiltrate into the tumors, the majority of CD8+ CTL and CD4+ Th are sequestered at the tumor 
margin. Furthermore, intra-tumoral CD8+ T cells show reduced expression of cytotoxic 
molecules compared with T cells in tumor-free liver tissues and blood. Expression of co-
inhibitory receptors PD-1 and CTLA4 as well as co-stimulatory receptor GITR are 
upregulated on tumor-infiltrating T cells compared to T cells in tumor-free liver tissues and 
blood. Stimulation of GITR by the soluble ligand or blocking PD-1 by a therapeutic human 
antibody enhanced the effector functions of CCA-derived CD8+ and CD4+ T cells ex vivo, 
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which indicates that these two molecules are potential targets for immunotherapy of CCA 
patients.  
In Chapter 8, we evaluated a proof of concept that agonists of co-stimulatory molecules may 
be effective for HCC immune therapy. We observed the highest GITR expression on 
CD4+Foxp3hiCD45RA- activated Treg in HCC tumors, although GITR expression on activated 
Treg in tumor-free liver tissues and blood was also higher than on CD4+ Th and CD8+ CTL in 
the same compartments. Furthermore, addition of recombinant GITR-ligand or humanized 
agonistic antibody to GITR to CD8+ and CD4+ T cells isolated from HCC tumors invigorated 
their responses to stimulations with polyclonal antigens and tumor antigens. Agonistic 
targeting of GITR may therefore be a potential strategy for single or combinatorial 
immunotherapy in HCC. 
Interestingly, PD-1-expressing cells are increased in CD8+ CTL, Th and Treg in HCC, LM-
CRC and CCA tumors, while TIM3-expressing cells are increased in CD8+ CTL and Treg, 
while CTLA4-expressing cells are increased in CD8+ CTL and Th, and GITR-expressing cells 
are increased in Treg in all liver tumors compared with paired tumor-free liver tissues and 
blood, but LAG3 is not upregulated in CCA tumors (some data are not shown in the thesis). 
In HCC, co-inhibitory receptors PD-1, TIM3 and LAG3 are selectively upregulated on intra-
tumoral tumor antigen-specific CD8+ T cells. The selective increased expression of these co-
inhibitory receptors on tumor antigen-specific T cells together with the expression of their 
respective ligands on antigen-presenting cells in HCC tumors suggests that these co-
inhibitory pathways may be involved in the regulation of tumor antigen-specific 
responsiveness of intra-tumoral T cells.    
In both HCC and LM-CRC, tumor-infiltrating CD8+ CTL and CD4+ Th that expressed PD-1, 
TIM3, LAG3 or CTLA4 displayed higher levels of activation markers, compared with their 
counterparts that did not express the corresponding co-inhibitory receptor, except for CD69 
expression on LAG3+CD8+ versus LAG3-CD8+ T cells. However, the tumor-infiltrating T cells 
expressing either co-inhibitory receptor displayed comparable or lower levels of effector 
cytokines and/or cytotoxic molecules. Expression of co-inhibitory receptors on T cells can be 
induced by recent T cell activation upon recognition of tumor antigens,(19, 20) but 
continuous expression of increasing numbers of co-inhibitory receptors often coincides with 
gradual loss of effector T cell functions due to chronic antigenic stimulation.(21-23) Our 
findings indicate that, in accordance with recent studies in other human cancers,(23-25) 
tumor-infiltrating T cells that express co-inhibitory receptors are probably tumor-reactive T 
cells, which continue to upregulate the expression of these receptors in response to chronic 
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stimulation by tumor antigens to prevent further over activation, and thereby are 
subsequently inhibited by the interactions of these receptors with their ligands on tumor cells 
or antigen-presenting cells. 
In all the in vitro functional assays of HCC, LM-CRC and CCA, we used total tumor-infiltrating 
mononuclear leukocytes which contained both T cells expressing co-inhibitory receptors and 
antigen-presenting cells expressing their ligands, because we were interested in the net 
effects of antibody interventions on intra-tumoral T cell responses in a context that resembled 
the tumor microenvironment as much as possible. Consequently, intra-tumoral Treg, Tr1 
cells and probably other types of immune suppressor cells were also present. Therefore, the 
reported functional effects of antibodies on effector T cells in these assays may be partly 
indirect, mediated by the effects of these antibodies on immune suppressor cells. A limitation 
of our in vitro assays is the lack of tumor cells which can also express ligands for co-
inhibitory receptors and exert other unknown immunosuppressive effects. Therefore tumor-
infiltrating T cells might be more suppressed in vivo than in our ex vivo culture models. 
In HCC, targeting either CTLA4 or GITR has been shown to both reduce the 
immunosuppression mediated by tumor-infiltrating Treg (Part I) and restore anti-tumor 
functions of tumor-infiltrating effector T cells (Part II). Although the mechanisms by which 
these molecules exert their immunomodulatory effects are still elusive, our results suggest 
that they can act either by abrogating the suppressive function of Treg or by rendering 
effector T cells resistant to Treg-mediated suppression. 
Additionally, other issues have already been discussed in the previous chapters. 
Overall conclusions and future perspectives 
The ultimate aim of this thesis is to provide new immunotherapeutic approaches to treat 
patients with primary liver cancer or CRC liver metastasis. Our studies show that, increased 
proportions of Treg and Tr1 cells and decreased proportions of cytotoxic lymphocytes in 
immune infiltrates within liver tumors, as well as elevated expression of several co-inhibitory 
receptors on tumor-infiltrating T cells and the presence of their ligands in human liver tumors, 
both contribute to an immunosuppressive tumor microenvironment in liver cancers. Co-
inhibitory pathways CTLA4-CD80/CD86, PD-1-PD-L1, TIM3-galectin 9, LAG3-MHC class II 
and co-stimulatory pathways GITR-GITR-ligand and ICOS-ICOS-ligand play an important 
role in regulating intra-tumor T cell immunity in patients with HCC, CCA or LM-CRC. This 
thesis provides new clues for immunotherapeutic interventions to overcome the 
abovementioned immune suppressive mechanisms and to reinforce the anti-tumor reactivity, 
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by demonstrating that combined blockade of PD-1/PD-L1 and TIM3, LAG3 or CTLA4 as well 
as stimulation of GITR are effective in reinvigorating tumor-derived T cells in HCC, antibody 
against LAG3 has similar potential for LM-CRC, while agonistic antibody of GITR and 
blocking antibody of PD-1/PD-L1 are suggested for CCA.    
Currently, several clinical trials exploring the effects of anti-PD-1 antibodies in CCA patients 
are ongoing. Clinical trials investigating whether combination treatments of anti-PD-1/PD-L1 
antibodies and anti-CTLA4 antibodies result in improved clinical efficacy are also ongoing in 
HCC and CCA patients. In addition, GITR agonistic antibody combined with PD-1 and/or 
CTLA4 antagonistic antibody, CD134 agonistic antibody combined with PD-1 and/or CTLA4 
antagonistic antibody, CD134 agonistic antibody in combination with CD137 agonistic 
antibody are being tested in HCC patients.(26)[ClinicalTrials.gov] However, clinical trials on 
immunotherapy with anti-TIM3 and anti-LAG3 antibodies have not been initiated in patients 
with liver cancer. Moreover, clinical studies on LAG3 antagonistic antibody for patients with 
LM-CRC and clinical studies on GITR agonistic antibody for patients with CCA are lacking. 
Further research on co-expression of different immune checkpoints and clinical efficacy of 
combinatorial immunotherapies in patients with liver cancer is definitely needed to improve 
the clinical outcome.  
 
 
 
Figure 1. Summary of the main findings of the thesis 
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Leverkanker is de op één na meest voorkomende oorzaak van kanker gerelateerde 
mortaliteit in de wereld. Hepatocellulair carcinoom (HCC) is de meest frequent voorkomende 
primaire leverkanker, cholangiocarcinoom (CCA) de tweede. In de lever gemetastaseerde 
colorectaal kanker (LM-CRC) is de meest voorkomende secundaire leverkanker, en de 
voornaamste doodsoorzaak van patiënten met colorectaal kanker (CRC). De huidige 
therapeutische mogelijkheden voor alle drie deze typen van leverkanker zijn heel beperkt. 
Vandaar dat er een dringende behoefte bestaat aan nieuwe en effectieve 
behandelmethoden. De doelen van dit proefschrift zijn: 1)  om te bepalen of regulatoire T-
cellen en co-inhibitoire immuun checkpoint routes bijdragen aan het immunosuppressieve 
micromilieu in levertumoren, en 2) om potentiël veelbelovende factoren te identificeren die 
deze immuun suppressieve mechanismen onderdrukken en daardoor de anti-tumor functie 
van de in de tumor infiltrerende T-cellen in patiënten met leverkanker versterken. In dit 
hoofdstuk zullen we de belangrijkste bevindingen samenvatten en bediscussiëren en 
suggesties geven voor toekomstig onderzoek. 
In hoofdstuk 1 geven we een overzicht van de actuele kennis over immunosuppressieve 
mechanismen in het tumor micromilieu van HCC, CCA en LM-CRC. We vatten de resultaten 
van klinische studies samen die proberen deze immunosuppressieve mechanismen te 
onderdrukken, we stellen alternatieve therapeutische benaderingen voor om deze 
mechanismen op te heffen gebaseerd op beschreven nieuwe inzichten van preklinische 
studies en we wijzen op actuele hiaten in onze kennis over immunosuppressieve 
mechanismen in het tumor micromilieu van leverkanker. We bediscussiëren 1) suppressieve 
immuun cel subsets zoals conventionele regulatoire T-cellen en type 1 regulatoire T-cellen 
die de functie van effector T-cellen kunnen onderdrukken, 2) co-inhibitoire interacties tussen 
T-cellen die co-inhibitoire receptoren tot expressie brengen en andere immuun cellen en 
tumor cellen, die de liganden voor deze receptoren tot expressie brengen, 3) enzymen in 
tumoren die metabolieten genereren die het immuunsysteem onderdrukken, 4) het 
verhinderen van de migratie van immuun effector cellen naar de tumor, wat leidt tot een te 
kort aan immuun cellen in leverkanker. 
Regulatie van intra-tumorale suppressieve T-cellen in leverkanker  
Deel I focust op conventionele regulatoire T-cellen (Treg) en type 1 regulatoire T-cellen 
(Tr1). We hebben bestudeerd hoe de immuun suppressie die wordt uitgeoefend door deze 
cellen kan worden onderdrukt in het tumor micromilieu (figuur 1). 
In hoofdstuk 2 laten we zien dat een oplosbare vorm van het natuurlijke ligand van de co-
stimulatoire receptor GITR en/of een blokkerende antistof tegen de co-inhibitoire receptor 
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CTLA4 de ex vivo suppressie van effector CD4+ T-cellen door CD4+Foxp3+ Treg uit HCC en 
LM-CRC tumoren  vermindert, waardoor de celdeling en cytokine productie van deze effector 
T-cellen wordt hersteld. Belangrijk is hierbij dat een combinatie van lage doses van beide 
behandelingen een sterker herstel van de functie van effector T cellen laat zien in 
aanwezigheid van uit de tumor geïsoleerde Treg dan iedere behandeling afzonderlijk. Onze 
data suggereren dat behandeling van HCC en LM-CRC patiënten met GITR-ligatie of 
antistoffen tegen CTLA4 de antigen specifieke T-cel responsen kan verbeteren in tumoren 
door  vermindering van de suppressie door in de tumor geïnfiltreerde Treg. Echter, als 
immunotherapeutische strategie kan een combinatie van een lage dosis van beiden 
medicijnen even effectief zijn als een monotherapie met een hoge dosis van één van deze 
medicijnen. 
In hoofdstuk 3 hebben we een populatie van in de tumor geïnfiltreerde Tr1 cellen 
geïdentificeerd die bijdraagt aan lokale immuun suppressie op een IL-10 afhankelijke manier 
in HCC en LM-CRC. De aantallen van Tr1 cellen in deze tumoren zijn positief gecorreleerd 
aan de aantallen in de tumor geïnfiltreerde plasmacytoïde dendritische cellen. We hebben 
aanwijzingen gevonden die erop wijzen  dat plasmacytoïde dendritische cellen via 
ICOS/ICOS-ligand interacties de IL-10 productie van Tr1 cellen stimuleren en hierdoor 
bijdragen aan de door de Tr1 veroorzaakte intra-tumorale immuun suppressie. Dus Tr1 
cellen kunnen mogelijk anti-tumor immuniteit onderdrukken in HCC en LM-CRC en daardoor 
de tumorprogressie bevorderen. Het blokkeren van  de interactie van ICOS op de Tr1 cel en 
ICOS-ligand op de plasmacytoïde dendritische cel kan dit intra-tumorale 
immunosuppressieve mechanisme verminderen en een nieuwe potentiële 
immunotherapeutische benadering bieden voor patiënten met solide tumoren waarin IL-10-
producerende CD4+ T-cellen aanwezig zijn. 
In hoofdstuk 4 suggereren we dat CD25 een minder aantrekkelijk doelwit is voor 
immunotherapie bij kanker bij mensen dan oorspronkelijk werd gesuggereerd door Arce 
Vargas et al., omdat CD25 niet alleen tot expressie komt op conventionele Treg, maar ook 
op CD4+Foxp3laagCD45RA-non-Treg die voorkomen in tumoren, tumorvrije weefsels, 
lymfeklieren en perifeer bloed van HCC en CRC patiënten. CD25 antistof-gemedieerde 
depletie van deze cellen kan de verhoging van anti-tumor immuniteit door Treg-depletie 
tegengaan. Doordat  intra-tumorale NK-cellen in kankerpatiënten minder CD16 (FcγR III) tot 
expressie brengen, kan bovendien het vermogen om immuun cellen in menselijke tumoren te 
depleteren door antistof-afhankelijke celgemedieerde cytotoxiciteit (ADCC), beperkter zijn 
dan eerder was verwacht. Daarom zijn CD25-depleterende antistoffen mogelijk niet geschikt 
voor intra-tumorale Treg-depletie bij mensen. Toekomstig onderzoek met betrekking tot 
Chapter 10 
- 168 - 
 
Treg-depletie met behulp van antistoffen zou zich moeten richten op andere doelwitten dan 
CD25. 
Regulatie van intra-tumorale effector T cellen in levertumoren 
Deel II focust op CD8+ cytotoxische T lymfocyten (CTL) en CD4+ T helper cellen (Th). In dit 
gedeelte hebben we bestudeerd hoe effector functies van tumor-infiltrerende T cellen kunnen 
worden versterkt door targeting van co-inhibitoire en co-stimulerende immuun checkpoint 
pathways (Figuur 1). 
In Hoofdstuk 5 concluderen we dat de co-inhibitoire receptoren PD-1, TIM3 en LAG3 
verhoogd tot expressie komen  op tumor antigen-specifieke CD8+ CTL geïsoleerd uit humane 
HCC-tumor weefsels. Myeloïde dendritische cellen, monocyten en B cellen in HCC tumoren 
brengen de liganden van deze receptoren tot expressie. Vergeleken met tumor-infiltrerende 
CD8+ CTL en CD4+ Th zonder co-inhibitoire receptoren, brengen de tumor-infiltrerende CTL 
en Th met deze receptoren, meer activatie markers tot expressie, maar is de hoeveelheid 
granzyme B en effector cytokines die ze tot expressie brengen, is vergelijkbaar of 
verminderd. Het blokkeren van één co-inhibitoire pathway had variabele effecten op ex vivo 
functionele responsen van HCC tumor infiltrerende lymphocyten, maar het combineren van 
een antagonistisch PD-L1 antistof met een antagonistisch TIM3, LAG3 of CTLA4 antilistof, 
versterkte ex vivo tumor-specifieke responsen van CD8+ en CD4+ T cellen geïsoleerd uit 
HCC in de meeste patiënten, en dit effect ervan was groter in vergelijking met alleen 
blokkering van PD-L1. We concluderen dat de eerdergenoemde combinatie therapie van co-
inhibitoire checkpoint antistoffen een veelbelovende immunotherapeutische strategie is voor 
HCC, die zou kunnen resulteren in een superieure klinische respons in een groter 
percentage van de patiënten vergeleken met monotherapie met één co-inhibitoire checkpoint 
antistof. 
In Hoofdstuk 6 laten we zien dat immuun cellen geïsoleerd uit DNA mismatch repair (MMR)-
proficiënte LM-CRC tumoren hogere proporties CD8+ T cellen, myeloïde dendritische cellen 
en monocyten bevatten dan immuun cellen geïsoleerd uit MMR-proficiënte primaire CRC 
tumoren. Dit suggereert een verhoogde cytotoxische en antigen-presenterende capaciteit 
van immuun infiltraten in LM-CRC. Daarnaast zagen we verhoogde expressie van co-
inhibitoire receptoren op intra-tumorale T cellen in MMR-proficiënte LM-CRC, wat suggereert 
dat de tumor-infiltrerende T cellen in MMR-proficiënte LM-CRC gevoeliger zijn voor immuun 
checkpoint antagonisten dan tumor-infiltrerende T cellen in MMR-proficiënte primaire CRC. 
Blokkade van LAG3 of PD1 door antistoffen verbeterde ex vivo de effector functies van CD8+ 
en CD4+ T cellen verkregen uit MMR-proficiënte LM-CRC tumoren.Van deze twee liet 
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blokkade van LAG3 de meest robuuste effecten zien op tumor-specifieke T-cel responsen. 
Bovendien was hogere LAG3 expressie op intra-tumorale CD8+ T cellen geassocieerd met 
langere progressie-vrije overleving in LM-CRC patiënten. Alles bijeengenomen zou LAG3 
een nieuwe en veelbelovende immunotherapeutische target kunnen zijn voor LM-CRC, zelfs 
voor het MMR-proficiënte tumor type. Klinische studies naarhet effect van anti-LAG3 
antilistof behandeling op LM-CRC wordt aangeraden om deze bevindingen te bevestigen.  
In Hoofdstuk 7 hebben we de samenstelling en karakteristieken van intra-tumorale immuun 
cel infiltraten in CCA geanalyseerd. In de CCA tumoren vonden we verlaagde aantallen 
cytotoxische lymfocyten en verhoogde aantallen Treg in vergelijking met de gepaarde 
tumorvrije leverweefsels. Waar Treg in de tumoren infiltreren, is het merendeel van de CD8+ 
CTL en CD4+ Th juist te vinden in het overgangsgebied tussen tumorvrij leverweefsel en de 
tumor. Daarnaast laten de intra-tumorale CD8+ T cellen verminderde expressie van 
cytotoxische moleculen zien vergeleken met T cellen in het tumorvrije leverweefsel en bloed, 
en is zowel de expressie van de co-inhibitoire receptoren PD-1 en CTLA4 als de co-
stimulerende receptor GITR hoger in de tumor-infiltrerende T cellen dan op de T cellen uit 
het tumorvrije leverweefsel en bloed. Stimulatie van GITR door het oplosbare ligand of het 
blokkeren van PD-1 door een therapeutische humane antistof, verbeterden de effector 
functies ex vivo van CD8+ en CD4+ T cellen verkregen uit CCA tumoren, wat aangeeft dat 
deze twee moleculen potentiële targets zijn voor immunotherapeutische behandeling van 
CCA patiënten. 
In Hoofdstuk 8 onderzochten we het concept dat  agonisten van co-stimulerende moleculen 
een effectieve immunotherapeutische behandeling kunnen bieden voor HCC. Geactiveerde 
CD4+FoxP3hoogCD45RA- Treg hadden de hoogste GITR expressie van alle immuuncellen in 
HCC tumoren. Ook in tumorvrij leverweefsel en bloed was de expressie van GITR  hogerop 
geactiveerde Treg dan op CD4+ Th en CD8+ CTL in dezelfde compartimenten. Toevoeging 
van recombinant GITR-ligand of een gehumaniseerde agonistische antistof tegen GITR aan 
CD8+ en CD4+ T cellen geïsoleerd uit HCC tumoren verhoogde hun responsen op 
polyclonale of tumorantigen-specifieke stimulatie. Dus agonistische targeting van GITR zou 
een potentiële strategie zijn voor mono- of combinatie immunotherapie van HCC. 
Algemene conclusies en toekomstperspectieven 
Het uiteindelijke doel van dit proefschrift is om nieuwe immunotherapeutische methoden te 
identificeren voor de behandeling van patiënten met primaire leverkanker of CRC 
levermetastasen. Onze studies tonen aan dat verhoogde aantallen Treg- en Tr1-cellen en 
verlaagde aantallen cytotoxische lymfocyten in immuun-infiltraten in tumoren bijdragen aan 
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een immunosuppressief tumor-micromilieu in levertumoren, evenals een verhoogde 
expressie van verschillende co-inhiberende receptoren op in de tumor geïnfiltreerde T-cellen 
en de aanwezigheid van hun liganden in de levertumoren. Beide factoren dragen bij aan een 
immunosuppressief tumor-micromilieu in leverkanker. De co-inhiberende routes CTLA4-
CD80/CD86, PD-1-PD-L1, TIM3-galectine 9, LAG3-MHC klasse II en de co-stimulerende 
routes GITR-GITR-ligand en ICOS-ICOS-ligand spelen een belangrijke rol  in de regulatie 
van intra-tumorale T-cel immuniteit bij patiënten met HCC, CCA of LM-CRC. Dit proefschrift 
biedt nieuwe suggesties voor immunotherapeutische interventies om de bovengenoemde 
immunosuppressieve mechanismen te onderdrukken en om de anti-tumor reactiviteit van in 
de tumoren geïnfiltreerde T cellen te verbeteren. Er wordt aangetoond dat gecombineerde 
blokkade van PD-1/PD-L1 en TIM3, LAG3 of CTLA4, evenals stimulatie van GITR, effectief 
zijn in het stimuleren van T-cellen afkomstig uit HCC tumoren. Antistoffen tegen LAG3 
bieden een vergelijkbare mogelijkheid voor LM-CRC, terwijl agonistische antistoffen tegen 
GITR en antistoffen die de interactie tussen PD-1/PD-L1 blokkeren worden voorgesteld voor 
CCA.  
Momenteel lopen er verschillende klinische onderzoeken naar de effecten van anti-PD-1-
antistoffen bij CCA-patiënten. Klinische studies bij HCC en CCA patiënten die onderzoeken 
of een combinatie van een anti-PD-1/PD-L1-antistof met eenanti-CTLA4-antistof leidt tot 
verbeterde klinische werkzaamheid zijn ook lopend. Bovendien worden in HCC patiënten de 
combinatie van een GITR-agonistische antistof met een PD-1 en/of CTLA4-antagonistische 
antistof, evenals een CD134-agonistische antistof gecombineerd met een PD-1 en/of 
CTLA4-antagonistische antistof, en een CD134-agonistische antistof in combinatie met een 
CD137-agonistische antistof getest. Echter, klinische trials met anti-TIM3 en anti-LAG3-
antistoffen zijn niet gestart bij patiënten met leverkanker. Bovendien ontbreken in patiënten 
met LM-CRC klinische studies naar antagonistische antistoffen tegen LAG3, en in patiënten 
met CCA ontbreken klinische studies met GITR-agonistische antistoffen. Verder onderzoek 
bij patiënten met leverkanker naar co-expressie van verschillende immuun checkpoints en 
klinische werkzaamheid van gecombineerde immunotherapieën is absoluut noodzakelijk om 
de klinische uitkomst te verbeteren. 
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